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List of Abbreviations 
 
 
ATC: Anatomical Therapeutic Chemical classification system 
 
DRUID: Driving Under the Influence of Drugs, Alcohol and Medicines 
 
EU: European Union 
 
ICADTS: International Council on Alcohol, Drugs and Traffic Safety 
 
PIL: Patient Information Leaflet 
 
SmPC: Summary of Product Characteristics 
 
WP: Work Package 
 
DG Sanco: Directorate General for Health & Consumers (SANCO) 
 
DG Move: European Commission Mobility & Transport 
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Executive Summary D.4.1.1 
 
Review of existing classification efforts. 
 
 
 
In total, 16 systems were found (table 9). Some of these systems are no true categorization 
systems: Germany directly reproduced ratings from Wolschrijn, and 5 systems have not defined 
categories (Greece, the Netherlands, Norway, Denmark and Finland). Only one true 
categorization system also included warning labels (France II). 
 
Clear relations can be seen between the different systems (figure 3). In this way, all 
categorizations (except Portugal) are linked to Wolschrijn. When looking at the structure of the 
systems, the largest evolution has been the number (and descriptions) of categories. The list by 
Wolschrijn included 7 categories. At first, the categories were copied (Belgium), but later on the 
categories were summarized and only three categories remained (Spain I). The most recent 
and extensive lists (France II and ICADTS) have maintained these three categories, but have 
added practical guidelines for patient and doctor. One list (ICADTS) introduced a calibration to 
BAC levels. 
 
Table 1: Comparison of classification and labeling systems 
 
# medicinal 
drugs Classification # categories 
Warning 
label Legal 
Wolschrijn 572 X 7   
Germany 406 Scale values   
Belgium 182 X 7   
Spain I (DGT/UVa) 363 X 3   
Spain II (semFYC/UVa) 395 X 4   
Spain    X  
France I (CERMT) 508 X 4   
France II (official) 311 X 3 X X 
ICADTS 389 X 3   
Portugal 241 X 5   
Greece I (legal) 89 NA  X 
Greece II (monographs) 92 NA   
The Netherlands 156 NA X  
Norway 87 NA X  
Denmark 83 NA X  
Finland 68 NA X  
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Figure 1: Relations between the different classification and labeling systems 
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Executive Summary D.4.2.1 
 
The establishment of criteria for a European categorization, based on expert 
consensus. 
 
 
 
The aim of this deliverable is to develop and agree on input for the establishment of a European 
categorisation system for medicines and driving. After a short review of the most significant 
existing developments of categorisation systems in Europe, a critical discussion has been 
presented to explain the need for such a categorisation system. It is clear that such a system 
will serve most of the needs of health care professionals, drug regulatory agencies, drug 
manufacturers and patients. For patients to make the best (and safest) use of their medicines, 
clear warnings and symbols are needed. Developments in France show clearly that a multi-level 
categorisation system is better in showing difference between the least and most impairing 
medicine within one therapeutic class and that warning labels are needed to guide patients in 
deciding about the use while taken the medicine. 
 
For the development of input for a European categorisation system it has been decided to 
address the Pharmacovigilance Working Party of the Committee for Medicinal Products for 
Human Use (CHPM). Together with WP 4 Partners three small-scale invitational workshops 
have been organised in 2008 in which representatives of regulatory agencies in 9 Member 
States participated. Based on their discussions a first step to harmonize the categorisation 
system could be achieved: the adoption of the Guidelines for the Summary of Product 
Characteristics in September 2009 (which applied as from 1st of May 2010), in which categories 
a) no or negligible influence, b) minor, c) moderate influence, and d) major influence on driving 
fitness are specified with some important guidance in special circumstances.  
 
In describing the various categories, discussions among WP 4 partners clearly showed that 
emphasis should be given to the evaluation of the active substances in order to increase the 
feasibility of such a system. In order to categorise a medicine with regard to driving, several 
steps are identified using data from different sources: pharmacodynamic and pharmacokinetic 
data; pharmaco-vigilance data, experimental and epidemiological data and additional data (e.g. 
from accidentology). In addition, for each category information for developing directions for 
health care professionals and warning levels and warning symbols could be presented. 
 
In the last two years (2010 and 2011) of Task 4.2 progress and steps forward based on the 
input from WP4 partners have been discussed with the Pharmacovigilance Working Party, 
resulting in consensus development based on a compromise. Currently national approaches 
differ substantially: from France at one end of the extreme (with three-level pictogram labelling) 
to Sweden at the other end where the existing pictogram was replaced with a generic warning in 
the patient leaflet. As a consequence the consensus was reached that a basic 2 level 
framework would be developed as the basis for warnings to the patient in the Patient 
Information Leaflet. For medicines without a potential relevant influence on driving (no or 
negligible, or minor influence) and for medicines with a potential relevant influence on driving 
(moderate influence, or major influence) the wording has been proposed.  
 
This consensus on the wording in the Patient Information Leaflet is another and important step 
to harmonize information to patients on a medicine’s impairing effects on fitness to drive. 
However, it is acknowledged by the Pharmaco-vigilance Working Party and WP4 partners that 
at the Member States’ level more activities are needed in order to reinforce the awareness of 
patients on the effects of medicines on fitness to drive, e.g. by the use of an alerting pictogram 
on the product packaging or further stratification of the number of categories of risk with a 
maximum of four.   
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In the recommendations of this Deliverable emphasis is given to improve information related to 
effects on driving in the Patient Information Leaflet by simple and patient-centred directions. The 
2 level systems for the Patient Information Leaflet should be further based on clarifying the 
criteria for the evidence in forming the categories. Therefore collaborative efforts by DRUID 
experts, and the members of the Pharmaco-vigilance Working Party, among other bodies, 
preferably with support of EU bodies, such as DG Sanco and DG Move, are recommended. 
Finally it is recommended, that the development of supplementary information for patients (e.g. 
warning levels and pictograms) and health care professionals (e.g. prescribing and dispensing 
guidelines) should be guided with input provided by DRUID results (D4.2.1, D 4.3.1, D 7.3.2 and 
D 7.4.2.) as well as experience in EU Member States. 
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Executive Summary D.4.3.1 
 
Establishment of framework for classification/categorisation and labelling of medicinal 
drugs and driving. 
 
 
 
The establishment of criteria for a European categorisation will have to serve most of the needs 
of all parties involved: health professionals, drug regulatory agencies, drug manufacturers and 
patients. Clear warnings and symbols are needed so patients use their medicines in the most 
optimal (and safest) way possible  
 
The DRUID WP4 expert group established and agreed that, according to its influence on the 
ability to drive, a medicine could, regarding to driving, be categorized as followed:  
 
• category 0 (no or negligible influence on fitness to drive),  
• category I (minor  influence on fitness to drive),  
• category II (moderate influence on fitness to drive),  
• and category III (severe influence on fitness to drive). 
 
The DRUID methodology on categorization/labelling on medicines and driving.  
 
In summary, categorisation of a medicine on driving includes several steps of evaluation after 
taken into account the conditions of use of the medicine on the European Union market: 
 
1. Pharmacodynamic and pharmacokinetic data 
2. Pharmacovigilance data (including prevalence of unwanted effects reported in the SmPC) 
3. Experimental and epidemiological data 
4. Additional data derived from the Patient Information Leaflet (PIL) and existing categorization 
systems 
5. Synthesis  
 
Basically conditions of use of the medicine, pharmacodynamics, pharmacokinetic data, and 
pharmacovigilance data (including prevalence of unwanted effects) were derived from the 
SmPC, while section 3 was based on a scientific literature search. Additional data step 
consisted of reviewing section 4.7 of the SmPC “Effects on ability to drive and use machines” 
and the PIL section on “driving and using machines” as well as reviewing the previous 
categorizations (if available) of the medicine in Belgium, France, Spain as well as to the 
ICADTS list. 
 
After evaluating all the available data, a provisional category was assigned to each active 
substance. The provisional category was proposed and discussed during WP4 meetings where 
a final and definitive category was assigned and approved by all WP4 partners.  
 
 
A mechanism for modifying the classification, based on new evidence.  
 
The existing methodology on DRUID categorization on medicines and driving, allows to, if new 
evidences emerges, re-categorise the medicine or confirm the previous categorisation following 
again the same 5 step process. 
 
 
Classification/categorization, labelling and patient oriented information for the relevant 
therapeutic groups of medicines available in the European Union market. 
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The aim of WP4 was to provide a categorization for the relevant therapeutic groups of 
medicines available on the European Union Market.  
 
In this way, DRUID task 4.3 was able to provide categorization, labelling and patient-oriented 
information for the following ATC groups (The Anatomical Therapeutic Chemical –ATC- 
classification system; http://www.whocc.no/). 
 
Individual medicines were categorized according to the DRUID classification system.   
 
A - ALIMENTARY TRACT AND METABOLISM 
B - BLOOD AND BLOOD FORMING ORGANS 
C - CARDIOVASCULAR SYSTEM 
D - DERMATOLOGICALS 
M - MUSCULO-SKELETAL SYSTEM 
N - NERVOUS SYSTEM 
N01 ANAESTHETICS 
N02 ANALGESICS 
N03 ANTIEPILEPTICS 
N04 ANTIPARKINSON 
N05 PSYCHOLEPTICS 
N05A Antipsychotics 
N05B Anxiolytics 
N05C Hypnotics and sedatives 
N06 PSYCHOANALEPTICS 
N06A Antidepressant 
N06B Psychostimulants, agents used for ADHD (Attention Deficit and 
Hyperactivity Disorder) and Nootropics 
N06C Psycholeptics and psychoanaleptics in combination 
N06D Anti-dementia drugs 
N07 OTHER NERVOUS SYSTEM  DRUGS 
R - RESPIRATORY SYSTEM 
S - SENSORY ORGANS 
 
Furthermore, Fact Sheets were produced for the N01-N07 (nervous system) and R06 
(respiratory system - antihistamines) ATC groups of medicines. Each fact sheet contains 
information on: source of information, presentations, indications, posology and method of 
administration, pharmacodynamic and pharmacokinetic properties, possible side-effects related 
to driving, Summary of Product Characteristics (SmPC) section 4.7 effects on effects on ability 
to drive and use machines, leaflet section on driving and using machines, studies on 
psychomotor performance and risk studies, current categorization in some EU countries, 
proposed  DRUID categorization, information for the patient, and place and date of agreement 
by the DRUID WP4 members. 
 
For analysis and categorisation The DRUID project has proposed a total of 3,054 medicines 
from these ATC groups. Of these 3,054 medicines, 1,513 have not been categorized, because 
they are not available on the European Union market (not available on DRUID WP4 countries 
Belgium, France, Greece, Germany, Netherlands, and Spain, as well as in the UK and Ireland), 
as there is no sense in categorizing/labelling medicines which are not available. 
 
The distribution of the 1,541 categorized medicines was as follows: Category 0 – 50,3%, 
Category I – 26%, Category II – 11,2%, Category III – 5,8%, Multiple category – 4,4% and the 
Depending on the medicine in combination 2,3%. 
 
 
Multiple categories: This appeared when a medicine can be included in more than one 
category. There can be several reasons for this: In most cases, the different categorization 
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depended on the route of administration (topical, oral, parenteral, etc). In the case of some 
medicines, in special ophthalmological preparations (S01), the different categorization 
depended on the presentation form of the medication (aqueous-vehicle, cream, drops or 
ointment, etc.), which is related with the duration of its action. In one case, codeine, 
categorization was based on the dose of codeine base administered. For two hypnotics, 
zolpidem and zaleplon, categorization was based on the time after the medication was taken. 
  
  
Depending on medicines in combination: This was stated when the categorization depended 
on another medicine combined with the one under evaluation.  
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DRUID WP4 categorization/labelling and patient-oriented information on medicines and driving: Alphabetical list  
      
 
 
A ATC CODE CATEGORIZATION 
labelling 
INFORMATION FOR THE PATIENT 
2-(4-chlorphenoxy)-ethanol D01AE06 NE NE 
Abciximab B01AC13 0 • No special advice 
Absorbable gelatine sponge  B02BC01 0 • No special advice 
Acadesine C01EB13 NE NE 
Acamprosate N07BB03 0 • The treatment has to be used according to the recommended dose. 
• Alcohol cessation can also cause behavioural changes and requires follow-up and 
counselling. 
• Driving with this treatment should require an approval by driving licence 
administration. 
Acarbose A10BF01 0 • No special advice 
Acebutolol C07AB04 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Acebutolol and thiazides C07BB04 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Aceclidine S01EB08 NE NE 
Aceclidine, combinations S01EB58 NE NE 
Aceclofenac M01AB16 I • Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
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treatment. 
Aceclofenac M02AA25 0 • No special advice 
Acefylline piperazine R03DA09 NE NE 
Acemetacin M01AB11 I • Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
  0 • No special advice 
Acepromazine N05AA04 NE NE 
Acetarsol A07AX02 NE NE 
Acetazolamide  
 
S01EC01 II • Inform the patient that this ocular medication causes drowsiness, fatigue and 
transient myopia which may impair the ability to drive or operate machinery.  
• Advise the patients to exercise caution in night driving and other hazardous 
occupations in conditions of poor illumination. 
Acetic acid S02AA10 NE NE 
Acetohexamide A10BB31 NE NE 
Acetophenazine N05AB07 NE NE 
Acetoxolone A02BX09 NE NE 
Acetylcarnitine N06BX12 NE NE 
Acetylcarnitine N06BX12 NE NE 
Acetylcholine  
 
S01EB09 II • Inform the patient that this ocular medication causes miosis which usually results in 
difficulties for his/her sight to adapt to the dark.  
• Advise the patients to exercise caution in night driving and other hazardous 
occupations in conditions of poor illumination 
Acetylcysteine R05CB01 
S01XA08 
0 • No special advice 
 
Acetyldigitoxin C01AA01 NE NE 
Acetyldigoxin C01AA02 NE NE 
Acetyldigoxin, combinations C01AA52 NE NE 
Acetyldihydrocodeine R05DA12 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (drowsiness, sedation) 
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• Advise the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Acetylglycinamide 
chloralhydrate 
N05CC03 NE NE 
Acetylic acid and 
corticosteroids 
M01BA03 NE NE 
Acetylleucine N07CA04 NE NE 
Acetylsalicylic acid A01AD05 
B01AC06 
N02BA01 
0 • No special advice 
 
 
Acetylsalicylic acid, 
combinations excl 
psycholeptics 
N02BA51 NE NE 
Acetylsalicylic acid, 
combinations with 
psycholeptics 
N02BA71 NE NE 
Acexamato de zinc A02BX 0 • No special advice 
Aciclovir D06BB03 0 • No special advice 
Aciclovir S01AD03 I  • Inform the patient that as with any ocular medication, if transient, blurred vision 
occurs at application.  
• Advice the patient that he/she should wait until his/her vision clears before driving or 
using machinery 
Aciclovir, combinations D06BB53 NE  
Acipimox C10AD06 0 • No special advice 
Acitretin  D05BB02 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (blurred or decreased night vision) and not to drive as long as 
side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Acriflavinium chloride R02AA13 NE  
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Acrivastine R06AX18 I • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
insomnia) 
• Advise the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Adapalene D10AD03 0 • No special advice 
Adapalene, combinations D10AD53 0 • No special advice 
Ademetionine A16AA02 NE  
Adenosine C01EB10 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Adinazolam N05BA07 NE NE 
Adrafinil N06BX17 NE NE 
Adrafinil N06BX17 NE NE 
Adrenalone A01AD06 NE NE 
Adrenalone B02BC05 NE NE 
Agalsidase alfa  A16AB03 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, somnolence, lethargy, lacrimation increased, 
tinnitus, vertigo, etc.) particularly during the first day of treatment, and not to drive as 
long as side-effects persist. 
Agalsidase beta  A16AB04 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, somnolence, lethargy, lacrimation increased, 
tinnitus, vertigo, etc.) particularly during the first day of treatment, and not to drive as 
long as side-effects persist. 
Agomelatine N06AX22 II • Inform your patient about the effects of the medication on reaction time as well as 
that the medication can cause side-effects that impair driving abilities (e.g. dizziness, 
drowsiness, sleepiness, blurred vision, etc.). 
• Advice your patient not to drive for the first few weeks of treatment or until the next 
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visit and to be careful in other situations, as well (e.g. operating machinery and 
working at heights). 
• Advice your patient not to drink alcohol nor use any other psychoactive substance 
when taking this medication. 
• In case of short-term use of the medication, advice your patient not to drive because 
his/her driving skills are still impaired for approximately 24 hours. 
Ajmaline C01BA05 NE  
Alanyl glutamine B05XB02 NE  
Alaproclate N06AB07 NE  
Albumin  B05AA01 0 • No special advice 
Albumin tannate A07XA01 NE  
Albumin tannate, combinations A07XA51 NE  
Alclofenac M01AB06 NE  
Alclometasone D07AB10 0 • No special advice 
Alclometasone S01BA10 NE  
Alcuronium M03AA01 III • Advise the patient not to drive or operate machinery until the effects of the 
anaesthetic, and the immediate effects of surgery have passed. 
• Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after 
anaesthesia 
Alendronic acid M05BA04 0 • No special advice 
Alendronic acid and 
colecalciferol 
M05BB03 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. headache, dizziness, and not to drive as long as side-
effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication 
Alfa1 antitrypsin B02AB02 0 • No special advice 
Alfacalcidol A11CC03 0 • No special advice 
 Alfaxalone N01AX05 NE  
 Alfentanil N01AH02 III • Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient (and explain to caregivers) not to drive until the next visit after start 
of treatment or after changes in dosage. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
 DRUID 6th Framework Programme         Deliverable D.4.4.1  
   Classification of medicinal drugs and driving: 
 Co-ordination and synthesis report.  
   Page 18 of 243 
 
  
 
   
 
 
machinery and working at heights) 
• Advise the patient to strictly follow the prescribed doses and the intake scheme.  
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
• Opiate cessation can also cause behavioral changes and requires follow-up and 
counseling. 
Algeldrate A02AB02 0 • No special advice 
Alginic acid A02BX13 NE  
Alglucerase A16AB01 NE  
Alglucosidase alfa  A16AB07 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, somnolence, lethargy, lacrimation increased, 
tinnitus, vertigo, etc.) particularly during the first day of treatment, and not to drive as 
long as side-effects persist. 
Alimemazine R06AD01 III • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred vision, tremor and reduced alertness) 
• Advise the patient not to drive until the next visit after start of treatment and also to 
be careful in other situations (e.g. using machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Alipogene tiparvovec C10AX10 NE  
Aliskiren C09XA02 0 • No special advice 
Aliskiren and 
hydrochlorothiazide 
C09XA52 0 • No special advice. 
 
Alitretinoin  
- Oral administration 
- Topical use 
D11AX19  
I 
 
0 
• Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (blurred or decreased night vision) and not to drive as long as 
side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Alizapride A03FA05 NE  
Allobarbital N05CA21 NE  
Allopurinol M04AA01 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. somnolence, dizziness   vertigo or ataxia), and not to 
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drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Allopurinol, combinations M04AA51 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. somnolence, dizziness   vertigo or ataxia), and not to 
drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Almagate A02AD03 0 • No special advice 
Almasilate A02AD05 0 • No special advice 
Alminoprofen M01AE16 NE  
Almitrine R07AB07 I • Inform the patient about the effects that the medicine can have on reaction time and 
that the medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advise the patient not to drive when this side effects occur and also to be careful in 
other situations (e.g. using machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Almotriptan N02CC05 II • Advise the patient not to drive during the first times, the drug is administered, until 
he/she knows his/her reactions.   
• Advise the patient not to drive within the first 4 hours after treatment. 
• Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to strictly follow the prescribed doses and intake scheme.  
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
Alogliptin A10BH04 NE  
Aloglutamol   A02AB06 0 • No special advice 
Alosetron A03AE01 NE  
Aloxiprin B01AC15 
N02BA02 
NE  
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Alprazolam N05BA12 III • Inform the patient about the effects of the medicine on reaction time, that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) and that reaction time can 
also be reduced without experiencing side effects. 
• Advice the patient not to drive until the next visit after start of treatment and also to 
be careful in other situations (e.g. using machinery and working at heights) 
• Advice the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
• One time (occasional) use: inform your patient that his/her response is still reduced 
for approximately 3 days. Advice your patient not to drive then. 
Alprenolol C07AA01 I • No special advice 
Alprostadil C01EA01 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Alteplase B01AD02 0 • No special advice 
Alteplase S01XA13 NE  
Althea root R05CA05 NE  
Altizide and potassium-sparing 
agents (spironolactone) 
C03EA04 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Alum S01XA07 NE  
Aluminium acetoacetate A02AB05 0 • No special advice 
Aluminium acetotartrate S02AA04 NE  
Aluminium chloride D10AX01 0 • No special advice 
Aluminium chlorohydrate D09AA08 
M05BX02 
NE  
Aluminium clofibrate C10AB03 NE  
Aluminium glycinate  A02AB07 0 • No special advice 
Aluminium hydroxide A02AB01 0 • No special advice 
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Aluminium nicotinate C10AD04 NE  
Aluminium oxide D10AX04 NE  
Aluminium phosphate A02AB03 0 • No special advice 
Aluminium preparations C05AX01 0 • No special advice 
Alverine A03AX08 0 • No special advice 
Alverine, combinations A03AX58 NE  
Alvimopan A06AH02 NE  
 Amantadine N04BB01 I • Advise the patient (and explain to caregivers) not to drive during the first days of 
treatment. 
• Some central nervous system unwanted effects (like confusion) are more common 
when amantadine is administered concurrently with anticholinergic agents. 
Ambazone R02AA01 NE  
Ambenonium N07AA30 NE  
Ambrisentan C02KX02 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Ambroxol R05CB06 0 • No special advice 
Ambutonium and 
psycholeptics 
A03CA07 NE  
Amcinonide   D07AC11 NE  
Amfepramone A08AA03 NE  
Amfetamine N06BA01 NE  
Amfetamine N06BA01 NE  
Amifampridine N07XX05 II • Advise the patient (and explain to caregivers) not to drive during the first days of 
treatment.   
• The treatment has to be used according to the recommended dose.  
• Vertigo and hearing loss requiring this treatment can also impair ability to drive. 
Amikacin D06AX12 0 • No special advice 
Amikacin S01AA21 NE  
Amiloride C03DB01 0 • No special advice. 
Amineptine N06AA19 NE  
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 Amino (diphenylhydantoin) 
valeric acid 
N03AB03 NE  
Amino acids B05BA01 0 • No special advice 
Aminoacridine D08AA02 0 • No special advice 
Aminobenzoic acid D02BA01 0 • No special advice 
 Aminobutyric acid (GABA) N03AG03 NE  
Aminomethylbenzoic Acid B02AA03 NE  
Aminophenazone N02BB03 NE  
Aminophenazone, 
combinations excl. 
Psycholeptics 
N02BB53 NE  
Aminophenazone, 
combinations with. 
Psycholeptics 
N02BB73 NE  
Aminophylline 
 
R03DA05 0 
 
I 
Oral: 
• No special advice  
Parenteral: 
• Inform the patient about the effects that the medicine can have on reaction time and 
that the medication can cause side effects that impair driving (insomnia, confusion, 
anxiety, vertigo, dizziness, tremor, visual disturbances) 
• Advise the patient not to drive when this side effects occur and also to be careful in 
other situations (e.g. using machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Aminophylline and adrenergics R03DB05 NE  
Aminophylline, combinations R03DA55 NE  
Amiocaproic acid  B02AA01 0 • No special advice 
Amiodarone C01BD01 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Amisulpride N05AL05 II • Inform the patient about the effects of the medicine on reaction time and that the 
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medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advice the patient not to drink alcohol when taking this medicine. 
Amitriptyline N06AA09 III • Inform your patient about the effects of the medication on reaction time as well as 
that the medication can cause side-effects that impair driving abilities (e.g. dizziness, 
drowsiness, sleepiness, blurred vision, etc.). 
• Advice your patient not to drive until the next visit and to be careful in other 
situations, as well (e.g. operating machinery and working at heights). 
• Advice your patient not to drink alcohol nor use any other psychoactive substance 
when taking this medication. 
• In case of short-term use of the medication, advice your patient not to drive because 
his/her driving skills are still impaired for approximately 24 hours. 
Amitryptiline and psycholeptics N06CA01 NE  
Amitryptiline and psycholeptics N06CA01 NE  
Amlexanox A01AD07 
R03DX01 
NE  
Amlodipine C08CA01 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Ammonium chloride B05XA04 0 • No special advice 
Amobarbital N05CA02 NE  
Amorolfine  D01AE16 0 • No special advice 
Amoxapine N06AA17 NE  
Amphotericin B  A01AB04 
A07AA07 
0 • No special advice 
 
Ampicilin S01AA19 NE  
Amrinone C01CE01 NE  
Ancrod B01AD09 NE  
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Androstanolone A14AA01 NE  
Anecortave S01LA02 NE  
Anethole trithione A16AX02 NE  
Angiotensinamide C01CX06 NE  
 Anileridine N01AH05 NE  
Aniracetam N06BX11 NE  
Anistreplase B01AD03 NE  
Antazoline R01AC04 
R06AX05 
NE  
Antibiotics in combination  with 
other drugs 
S01AA20 Depending on the 
medicine in 
combination 
Depending on the medicine in combination 
Antiinfectives, combinations S02AA30 0 • No special advice 
Antiinfectives, combinations S03AA30 0 • No special advice 
Antimony pentasulfide R05CA07 NE  
Antithrombin III B01AB02 0 • No special advice 
 Apomorphine N04BC07 II • Advise the patient (and explain to caregivers) not to drive during the first days of 
treatment. 
• Inform patients that unwanted effects are seen rapidly during the dosage adjustment 
period. 
• Advise the patient not to drive if the medication makes you sleepy. 
• Advise the patient (and explain to caregivers) not to drive at all if suffering from 
“sleep attacks”. 
• Advise the patient (and explain to caregivers) not to drive at all if suffering from 
severe fluctuations in mobility “(“on-off” phenomena). 
Apraclonidine S01EA03 II • Inform the patient that this ocular medication may cause fatigue and/or drowsiness, 
blurred and/or abnormal vision which may impair the ability to drive or operate 
machinery, especially at night or in reduced lighting.                                                                                                                                                                   
• Advise the patient that he/she should wait until these symptoms have cleared before 
driving or using machinery. 
Aprepitant A04AD12 0 • No special advice 
Aprindine C01BB04 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
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etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Aprobarbital N05CA05 NE  
Apronal N05CM12 NE  
Aprotinin B02AB01 0 • No special advice 
Arbutamine C01CA22 NE  
Argatroban B01AE03 NE  
Arginine glutamate  A05BA01 NE  
Arginine hydrochloride B05XB01 NE  
Aripiprazole 
 
N05AX12 II 
 
 
 
 
 
 
 
 
III 
Oral administration: 
• Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first few days of treatment or until the next 
visit after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advice the patient not to drink alcohol when taking this medicine. 
 
Parenteral administration 
• Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive until the next visit after start of treatment and also to 
be careful in other situations (e.g. using machinery and working at heights) 
• Advice the patient not to drink alcohol when taking this medicine. 
 Articaine N01BB08 NE  
 Articaine combinations N01BB58 0 
 
 
 
I 
 
 
Categorization, labelling and information to the patient  depending of the route of 
administration 
 
Topic administration (skin, mucous) 
 
Infiltration (dental anaesthesia) 
Intrarticular, intrabursal, tendon sheath administration, etc.. 
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II 
 
 
 
 
 
III 
 
 
- Advise the patient not to drive or operate machinery until the effect of the 
anaesthesia and the immediate effects of surgery are passed. 
 
Ocular administration: 
- Advise at the patient that their sight may become blurred, and not to drive or operate 
machinery during the first 24 hours after using local anesthetics. 
 
Regional anaesthesia (nerve-block, intravenous regional anaesthesia). 
Spinal /Epidural 
- Advise the patient (and explain to caregivers), in the event an early discharge is 
envisaged following  regional / epidural / spinal anaesthesia, not to drive or operate 
machinery during the first 24 hours after anaesthesia.  
- Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after 
anaesthesia 
Artificial tears and other 
indifferent preparations 
S01XA20 0 • No special advice 
Ascorbic acid S01XA15 NE  
Astemizole  R06AX11 I • Inform the patient about the effects that the medicine can have on reaction time and 
that the medication can cause side effects that impair driving (somnolence, 
insomnia, drowsiness) 
• Advise the patient not to drive when this side effects occur and also to be careful in 
other situations (e.g. using machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Atenolol C07AB03 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Atenolol - chlortalidone C07FB03 NE  
Atenolol - nifedipine C07FB03 NE  
Atenolol and other 
antihypertensives 
C07FB03 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
 DRUID 6th Framework Programme         Deliverable D.4.4.1  
   Classification of medicinal drugs and driving: 
 Co-ordination and synthesis report.  
   Page 27 of 243 
 
  
 
   
 
 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Atenolol and other diuretics C07CB03 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Atenolol and other diuretics, 
combinations 
C07CB53 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Atenolol and thiazide C07BB03 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Atenolol, thiazides and other 
diuretics 
C07DB01 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Atomoxetine N06BA09 I • Inform your patient about the effects of the medication on reaction time as well as 
that the medication can cause side-effects that impair driving abilities (e.g. dizziness, 
drowsiness, sleepiness, blurred vision, etc.). 
• Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities. 
• Advise your patient not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any other psychoactive substance 
when taking this medication. 
Atorvastatin C10AA05 0 • No special advice 
Atorvastatin and amlodipine C10BX03 NE  
Atracurium M03AC04 III • Advise the patient not to drive or operate machinery until the effects of the 
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anaesthetic, and the immediate effects of surgery have passed. 
• Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after 
anaesthesia 
Atropine  A03BA01 III 
 
 
 
 
 
 
• Inform the patient that this medication may cause dilated pupils with loss of 
accommodation and photophobia and increased intraocular pressure and headache, 
mental confusion or excitement (especially in the elderly), drowsiness, which may 
impair their ability to drive.  
• Advise the patient not to drive until the next visit after start of treatment and also to 
be careful in other situations (e.g. using machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Atropine S01FA01 III • Inform the patient that this ocular medication may cause transient blurring of vision 
or that he/she may suffer from photophobia and that this may impair their ability to 
drive under certain circumstances. Complete recovery from the effects of mydriatic 
anticholinergics may take up to 24 hours. 
• Advise the patients not to drive or operate hazardous machinery until 24 hours after 
receiving ocular medication (recovery occurs within 24 hours) or until vision is clear. 
Atropine and psycholeptics A03CB03 NE  
Atropine+escopolamine+pheny
lephrine 
S01FAP1 III • Inform the patient that this ocular medication may cause transient blurring of vision 
or that he/she may suffer from photophobia and that this may impair their ability to 
drive under certain circumstances. Complete recovery from the effects of mydriatic 
anticholinergics may take up to 24 hours. 
• Advise the patients not to drive or operate hazardous machinery until 24 hours after 
receiving ocular medication (recovery occurs within 24 hours) or until vision is clear. 
Attapulgite A07BC04 NE  
Attapulgite, combinations 
(combination with morphine) 
A07BC54 II • Inform the patient that the medication can cause side effects (dizziness, drowsiness 
and somnolence) Patients receiving it should not drive or operate machinery unless 
it has been shown that their physical and mental capacity remains unaffected. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights). 
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
Auranofin M01CB03 NE  
Aurothioglucose M01CB04 NE  
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Aurotioprol M01CB05 NE  
Azapetine C04AX30 NE  
Azapropazone M01AX04 NE  
Azatadine R06AX09 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness) 
• Advise the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Azelaic acid D10AX03 0 • No special advice 
 R06AX19 
 
 
 
 
 
I 
 
 
 
 
 
• Inform the patient about the effects that the medicine can have on reaction time and 
that the medication can cause side effects that impair driving (drowsiness, 
somnolence) 
• Advise the patient not to drive when this side effects occur and also to be careful in 
other situations (e.g. using machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Azelastine S01GX07 I • Inform the patient that this ocular medication may cause side effects including local 
irritation, temporary blurred vision or other visual disturbances, transient stinging and 
burning after instillation. 
• Advise the patient that if he/she experiences these symptoms, he/she should wait 
until they have cleared before driving or using machinery. 
Azelastine antazoline R01AC03 0 • No special advice 
Azidamfenicol S01AA25 NE  
Azithromycin S01AA26 0 • No special advice 
    
B ATC CODE CATEGORIZATION 
labelling 
INFORMATION FOR THE PATIENT 
Bacitracin D06AX05 0 • No special advice 
Bacitracin R02AB04 NE  
Baclofen M03BX01 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
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sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advice the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
• One time (occasional) use: inform your patient that his/her response is reduced. 
Advice your patient not to drive then. 
Balsalazide A07EC04 0 • No special advice 
Bambuterol R03CC12 NE  
Bamethan C04AA31 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Bamifylline R03DA08 NE  
Bamipine D04AA15 
R06AX01 
NE  
 Barbexaclone N03AA04 NE  
Barbital N05CA04 NE  
Barbiturates in combinations 
with other drugs 
N05CB02 NE  
Barnidipine C08CA12 NE  
Batroxobin  B02BX03 NE  
Becaplermin A01AD08 
D03AX06 
0 • No special advice 
 
 Beclamide N03AX30 NE  
Beclometasone A07EA07 
D07AC15 
R01AD01 
R03BA01 
0 • No special advice 
 
Beclometasone and antibiotics D07CC04 0 • No special advice 
Befunolol S01ED06 I • Inform the patient that as with any ocular medication, if transient, blurred vision 
 DRUID 6th Framework Programme         Deliverable D.4.4.1  
   Classification of medicinal drugs and driving: 
 Co-ordination and synthesis report.  
   Page 31 of 243 
 
  
 
   
 
 
occurs at application.  
• Advice the patient that he/she should wait until his/her vision clears before driving or 
using machinery. 
Belladonna total alkaloids A03BA04 NE  
Belladonna total alkaloids and 
psycholeptics 
A03CB02 NE  
Bemegride R07AB05 NE  
Bemiparin B01AB12 0 • No special advice 
Benazepril C09AA07 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Benazepril and diuretics C09BA07 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Bencyclane C04AX11 NE  
Bendazac M02AA11 
S01BC07 
NE  
Bendroflumethiazide C03AA01 0 • No special advice 
Bendroflumethiazide and 
potassium 
C03AB01 0 • No special advice 
Bendroflumethiazide and 
potassium-sparing agents 
(spirolactone) 
C03EA13 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Benflumethiazide - reserpine C02LA01 NE  
Benfluorex A10BX06 
C10AX04 
NE  
Benfotiamine  A11DA03 0 • No special advice 
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Benidipine C08CA15 NE  
Benorilate N02BA10 NE  
Benoxaprofen M01AE06 NE  
Benperidol N05AD07 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advice the patient not to drink alcohol when taking this medicine. 
Benproperine R05DB02 NE  
Benzalkonium  D08AJ01 
D09AA11 
R02AA16 
0 • No special advice 
 
 
 Benzatropine N04AC01 NE  
 Benzbromarone M04AB03 NE  
Benzethonium R02AA09 NE  
Benzethonium chloride D08AJ08 0 • No special advice 
Benzethonium chloride, 
combinations 
D08AJ58 0 • No special advice 
Benzilone A03AB01 NE  
Benziodarone C01DX04 NE  
Benziodarone, combinations C01DX54 NE  
Benzocaine C05AD03 
D04AB04 
0 • No special advice  
 
Benzocaine N01BA05 
 
 
 
 
 
 
 
 
 
 
 
0 
 
 
 
 
I 
Categorization, labelling and information to the patient  depending of the route 
of administration 
 
Topic administration (skin, mucous) 
 
Infiltration (dental anaesthesia) 
Intrarticular, intrabursal, tendon sheath administration, etc.. 
- Advise the patient not to drive or operate machinery until the effect of the 
anaesthesia and the immediate effects of surgery are passed. 
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R02AD01 
 
 
 
 
II 
 
 
 
 
III 
 
 
Ocular administration: 
- Advise at the patient that their sight may become blurred, and not to drive or operate 
machinery during the first 24 hours after using local anesthetics. 
 
Regional anaesthesia (nerve-block, intravenous regional anaesthesia). 
Spinal /Epidural 
- Advise the patient (and explain to caregivers), in the event an early discharge is 
envisaged following  regional / epidural / spinal anaesthesia, not to drive or operate 
machinery during the first 24 hours after anaesthesia.  
- Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after 
anaesthesia 
Benzocaine R02AD01 0 • No special advice 
Benzoctamide N05BD01 NE  
Benzododecinium D09AA05 NE  
Benzonatate R05DB01 NE  
Benzoxonium chloride A01AB14 
D08AJ05 
NE  
Benzoyl peroxide D10AE01 0 • No special advice 
Benzoyl peroxide, 
combinations 
D10AE51 0 • No special advice 
Benzydamine A01AD02 
M02AA05 
0 • No special advice 
Benzydamine M01AX07 
 
I • Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
Benzylpenicilin S01AA14 NE  
Bepridil C08EA02 NE  
Beraprost B01AC19 NE  
Bergapten D05BA03 NE  
Betacarotene A11CA02 0 • No special advice 
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D02BB01  
Betahistine N07CA01 I • The treatment has to be used according o the recommended dose to avoid side 
effect on driving. 
• Vertigo and hearing loss requiring this treatment can also impair ability to drive. 
Betaine A16AA06 0 • No special advice 
Betaine hydrochloride A09AB02 NE  
Betamethasone A07EA04 
C05AA05 
D07AC01 
D07XC01 
R01AD06 
0 • No special advice 
 
Betamethasone R03BA04 
S01BA06 
S02BA07 
S03BA03 
NE  
Betamethasone 
(Corticosteroids/antiinfectives/
mydriatics in combination) 
S01CB04 Depending on the 
mydriatic in 
combination 
• Depending on the mydriatic in combination 
Betamethasone and antibiotics D07CC01 0 • No special advice 
Betamethasone and 
antiinfectives 
- Drops 
- Oinment 
S01CA05  
0 
I 
• Inform the patient that as with any ocular medication, if transient, vision occurs at 
application.  
• Advice the patient that he/she should wait until his/her vision clears before driving or 
using machinery. 
Betamethasone and 
antiinfectives 
S03CA06 0 • No special advice 
Betamethasone and 
antiseptics 
D07BC01 0 • No special advice 
Betamethasone and mydriatics S01BB04 Depending on the 
mydriatic in 
combination 
• Depending on the mydriatic in combination 
Betanidine C02CC01 NE  
Betaxolol C07AB05 
 
 
I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
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• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Betaxolol S01ED02 I • Inform the patient that as with any ocular medication, if transient, blurred vision 
occurs at application.  
• Advice the patient that he/she should wait until his/her vision clears before driving or 
using machinery. 
Betaxolol, combinations S01ED52 NE  
Bethanechol N07AB02 NE  
Bevantolol C07AB06 NE  
Bevantolol and thiazides C07BB06 NE  
Bevonium A03AB13 NE  
Bevonium and Analgesics A03DA03 NE  
Bevonium and psycholeptics A03CA06 NE  
Bezafibrate C10AB02 0 • No special advice 
Bezitramide N02AC05 NE  
Bibenzonium bromide R05DB12 NE  
Bibrocathol S01AX05 NE  
Bietaserpine C02AA07 NE  
Bietaserpine and diuretics C02LA07 NE  
Bietaserpine, combinations C02AA57 NE  
Bifemelane N06AX08 NE  
Bifonazole D01AC10 NE  
Bifonazole, combinations D01AC60 NE  
Bimatoprost  S01EE03 I • Inform the patient that as with any ocular medication, if transient, blurred vision 
occurs at application.  
• Advice the patient that he/she should wait until his/her vision clears before driving or 
using machinery. 
Biotin A11HA05 0 • No special advice 
Biperiden  
- Oral administration 
- Parenteral administration 
N04AA02  
II 
III 
• Advise the patient (and explain to caregivers) not to drive during the first days of 
treatment. 
• Inform patients that unwanted effects are seen rapidly during the dosage adjustment 
period. 
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• Advise the patient (and explain to caregivers) not to drive at all if suffering from “sleep 
attacks”. 
• Advise the patient (and explain to caregivers) not to drive at all if suffering from 
severe fluctuations in mobility “(“on-off” phenomena). 
Biphenylol D08AE06 NE  
Bisacodyl A06AB02 
A06AG02 
0 • No special advice 
 
Bisacodyl, combinations A06AB52 0 • No special advice 
Bismuth preparations, 
combinations 
C05AX02 0 • No special advice 
 
Bismuth subcitrate A02BX05 0 • No special advice 
Bismuth subnitrate A02BX12 NE  
Bisoprolol C07AB07 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Bisoprolol - 
hydrochlorothiazide 
C07BB 
Not yet 
determined 
NE  
Bisoprolol and thiazide C07BB07 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Bisoprolol, combinations C07AB57 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Bisoxatin A06AB09 NE  
Bithionol D10AB01 NE  
Bitolterol R03AC17 NE  
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Bivalirudin B01AE06 0 • No special advice 
Blood plasma B05AX03 NE  
Bopindolol C07AA17 NE  
Bopindolol and other diuretics C07CA17 NE  
Boric acid  S02AA03 NE  
 Bornaprine N04AA11 NE  
Bosentan C02KX01 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Botulinum toxin A 
Botulinum toxin B 
M03AX01 II 
II 
• Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (muscle weakness, 
somnolence, dizziness and visual disturbance) 
• Advice the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advice the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Bretylium tosilate C01BD02 NE  
Brimonidine S01EA05 II • Inform the patient that this ocular medication may cause fatigue and/or drowsiness, 
blurred and/or abnormal vision which may impair the ability to drive or operate 
machinery, especially at night or in reduced lighting.                                                                                                                                                                   
• Advise the patient that he/she should wait until these symptoms have cleared before 
driving or using machinery. 
Brinase B01AD06 NE  
Brinzolamide S01EC04 I • Inform the patient that as with any ocular medication, if transient, blurred vision 
occurs at application.  
• Advice the patient that he/she should wait until his/her vision clears before driving or 
using machinery. 
Bromazepam N05BA08 III • Inform the patient about the effects of the medicine on reaction time, that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) and that reaction time can 
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also be reduced without experiencing side effects. 
• Advice the patient not to drive until the next visit after start of treatment and also to 
be careful in other situations (e.g. using machinery and working at heights) 
• Advice the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
• One time (occasional) use: inform your patient that his/her response is still reduced 
for approximately 3 days. Advice your patient not to drive then. 
Bromazine R06AA01 NE  
Bromelains B06AA11 NE  
Bromhexine R05CB02 0 • No special advice 
Bromides N05CM11 NE  
Bromisoval N05CM03 NE  
Bromochlorosalicylanilide D01AE01 NE  
 Bromocriptine N04BC01 II • Advise the patient (and explain to caregivers) not to drive during the first days of 
treatment. 
• Inform patients that unwanted effects are seen during the dosage adjustment period. 
• Advise the patient (and explain to caregivers) to avoid drinking alcohol whilst taking 
the medicine 
• Advise the patient (and explain to caregivers) not to drive at all if suffering from 
“sleep attacks”. 
• Advise the patient (and explain to caregivers) not to drive at all if suffering from 
severe fluctuations in mobility “(“on-off” phenomena). 
Bromopride A03FA04 NE  
Bromperidol 
- Oral administration 
- Parenteral administration: 
depot i.m. 
N05AD06 II 
 
 
 
 
 
 
 
 
III 
Oral administration: 
• Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advice the patient not to drink alcohol when taking this medicine. 
 
Parenteral administration 
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• Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive until the next visit after start of treatment and also to 
be careful in other situations (e.g. using machinery and working at heights) 
• Advice the patient not to drink alcohol when taking this medicine. 
Brompheniramine R06AB01 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
restlessness, sedation) 
• Advise the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Brompheniramine, 
combinations 
R06AB51 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
restlessness, sedation) 
• Advise the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Brotizolam N05CD09 III • Inform the patient about the effects of the medicine on reaction time, that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) and that reaction time can 
also be reduced without experiencing side effects. 
• Advice the patient not to drive until the next visit after start of treatment and also to 
be careful in other situations (e.g. using machinery and working at heights) 
• Advice the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
• One time (occasional) use: inform your patient that his/her response is still reduced 
for approximately 24 hours. Advice your patient not to drive then. 
Broxyquinoline A07AX01 NE  
Bucetin N02BE04 NE  
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Bucetin, combinations excl. 
Psycholeptics 
N02BE54 NE  
Bucetin, combinations with 
Psycholeptics 
N02BE74 NE  
Bucillamine M01CC02 NE  
Bucladesine C01CE04 NE  
Buclizine R06AE01 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred vision and reduced alertness) 
• Advise the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Buclizine, combinations R06AE51 II 
 
 
•  Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness and 
reduced alertness) 
• Advise the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Budesonide  A07EA06 
D07AC09 
R01AD05 
R03BA02 
0 • No special advice 
 
 
 
 Budipine N04BX03 NE  
Bufexamac M01AB17 
M02AA09 
NE  
Buflomedil C04AX20 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
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Buformin A10BA03 NE  
Bufylline  R03DA10 NE  
Bumadizone M01AB07 NE  
Bumetanide C03CA02 0 • No special advice 
Bumetanide and potassium C03CB02 0 • No special advice 
Bumetanide and potassium-
sparing agents 
C03EB02 0 • No special advice 
Bunaftine C01BD03 NE  
Buphenine C04AA02 I Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) 
and not to drive as long as side-effects persist. 
  
Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
 Bupivacaine N01BB01  
 
 
0 
 
 
 
I 
 
 
 
II 
 
 
 
III 
Categorization, labelling and information to the patient  depending of the route of 
administration 
 
Topic administration (skin, mucous) 
 
Infiltration (dental anaesthesia) 
Intrarticular, intrabursal, tendon sheath administration, etc.. 
• Advise the patient not to drive or operate machinery until the effect of the 
anaesthesia and the immediate effects of surgery are passed. 
 
Ocular administration: 
• Advise at the patient that their sight may become blurred, and not to drive or operate 
machinery during the first 24 hours after using local anesthetics. 
 
Regional anaesthesia (nerve-block, intravenous regional anaesthesia). 
Spinal /Epidural 
• Advise the patient (and explain to caregivers), in the event an early discharge is 
envisaged following  regional / epidural / spinal anaesthesia, not to drive or operate 
machinery during the first 24 hours after anaesthesia.  
• Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after 
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anaesthesia 
 Bupivacaine combinations 
 
N01BB51  
 
 
0 
 
 
 
I 
 
 
 
II 
 
 
 
III 
Categorization, labelling and information to the patient  depending of the route of 
administration 
 
Topic administration (skin, mucous) 
 
Infiltration (dental anaesthesia) 
Intrarticular, intrabursal, tendon sheath administration, etc.. 
• Advise the patient not to drive or operate machinery until the effect of the 
anaesthesia and the immediate effects of surgery are passed. 
 
Ocular administration: 
• Advise at the patient that their sight may become blurred, and not to drive or operate 
machinery during the first 24 hours after using local anesthetics. 
 
Regional anaesthesia (nerve-block, intravenous regional anaesthesia). 
Spinal /Epidural 
• Advise the patient (and explain to caregivers), in the event an early discharge is 
envisaged following  regional / epidural / spinal anaesthesia, not to drive or operate 
machinery during the first 24 hours after anaesthesia.  
• Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after 
anaesthesia 
Bupranolol C07AA19 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Buprenorphine 
- Oral administration 
- Parenteral admin. 
- Transdermal admin  
N02AE01 
 
 
 
 
 
III 
III 
III/II* 
*) prolonged release 
formulation; when a 
steady state of 
• Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient (and explain to caregivers) not to drive until the next visit after 
start of treatment or after changes in dosage. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to strictly follow the prescribed doses and the intake scheme.  
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dosage has been 
reached 
• Advise the patient  to avoid any alcohol or other psychoactive substances during the 
treatment. 
• Opiate cessation can also cause behavioral changes and requires follow-up and 
counseling. 
Buprenorphine 
- Oral administration: 
- Transdermal patch:  
- Parenteral administration: 
N07BC01  
II 
 
II 
 
III 
• Advise the patient (and explain to caregivers) not to drive during the first days of 
treatment and after changes in doses. 
• Advise the patient to strictly follow the prescribed doses, the treatment and delivery 
procedures and to avoid any alcohol or other psychoactive substances during the 
treatment. 
• Opiate cessation can also cause behavioural changes and requires follow-up and 
counselling. 
• Driving with this treatment should require an approval by driving licence 
administration. 
Buprenorphine, combinations 
(buprenorphine+naloxone) 
N07BC51 
III 
• Advise the patient (and explain to caregivers) not to drive during the first days of 
treatment and after changes in doses. 
• Advise the patient to strictly follow the prescribed doses, the treatment and delivery 
procedures and to avoid any alcohol or other psychoactive substances during the 
treatment. 
• Opiate cessation can also cause behavioural changes and requires follow-up and 
counselling. 
• Driving with this treatment should require an approval by driving licence 
administration. 
Bupropion (amfebutamone) N07BA02 II • Advise the patient (and explain to caregivers) not to drive during the first days of 
treatment and after changes in doses. 
• The treatment has to be used according to the recommended dose. 
• Advise the patient about possibles effects on behavior. 
• Smoking cessation can also cause behavioural changes. 
Buspirone N05BE01 I • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first few hours after taking the medicine and 
also to be careful in other situations (e.g. using machinery and working at heights) 
• Advice the patient not to drink alcohol or use other psychoactive substances when 
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taking this medicine. 
Butalamine C04AX23 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Butamirate R05DB13 NE  
 Butanilicaine N01BB05 NE  
Butaperazine N05AB09 NE  
Butenafine  D01AE23 NE  
Butizide and potassium-
sparing agents(spironolactone) 
C03EA14 NE  
Butobarbital N05CA03 NE  
Butorphanol N02AF01 NE  
Butriptyline N06AA15 NE  
Butylscopolamine  
- Oral administration 
 
 
 
 
 
- Parenteral administration 
(i.v) 
A03BB01  
I 
 
 
 
 
 
 
II 
Oral administration 
• Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. possible visual accommodation disturbances), and not 
to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
 
Parenteral administration 
• Inform the patient that this medication causes visual accommodation disturbances 
so you should not drive or operate machinery after parenteral administration until 
vision has normalised. 
• Advise the patient that he should wait until his sight returns to normal before driving 
or using any tools or machines. 
Butylscopolamine and 
analgesics. 
- Oral administration 
 
 
 
A03DB04  
I 
 
 
 
 
Oral administration 
• Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. possible visual accommodation disturbances), and not 
to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
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- Parenteral administration  
 
 
 
II 
 
Parenteral administration 
• Inform the patient that this medication causes visual accommodation disturbances 
so you should not drive or operate machinery after parenteral administration until 
vision has normalised. 
• Advise the patient that he should wait until his sight returns to normal before driving 
or using any tools or machines. 
    
C ATC CODE CATEGORIZATION 
labelling 
INFORMATION FOR THE PATIENT 
C1-inhibitor B02AB03 0 • No special advice 
 Cabergoline N04BC06 II • Advise the patient (and explain to caregivers) not to drive during the first days of 
treatment. 
• Inform patients that unwanted effects are seen rapidly during the dosage adjustment 
period. 
• Advise the patient (and explain to caregivers) not to drive at all if suffering from 
“sleep attacks” 
• Advise the patient (and explain to caregivers) not to drive at all if suffering from 
severe fluctuations in mobility “(“on-off” phenomena). 
Cadexomer iodine D03AX01 NE  
Cadmium compounds D11AC02 0 • No special advice 
Cadralazine C02DB04 NE  
Cafedrine C01CA21 NE  
Caffeine N06BC01 NE  
Calcifediol A11CC06 0 • No special advice 
Calcipotriol D05AX02 0 • No special advice 
Calcipotriol, combinations D05AX52 0 • No special advice 
Calcitriol A11CC04 
D05AX03 
0 • No special advice 
 
Calcium (different salts in 
combination) 
A12AA20 0 • No special advice 
Calcium acetate anhydrous A12AA12 0 • No special advice 
Calcium alginate  B02BC08 NE  
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Calcium carbasalate - 
metoclopramide 
N02BA15 NE  
Calcium carbimide N07BB02 II • Advise the patient (and explain to caregivers) not to drive during the first days of 
treatment and after changes in doses.  
• Advise the patient to strictly follow the prescribed doses and to avoid any alcohol or 
other psychoactive substances during the treatment. 
• Alcohol cessation can also cause behavioural changes and requires follow-up and 
counselling. 
• Driving with this treatment should require an approval by driving licence 
administration. 
Calcium carbonate  A02AC01 
A12AA04 
0 • No special advice 
 
Calcium chloride A12AA07 
B05XA07 
0 • No special advice 
 
Calcium citrate lysine complex A12AA09 0 • No special advice 
Calcium compounds A07XA03 NE  
Calcium dobesilate C05BX01 0 • No special advice 
Calcium dobesilate, 
combinations 
C05BX51 0 • No special advice 
Calcium glubionate A12AA02 0 • No special advice 
Calcium glucoheptonate A12AA10 0 • No special advice 
Calcium gluconate A12AA03 0 • No special advice 
Calcium gluconate D11AX03 NE  
Calcium glycerylphosphate A12AA08 0 • No special advice 
Calcium hexamine thiocyanate R01AX01 NE  
Calcium lactate A12AA05 0 • No special advice 
Calcium lactate gluconate A12AA06 0 • No special advice 
Calcium laevulate A12AA30 0 • No special advice 
Calcium pangamate A12AA11 0 • No special advice 
Calcium pantothenate A11HA31 
D03AX04 
NE  
Calcium phosphate A12AA01 0 • No special advice 
Calcium silicate  A02AC02 0 • No special advice 
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Camazepam N05BA15 NE  
Camolenic acid D11AX02 NE  
Camostat B02AB04 NE  
Camphora C01EB02 NE  
Camylofin A03AA03 NE  
Camylofin and analgesics A03DA05 NE  
Candesartan C09CA06 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Candesartan and diuretics C09DA06 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Canrenone C03DA03 NE  
Capsaicin M02AB01 
N01BX04 
0 • No special advice 
Captodiame N05BB02 NE  
Captopril C09AA01 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Captopril and diuretics C09BA01 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Carbachol N07AB01 
S01EB02 
NE  
 Carbamazepine N03AF01 II Advise the patient not to drive during the first days of treatment as well as after 
dose increases. 
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General warnings: 
• Advise the patient to take the medicine as prescribed by the physician. 
• Advise the patient not to stop taking the medicine suddenly, and to inform the 
physician – doctor if he/she should do so. 
• Advise the patient not to drink alcohol while taking this medication. 
 
Trigeminal neuralgia and prophylaxis of manic-depressive psychosis; 
• Advice the patient not to drive during the first days of treatment as well as after dose 
increases. 
Carbamide B05BC02 NE  
Carbamide D02AE01 0 • No special advice 
Carbamide, combinations D02AE51 0 • No special advice 
Carbamide products D02AE 0 • No special advice 
Carbasalate calcium B01AC08 0 • No special advice 
Carbasalate calcium 
combinations excl. 
Psycholeptics 
N02BA65 NE  
Carbazochrome  B02BX02 NE  
Carbenoxolone  A02BX01 0 • No special advice 
Carbenoxolone, combinations 
excl. psycholeptics 
A02BX51 NE  
Carbenoxolone, combinations 
with psycholeptics 
A02BX77 NE  
Carbinoxamine R06AA08 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advise the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Carbocisteine R05CB03 0 • No special advice 
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Carbocromen C01DX05 NE  
Carbohydrates B05BA03 0 • No special advice 
Carbon dioxide producing 
drugs 
A06AX02 NE  
Carbromal N05CM04 NE  
Carbutamide A10BB06 NE  
Carbuterol R03AC10 
R03CC10 
NE  
Cardioplegia solutions B05XA16 0 • No special advice 
Carglumic acid A16AA05 0 • No special advice 
 
Carisoprodol 
 
 
M03BA02 
 
II 
• Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advice the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
• One time (occasional) use: inform your patient that his/her response is reduced. 
Advice your patient not to drive then 
Carisoprodol, combinations 
excl. psycholeptics 
M03BA52 II 
Carisoprodol, combinations 
with psycholeptics 
M03BA72 II 
Caroverine A03AX11 NE  
Carteolol C07AA15 
 
 
 
 
 
 
 
I 
• Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication 
 S01ED05 I • Inform the patient that as with any ocular medication, if transient, blurred vision 
occurs at application.  
• Advice the patient that he/she should wait until his/her vision clears before driving or 
using machinery. 
Carteolol, combinations S01ED55 NE  
Carvedilol C07AG02 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
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etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Cascara A06AB07 0 • No special advice 
Cascara, combinations A06AB57 0 • No special advice 
Casopitant A04AD13 NE  
Castor oil  A06AB05 0 • No special advice 
Cathine A08AA07 NE  
Celecoxib M01AH01 I • Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
Celiprolol C07AB08 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Ceratonia A07XA02 NE  
Cerium oxalate A04AD02 NE  
Cerivastatin C10AA06 NE  
Cetiedil C04AX26 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Cetirizine R06AE07 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred vision and reduced alertness) 
• Advise the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
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• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Cetrimide D08AJ04 
D11AC01 
0 • No special advice 
Cetrimonium  D08AJ02 0 • No special advice 
Cetrimonium R02AA17 NE  
Cetylpyridinium B05CA01 NE  
Cetylpyridinium D08AJ03 
D09AA07 
R02AA06 
0 • No special advice 
 
 
Chenodeoxycholic acid A05AA01 NE  
Chloral hydrate N05CC01 NE  
Chloralodol N05CC02 NE  
Chloramphenicol D06AX02 
D10AF03 
0 • No special advice 
Chloramphenicol 
- Drops 
- Oinment 
S01AA01  
0 
I 
• Inform the patient that as with any ocular medication, if transient, blurred vision 
occurs at application.  
• Advice the patient that he/she should wait until his/her vision clears before driving or 
using machinery. 
Chloramphenicol S02AA01 
S03AA08 
NE  
Chlorbenzoxamine A03AX03 NE  
Chlorcyclizine R06AE04 NE  
Chlordiazepoxide N05BA02 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advice the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
• One time (occasional) use: inform your patient that his/her response is still reduced 
for 3 days. Advice your patient not to drive then. 
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Chlorhexidine A01AB03 
D08AC02 
D09AA12 
R02AA05 
0 • No special advice 
 
 
 
Chlorhexidine B05CA02 
S02AA09 
S03AA04 
NE NE 
Chlorhexidine, combinations D08AC52 0 • No special advice 
 
Chlormezanone 
 
 
M03BB02 
 
II 
• Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advice the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
• One time (occasional) use: inform your patient that his/her response is reduced. 
Advice your patient not to drive then. 
Chlormezanone, combinations 
excl. psycholeptics 
M03BB52 II 
Chlormezanone, combinations 
with psycholeptics 
M03BB72 II 
Chlormidazole D01AC04 NE  
Chlorobutanol  A04AD04 NE  
Chlorobutanol, combinations A04AD54 0 • No special advice 
Chloroform N01AB02 NE  
Chloroprednisolone and 
antiinfectives 
S01CA09 NE  
 Chloroprocaine N01BA04 NE  
Chloropyramine D04AA09 
R06AC03 
NE  
Chloropyramine, combinations R06AC53 NE  
Chlorothiazide C03AA04 NE  
Chlorothiazide and potassium C03AB04 NE  
Chlorothiazide, combinations C03AH01 NE  
Chloroxylenol D08AE05 0 • No special advice 
Chlorphenamine R06AB04 II • Inform the patient about the effects of the medicine on reaction time and that the 
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medication can cause side effects that impair driving (dizziness, drowsiness, 
restlessness, sedation) 
• Advise the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Chlorphenamine, combinations R06AB54 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
restlessness, sedation) 
• Advise the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Chlorphenesin D01AE07 NE  
Chlorphenoxamine D04AA34 NE  
Chlorphenoxamine R06AA06 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advise the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Chlorphenoxamine, 
Combinations 
R06AA56 NE  
Chlorproethazine N05AA07 NE  
Chlorpromazine 
*Oral administration 
*Parenteral administration 
N05AA01 III 
 
• Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive until the next visit after start of treatment and also to 
be careful in other situations (e.g. using machinery and working at heights) 
• Advice the patient not to drink alcohol when taking this medicine. 
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• In short-term use (eg intractable hiccup, nausea and vomiting) inform your patient 
that his/her response is still reduced for approximately 24 hours. Advice the patient 
not to drive then. 
Chlorpropamide A10BB02 I • Advise your patient to take precautions to avoid hypoglycaemia, this may constitute 
a risk in situations where these abilities are of special importance (e.g. driving a car 
or operating machinery), and not to drive as long as side-effects persist. 
• If your patient has frequent episodes or if he/she find it hard to recognise 
hypoglycaemia. The advisability of driving should be considered in these 
circumstances. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication 
Chlorprothixene N05AF03 NE  
Chlorquinaldol  D08AH02 0 • No special advice 
Chlorquinaldol R02AA11 NE  
Chlortalidone C03BA04 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Chlortalidone and potassium C03BB04 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Chlortalidone and potassium-
sparing agents (spirolactone) 
C03EA06 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Chlortetracycline A01AB21 
D06AA02 
0 • No special advice 
 
Chlortetracycline 
- Drops 
S01AA02 0 
I 
• Inform the patient that as with any ocular medication, if transient, blurred vision 
occurs at application.  
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- Oinment • Advice the patient that he/she should wait until his/her vision clears before driving or 
using machinery. 
 
Chlorzoxazone 
 
 
M03BB03 
 
II 
• Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advice the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
• One time (occasional) use: inform your patient that his/her response is reduced. 
Advice your patient not to drive then. 
Chlorzoxazone, combinations 
excl. psycholeptics 
M03BB53 II 
Chlorzoxazone, combinations 
with psycholeptics 
M03BB73 II 
Cholic acid A05AA03 NE  
Choline alfoscerate N07AX02 NE  
Choline salicylate N02BA03 NE  
Choline theophyllinate R03DA02 NE  
Choline theophyllinate and 
adrenergics 
R03DB02 NE  
Chondroitin sulfate M01AX25 NE  
Chondroitin sulfate-iron 
complex 
B03AB07 NE  
Chymopapain  M09AB01 NE  
Chymotrypsin B06AA04 
S01KX01 
NE  
Cibenzoline C01BG07 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Ciclesonide R03BA08 0 • No special advice 
Cicletanine C03BX03 0 • No special advice 
Ciclonicate C04AC07 NE  
Ciclonium and analgesics A03DA04 NE  
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Ciclopirox  D01AE14 0 • No special advice 
Ciclosporin S01XA18 NE  
Cilansetron A03AE03 NE  
Cilazapril C09AA08 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Cilazapril and diuretics C09BA08 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Cilnidipine C08CA14 NE  
Cilostazol  B01AC 0 • No special advice 
Cimetidine  A02BA01 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness) particularly during the first day of treatment, 
and not to drive as long as side-effects persist. 
Cimetidine, combinations  A02BA51 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness) particularly during the first day of treatment, 
and not to drive as long as side-effects persist. 
Cimetropium bromide A03BB05 NE  
Cinchocaine C05AD04 
D04AB02 
0 • No special advice 
 Cinchocaine N01BB06 
S01HA06 
NE  
Cinchophen M04AC02 NE  
Cinepazet C01DX14 NE  
Cinepazide C04AX27 NE  
Cinitapride  A03FA 
(not ATC 
code) 
0 • No special advice 
Cinnarizine N07CA02 II • Advise the patient (and explain to caregivers) not to drive during the first days of 
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treatment.   
• The treatment has to be used according to the recommended dose.  
• Vertigo and hearing loss requiring this treatment can also impair ability to drive. 
Cinnarizine, combinations N07CA52 NE  
Cinolazepam N05CD13 NE  
Ciprofibrate C10AB08 0 • No special advice 
Ciprofloxacin 
- Drops 
- Oinment  
S01AX13  
0 
I 
• Inform the patient that as with any ocular medication, if transient, blurred vision 
occurs at application.  
• Advice the patient that he/she should wait until his/her vision clears before driving or 
using machinery. 
Ciprofloxacin S02AA15 0 • No special advice 
Ciprofloxacin S03AA07 NE  
Cisapride A03FA02 0 • No special advice 
Cisatracurium M03AC11 III • Advise the patient not to drive or operate machinery until the effects of the 
anaesthetic, and the immediate effects of surgery have passed. 
• Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after 
anaesthesia 
Citalopram N06AB04 I • Inform your patient about the effects of the medication on reaction time as well as 
that the medication can cause side-effects that impair driving abilities (e.g. dizziness, 
drowsiness, sleepiness, blurred vision, etc.). 
• Advice your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities. 
• Advice your patient not to drive as long as side-effects persist. 
• Advice your patient not to drink alcohol nor use any other psychoactive substance 
when taking this medication. 
Citicoline N06BX06 NE  
Citiolone A05BA04 NE  
Citric acid  A09AB04 0 • No special advice 
Clebopride  A03FA06 0 • No special advice 
Clemastine D04AA14 NE  
Clemastine R06AA04 III • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (fatigue, drowsiness) 
• Advise the patient not to drive until the next visit after start of treatment and also to 
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be careful in other situations (e.g. using machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine 
Clemastine, combinations  R06AA54 III • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness and 
reduced alertness) 
• Advise the patient not to drive until the next visit after start of treatment and also to 
be careful in other situations (e.g. using machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Clenbuterol R03AC14 
R03CC13 
NE  
Clidinium and psycholeptics A03CA02 NE  
Clindamycin D10AF01 0 • No special advice 
Clindamycin, combinations D10AF51 0 • No special advice 
Clioquinol  D08AH30 0 • No special advice 
Clioquinol D09AA10 
S02AA05 
0 • No special advice 
Clobazam N05BA09 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advice the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
• One time (occasional) use: inform your patient that his/her response is still reduced 
for approximately 3 days to one week. Advice your patient not to drive then. 
Clobenzorex A08AA08 NE  
Clobetasol D07AD01 0 • No special advice 
Clobetasol and antibiotics D07CD01 NE  
Clobetasone D07AB01 0 • No special advice 
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Clobetasone S01BA09 NE  
Clobetasone and antiinfectives S01CA11 NE  
Clobutinol R05DB03 NE  
Clocortolone D07AB21 NE  
Clodronic acid  M05BA02 0 • No special advice 
Clofedanol R05DB10 NE  
Clofenamide C03BA07 NE  
Clofenamide and potassium C03BB07 NE  
Clofezone M01AA05 
M02AA03 
NE  
Clofibrate C10AB01 NE  
Clofibride C10AB10 NE  
Clomethiazol N05CM02 I • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first 8 hours after taking the medicine and also 
to be careful in other situations (e.g. using machinery and working at heights) 
• Advice the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Clomipramine N06AA04 II • Inform your patient about the effects of the medication on reaction time as well as 
that the medication can cause side-effects that impair driving abilities (e.g. dizziness, 
drowsiness, sleepiness, blurred vision, etc.). 
• Advice your patient not to drive for the first few weeks of treatment or until the next 
visit and to be careful in other situations, as well (e.g. operating machinery and 
working at heights). 
• Advice your patient not to drink alcohol nor use any other psychoactive substance 
when taking this medication. 
• In case of short-term use of the medication, advice your patient not to drive because 
his/her driving skills are still impaired for approximately 24 hours. 
• In case of short-term use of the medication, advice your patient not to drive because 
his/her driving skills are still impaired for approximately 24 hours. 
 Clonazepam 
-  Oral administration 
N03AE01  
II 
III 
Advise the patient not to drive during the first days of treatment as well as after 
dose increases. 
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-  Parenteral administration General warnings: 
• Advise the patient to take the medicine as prescribed by the physician. 
• Advise the patient not to stop taking the medicine suddenly, and to inform the 
physician – doctor if he/she should do so. 
• Advise the patient not to drink alcohol while taking this medication. 
Clonidine C02AC01 II • Inform your patient that the medication can cause side effects that impair driving 
abilities (e.g. dizziness, drowsiness, hypotension, fatigue, etc.). 
• Advise your patient not to drive for the first few days of treatment and to be careful in 
other situations, as well (e.g. operating machinery and working at heights). 
 
Advise the patient not to drink alcohol nor use any psychoactive substance when 
taking this medicine. 
 N02CX02 II • Advise the patient not to drive during the first times, the drug is administered, until 
he/she knows his/her reactions.   
• Advise the patient not to drive within the first 4 hours after treatment. 
• Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to strictly follow the prescribed doses and intake scheme.  
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
 S01EA04  • Inform the patient that this ocular medication may cause fatigue and/or drowsiness, 
blurred and/or abnormal vision which may impair the ability to drive or operate 
machinery, especially at night or in reduced lighting.    
•  Advise the patient that he/she should wait until these symptoms have cleared 
before driving or using machinery.                                                                                           
Clonidine and diuretics C02LC01 II • Inform your patient that the medication can cause side effects that impair driving 
abilities (e.g. dizziness, drowsiness, hypotension, fatigue, etc.). 
• Advise your patient not to drive for the first few days of treatment and to be careful in 
other situations, as well (e.g. operating machinery and working at heights). 
• Advise the patient not to drink alcohol nor use any psychoactive substance when 
taking this medicine. 
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Clonidine and diuretics, 
combinations with other drugs 
C02LC51 II • Inform your patient that the medication can cause side effects that impair driving 
abilities (e.g. dizziness, drowsiness, hypotension, fatigue, etc.). 
• Advise your patient not to drive for the first few days of treatment and to be careful in 
other situations, as well (e.g. operating machinery and working at heights). 
• Advise the patient not to drink alcohol nor use any psychoactive substance when 
taking this medicine. 
Clonixin N02BG 
Not yet 
determined 
NE  
Clopamide C03BA03 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist.  
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Clopamide and potassium C03BB03 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist.  
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Clopenthixol N05AF02 NE  
Cloperastine R05DB21 I • Inform the patient about the effects that the medicine can have on reaction time and 
that the medication can cause side effects that impair driving (drowsiness, sedation, 
accommodation disorder) 
• Advise the patient not to drive when this side effects occur and also to be careful in 
other situations (e.g. using machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Clopidogrel B01AC04 0 • No special advice 
Clopidogrel + Acetilsalicilic 
acid 
B01AC30 Depending on the 
medicine in 
combination 
• Depending on the medicine in combination 
Cloranolol C07AA27 NE  
Clorazepate combinations N05CX04 NE  
Clorexolone C03BA12 NE  
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Clorexolone, comb. with 
psycholeptics 
C03BA82 NE  
Clorhexidine S01AX09 NE  
Cloricromen B01AC02 NE  
Cloridarol C01DX15 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Clorindione B01AA09 NE  
Clotiapine 
- Oral administration 
 
 
 
 
 
 
 
- Parenteral administration: 
i.m./i.v. 
N05AX09  
II 
 
 
 
 
 
 
 
 
 
III 
Oral administration: 
• Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advice the patient not to drink alcohol when taking this medicine. 
• In short-term use, inform your patient that his/her response is still reduced for 
approximately 24 hours. Advice the patient not to drive then. 
 
Parenteral administration 
• Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive until the next visit after start of treatment and also to 
be careful in other situations (e.g. using machinery and working at heights) 
• Advice the patient not to drink alcohol when taking this medicine. 
• In short-term use, inform your patient that his/her response is still reduced for 
approximately 24 hours. Advice the patient not to drive then. 
Clotiazepam N05BA21 III • Inform the patient about the effects of the medicine on reaction time, that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) and that reaction time can 
also be reduced without experiencing side effects. 
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• Advice the patient not to drive until the next visit after start of treatment and also to 
be careful in other situations (e.g. using machinery and working at heights) 
• Advice the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
• One time (occasional) use: inform your patient that his/her response is still reduced 
for approximately 3 days. Advice your patient not to drive then. 
Clotrimazole A01AB18 NE  
Clotrimazole D01AC01 0 • No special advice 
Clovoxamine N06AA 
Not yet 
determined 
NE  
Cloxazolam N05BA22 NE  
Clozapine N05AH02 III • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advice the patient not to drink alcohol when taking this medicine. 
Coagulation factor IX  B02BD04 0 • No special advice 
Coagulation factor IX, II, VII 
and X in combination  
B02BD01 0 • No special advice 
Coagulation factor VII (in 
combination with other factors) 
B02BD05 0 • No special advice 
Coagulation factor VIII  B02BD02 0 • No special advice 
Coagulation factor XIII  B02BD07 NE  
Cobamamide B03BA04 0 • No special advice 
Cocaine N01BC01 
R02AD03 
S01HA01 
S02DA02 
NE  
Cod-liver oil ointments D03AA 0 • No special advice 
Codeine  R05DA04  > 20 mg: 
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> 20 mg 
 
 
 
 
 
 
 
≤ 20 mg 
II 
 
 
 
 
 
 
 
I 
• Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
confusion, tiredness, vertigo, blurred vision and reduced alertness) 
• Advise the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
≤ 20 mg: 
• Inform the patient about the effects that the medicine can have on reaction time and 
that the medication can cause side effects that impair driving (dizziness, drowsiness, 
confusion, tiredness, vertigo, blurred vision and reduced alertness) 
• Advise the patient not to drive when this side effects occur and also to be careful in 
other situations (e.g. using machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Codeine, combinations excl 
.psycholeptics 
> 20 mg 
 
 
≤ 20 mg 
N02AA59  
 
 
II 
 
 
I 
• Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• When using more than 20mg:  Advise the patient (and explain to caregivers) not to 
drive until the next visit after start of treatment or after changes in dosage. 
• Advise the patient to strictly follow the prescribed doses and the intake scheme.  
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
Codeine, combinations with 
psycholeptics 
N02AA79 NE  
Colchicine M04AC01 0 • No special advice 
Colecalciferol A11CC05 0 • No special advice 
Colesevelam C10AC04 0 • No special advice 
Colestipol C10AC02 0 • No special advice 
Colestyramine C10AC01 0 • No special advice 
Colextran C10AC03 0 • No special advice 
 DRUID 6th Framework Programme         Deliverable D.4.4.1  
   Classification of medicinal drugs and driving: 
 Co-ordination and synthesis report.  
   Page 65 of 243 
 
  
 
   
 
 
Colfosceril palmitate  R07AA01 NE  
Colistin A07AA10 0 • No special advice 
Collagen  B02BC07 NE  
Collagen, combinations D11AX57 NE  
Collagenase D03BA02 NE  
Collagenase, combinations D03BA05 NE  
Comb. of rauwolfia alkaloids 
and diuretics incl. other 
combinations 
C02LA50 NE  
Combinations (Adrenergic and 
dopaminergic agents) 
C01CA30 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Combinations (Aluminium 
compounds) 
A02AB10 0 • No special advice 
Combinations (Analgesics and 
anesthetics) 
S02DA30 Depending on the 
medicine in 
combination 
• Depending on the medicine in combination 
 Combinations (Anesthetics, 
local, amides) 
N01BB20 NE  
Combinations (Antifungals for 
topical use, Antibiotics) 
D01AA20 NE  
Combinations 
(Butylpyrazolidine) 
M01AA99 NE  
Combinations (Calcium 
compounds) 
A02AC10 0 • No special advice 
Combinations (Caries 
prophylactic agents) 
A01AA30 NE  
Combinations (Enemas) A06AG20 0 • No special advice 
Combinations (Expectorants) R05CA10 NE  
Combinations (Imidazole and 
triazole derivatives) 
D01AC20 NE  
Combinations (Insulins and A10AB30 I • Advise your patient to take precautions to avoid hypoglycaemia, this may constitute 
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analogues for injection, fast-
acting) 
a risk in situations where these abilities are of special importance (e.g. driving a car 
or operating machinery), and not to drive as long as side-effects persist. 
• If your patient have frequent episodes or if he/she find it hard to recognise 
hypoglycaemia. The advisability of driving should be considered in these 
circumstances.  
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication 
Combinations (Insulins and 
analogues for injection, 
intermediate-acting) 
A10AC30 I 
Combinations (Insulins and 
analogues for injection, 
intermediate-acting combined 
with fast-acting) 
A10AD30 I 
Combinations (Insulins and 
analogues for injection, long-
acting) 
A10AE30 I 
Combinations (Irrigating 
solutions, Antiinfectives) 
B05CA10 NE  
Combinations (Irrigating 
solutions, Salt solutions) 
B05CB10 0 • No special advice 
Combinations (Local 
anesthetics) 
S01HA30 I • Inform the patient that his/her eyesight may become blurred.  
• Advise him/her not to drive or operate machinery during the first 24 hours following 
the useof a local anaesthetic. 
Combinations (Local 
hemostatics) 
B02BC30 0 • No special advice 
Combinations (Lung 
surfactants) 
R07AA30 NE  
Combinations (Magnesium 
compounds) 
A02AA10 0 • No special advice 
Combinations (Mucolytics) R05CB10 NE  
Combinations (Opium 
alkaloids and derivatives) 
R05DA20 Depending on the 
medicine in 
combination 
• Depending on the medicine in combination 
Combinations (Other cough 
suppressants) 
R05DB20 NE  
Combinations (Other intestinal 
adsorbents) 
A07BC30 NE  
Combinations (Other irrigating B05CX10 0 • No special advice 
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solutions)  
Combinations (Other nasal 
preparations) 
R01AX30 NE  
Combinations (Platelet 
aggregation inhibitors excl. 
heparin) 
B01AC30 Depending on the 
medicine in 
combination 
• Depending on the medicine in combination 
Combinations (Solutions for 
parenteral nutrition) 
B05BA10 0 • No special advice 
Combinations (Vitamin A and 
D, incl. combinations of the 
two) 
A11CC20 Depending on the 
medicine in 
combination 
• Depending on the medicine in combination 
Combinations of barbiturates N05CB01 NE  
Combinations of 
corticosteroids 
D07AB30 
D07XB30 
0 • No special advice 
 
Combinations of different 
antibiotics 
S01AA30 Depending on the 
medicine in 
combination 
• Depending on the medicine in combination 
Combinations of electrolytes B05XA30 0  
Combinations of rauwolfia 
alkaloids 
C02AA03 NE  
Combinations of rauwolfia 
alkoloids, combinations 
C02AA53 NE  
Combinations of xanthines R03DA20 NE  
Combinations (Other 
antifungals for topical use) 
D01AE20 NE  
Combinations, (potassium) A12BA30 Depending on the 
medicine in 
combination 
• Depending on the medicine in combination 
Conivaptan C03XA02 NE  
Contact laxatives in 
combination 
A06AB20 0 • No special advice 
Contact laxatives in 
combination with belladonna 
alkaloids 
A06AB30 NE  
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Cortisone S01BA03 NE  
Cosfocreatine C01EB06 NE  
Cough suppressants and 
expectorants 
R05FB02 Depending on the 
medicine in 
combination 
• Depending on the medicine in combination 
Cough suppressants and 
mucolytics 
R05FB01 Depending on the 
medicine in 
combination 
• Depending on the medicine in combination 
Crataegus glycosides C01EB04 NE  
Creatinolfosfate C01EB05 NE  
Creosote R05CA08 NE  
Cromoglicic acid A07EB01 
R01AC01 
R03BC01 
0 • No special advice 
 
Cromoglicic acid D11AH03 NE  
Cromoglicic acid S01GX01 I • Inform the patient that this ocular medication may cause side effects including local 
irritation, temporary blurred vision or other visual disturbances, transient stinging and 
burning after instillation. 
• Advise the patient that if he/she experiences these symptoms, he/she should wait 
until they have cleared before driving or using machinery. 
Cromoglicic acid, combinations R01AC51 
S01GX51 
NE  
Crospovidone A07BC03 NE  
Curcuma A05AX  
Not yet 
determined 
0 • No special advice 
Cxyphenonium, combinations A03AB53 NE  
Cyacobalamin B03BA01 0 • No special advice 
Cyamemazine N05AA06 NE  
Cyanocobalamin tannin 
complex 
B03BA02 NE  
Cyanocobalamin, 
combinations 
B03BA51 0 • No special advice 
Cyclandelate C04AX01 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
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his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist.  
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Cyclizine  R06AE03 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred vision and reduced alertness) 
• Advise the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Cyclizine, combinations R06AE53 Depending on the 
medicine in 
combination 
• Depending on the medicine in combination 
Cyclobarbital N05CA10 NE  
Cyclobenzaprine M03BX08 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advice the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
• One time (occasional) use: inform your patient that his/her response is reduced. 
Advice your patient not to drive then. 
Cyclobutyrol A05AX03 0 • No special advice 
Cyclopentamine R01AA02 NE  
Cyclopenthiazide C03AA07 0 • No special advice 
Cyclopenthiazide and 
potassium. 
C03AB07 NE  
Cyclopenthiazide and 
potassium-sparing agents 
(spironolactone) 
C03EA07 NE  
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Cyclopentolate S01FA04 III • Inform the patient that this ocular medication may cause transient blurring of vision 
or that he/she may suffer from photophobia and that this may impair their ability to 
drive under certain circumstances. Complete recovery from the effects of mydriatic 
anticholinergics may take up to 24 hours. 
• Advise the patients not to drive or operate hazardous machinery until 24 hours after 
receiving ocular medication (recovery occurs within 24 hours) or until vision is clear. 
Cyclothiazide C03AA09 NE  
Cyclothiazide and potassium C03AB09 NE  
Cymarin C01AC03 NE  
Cyproheptadine R06AX02 II • Inform the patient that the medication can cause side effects (dizziness, drowsiness 
and somnolence) Patients receiving it should not drive or operate machinery unless 
it has been shown that their physical and mental capacity remains unaffected. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
    
D ATC CODE CATEGORIZATION 
labelling 
INFORMATION FOR THE PATIENT 
Dabigatran etexilate B01AE07 0 • No special advice  
Dalteparin B01AB04 0 • No special advice 
Danaparoid B01AB09 0 • No special advice 
Dantrolene M03CA1 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advice the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
• One time (occasional) use: inform your patient that his/her response is reduced. 
Advice your patient not to drive then. 
Dantron A06AB03 0 • No special advice 
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Dantron, combinations A06AB53 0 • No special advice 
Dantron, incl. Combinations A06AG03 0 • No special advice 
 
Dapiprazole S01EX02 NE  
Dapsone D10AX05 0 • No special advice 
Darbepoetin alfa B03XA02 0 • No special advice 
Deanol N06BX04 I • Inform your patient about the effects of the medication on reaction time as well as 
that the medication can cause side-effects that impair driving abilities (e.g. dizziness, 
drowsiness, sleepiness, blurred vision, etc.). 
• Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities. 
• Advise your patient not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any other psychoactive substance 
when taking this medication 
Debrisoquine C02CC04 NE  
Defibrotide B01AX01 NE  
Delapril C09AA12 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Delapril and diuretics C09BA12 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Delapril and manidipine C09BB12 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Demecarium S01EB04 NE  
Demeclocycline D06AA01 NE  
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Denosumab  M05BX04 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. visual disturbances), and not to drive as long as side-
effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication 
Deptropine R06AX16 NE  
Dequalinium D08AH01 
R02AA02 
0 • No special advice 
Dermatan sulfate B01AX04 NE  
Deserpidine C02AA05 NE  
Deserpidine and diuretics. C02LA03 NE  
 Desflurane N01AB07 III • Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient (and explain to caregivers) not to drive until the next visit after 
start of treatment or after changes in dosage. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to strictly follow the prescribed doses and the intake scheme.  
• Advise the patient to avoid any alcohol or other psychoactive substances during 
the treatment. 
• Opiate cessation can also cause behavioral changes and requires follow-up and 
counseling. 
 Desipramine N06AA01 NE  
Desirudin B01AE01 0 • No special advice 
Deslanoside C01AA07 NE  
Desloratadine R06AX27 I • Inform the patient about the effects that the medicine can have on reaction time 
and that the medication can cause side effects that impair driving (drowsiness, 
fatigue) 
• Advise the patient not to drive when this side effects occur and also to be careful 
in other situations (e.g. using machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Desonide D07AB08 NE  
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S01BA11 
Desonide and antiseptics D07BB02 NE  
Desoximetasone D07AC03 0 • No special advice 
Desoximetasone D07XC02 NE  
Desoxyribonuclease B06AA10 NE  
Desvenlafaxine N06AX23 NE  
Dexamafetamine N06BA02 II • Inform your patient about the effects of the medication on reaction time as well as 
that the medication can cause side-effects that impair driving abilities (e.g. dizziness, 
drowsiness, sleepiness, blurred vision, etc.). 
• Advise your patient not to drive for the first few weeks of treatment or until the next 
visit and to be careful in other situations, as well (e.g. operating machinery and 
working at heights). 
• Advise your patient not to drink alcohol nor use any other psychoactive substance 
when taking this medication. 
• In case of short-term use of the medication, advise your patient not to drive because 
his/her driving skills are still impaired for approximately 24 hours. 
Dexamethasone A01AC02 
C05AA09 
D07AB19 
D07XB05 
D10AA03 
R01AD03 
0 • No special advice 
 
 
 
 
Dexamethasone 
- Drops 
- Oinment 
S01BA01  
0 
I 
• Inform the patient that as with any ocular medication, if transient, blurred vision 
occurs at application.  
• Advice the patient that he/she should wait until his/her vision clears before driving or 
using machinery. 
Dexamethasone S01CB01 Depending on the 
mydriatic in 
combination 
• Depending on the mydriatic in combination 
Dexamethasone S02BA06 
S03BA01 
NE 
 
 
 
Dexamethasone and 
antibiotics 
D07CB04 NE  
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Dexamethasone and 
antiinfectives 
- Drops 
- Oinment 
S01CA01  
 
0 
I 
• Inform the patient that as with any ocular medication, if transient, vision occurs at 
application.  
• Advice the patient that he/she should wait until his/her vision clears before driving or 
using machinery. 
Dexamethasone and 
antiinfectives 
S02CA06 
S03CA01 
0 • No special advice 
 
Dexamethasone, combinations R01AD53 NE  
Dexamfetamine N06BA02 
 
II • Inform your patient about the effects of the medication on reaction time as well as 
that the medication can cause side-effects that impair driving abilities (e.g. dizziness, 
drowsiness, sleepiness, blurred vision, etc.). 
• Advise your patient not to drive for the first few weeks of treatment or until the next 
visit and to be careful in other situations, as well (e.g. operating machinery and 
working at heights). 
• Advise your patient not to drink alcohol nor use any other psychoactive substance 
when taking this medication. 
• In case of short-term use of the medication, advise your patient not to drive because 
his/her driving skills are still impaired for approximately 24 hours. 
Dexbrompheniramine R06AB06 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
restlessness, sedation) 
• Advise the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Dexbrompheniramine, 
combinations 
R06AB56 NE  
Dexchlorpheniramine R06AB02 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
restlessness, sedation) 
• Advise the patient not to drive for the first few days of treatment or until the next 
visit after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
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taking this medicine. 
Dexchlorpheniramine 
Combinations 
R06AB52 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
restlessness, sedation) 
• Advise the patient not to drive for the first few days of treatment or until the next 
visit after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
 Dexetimide N04AA08 NE  
Dexfenfluramine A08AA04 NE  
 
Dexibuprofen 
 
 
M01AE14 
 
I 
• Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
Dexketoprofen M01AE17 I 
Dexmedetomidine N05CM18 NE  
Dexpanthenol A11HA30 0 • No special advice 
Dexpanthenol D03AX03 
S01XA12 
NE  
Dextran   B05AA05 0 • No special advice 
Dextranomer D03AX02 NE  
Dextriferron B03AB05 NE  
Dextriferron B03AC01 0 • No special advice 
Dextriferron (carboximaltosa) B03AD04 0 • No special advice 
Dextromethorphan R05DA09 I • Inform the patient about the effects that the medicine can have on reaction time and 
that the medication can cause side effects that impair driving (dizziness, excitation, 
confusion) 
• Advise the patient not to drive when this side effects occur and also to be careful in 
other situations (e.g. using machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
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Dextromoramide N02AC01 NE  
Dextropropoxyphene N02AC04 NE  
Dextropropoxyphene 
combinations excl. 
psycholeptics 
N02AC54 NE  
Dextropropoxyphene, comb. 
With psycholepctics 
N02AC74 NE  
Dextrothyroxine C10AX01 NE  
Dezocine N02AX03 NE  
Diacerein M01AX21 NE  
Diamorphine N02AA09 NE  
Diastase A09AA01 NE  
Diazepam N05BA01 III • Inform the patient about the effects of the medicine on reaction time, that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) and that reaction time can 
also be reduced without experiencing side effects. 
• Advice the patient not to drive until the next visit after start of treatment and also to 
be careful in other situations (e.g. using machinery and working at heights) 
• Advice the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
• One time (occasional) use: inform your patient that his/her response is still reduced 
for approximately 3 days to one week. Advice your patient not to drive then. 
Diazoxide C02DA01 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Dibenzepin N06AA08 III • Inform your patient about the effects of the medication on reaction time as well as 
that the medication can cause side-effects that impair driving abilities (e.g. dizziness, 
drowsiness, sleepiness, blurred vision, etc.). 
• Advice your patient not to drive until the next visit and to be careful in other 
situations, as well (e.g. operating machinery and working at heights). 
• Advice your patient not to drink alcohol nor use any other psychoactive substance 
when taking this medication. 
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• In case of short-term use of the medication, advice your patient not to drive because 
his/her driving skills are still impaired for approximately 24 hours. 
Dibotermin alfa (Kit for implant) M05BC01 0 • No special advice 
Dibrompropamidine D08AC01 0 • No special advice 
Dibrompropanamidine S01AX14 NE  
Dibunate R05DB16 NE  
Dichloralphenazone N05CC04 NE  
Dichlorobenzyl alcohol R02AA03 0 • No special advice 
Diclofenac M01AB05 
N02BG 
I • Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
Diclofenac (ophtalmologic use) S01BC03 0 • No special advice 
Diclofenac (topic use) M02AA15 
D11AX18 
0 
• No special advice 
Diclofenac and antiinfectives S01CC01 0 • No special advice 
Diclofenac, combinations M01AB55 I • Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
Diclofenamide S01EC02 I • Inform the patient that as with any ocular medication, if transient, blurred vision 
occurs at application.  
• Advice the patient that he/she should wait until his/her vision clears before driving or 
using machinery. 
Dicoumarol B01AA01 NE  
Dicycloverine A03AA07 0 • No special advice 
Didecyldimethylammo 
nium chloride 
D08AJ06 NE  
 Diethyl ether N01AA01 NE  
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Difemerine A03AA09 NE  
Difenoxin A07DA04 NE  
Difenpiramide M01AB12 NE  
Diflorasone  
 D07AC1
0 
0 • No special advice 
Diflucortolone D07AC06 0 • No special advice 
Diflucortolone D07XC04 NE  
Diflucortolone and antiseptics D07BC04 0 • No special advice 
Diflunisal N02BA11 NE  
Difluprednate D07AC19 NE  
Digitalis leaves C01AA03 NE  
Digitoxin C01AA04 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Digoxin C01AA05 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Dihexyverine A03AA08 NE  
Dihydralazine C02DB01 NE  
Dihydralazine and diuretics C02LG01 NE  
Dihydralazine and diuretics, 
combinations with other drugs 
C02LG51 NE  
Dihydrocodeine  N02AA08 III/II* 
*)prolonged release 
formulation; when a 
steady state of 
dosage has been 
reached 
• Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient (and explain to caregivers) not to drive until the next visit after 
start of treatment or after changes in dosage. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
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• Advise the patient to strictly follow the prescribed doses and the intake scheme.  
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
• Opiate cessation can also cause behavioral changes and requires follow-up and 
counseling. 
Dihydrocodeine combinations N02AA58 NE  
Dihydroergocristine C04AE04 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Dihydroergocristine, 
combinations 
C04AE54 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
 Dihydroergocrypti    mesylate N04BC03 NE  
Dihydroergocryptine mesylate N04BC03 NE  
Dihydroergotamine N02CA01 NE  
Dihydrostreptomycin S01AA15 NE  
Dihydrotachysterol A11CC02 0 • No special advice 
Dihydroxialumini sodium 
carbonate 
A02AB04 0 • No special advice 
Diiodohydroxypropane D08AG04 NE  
Diisopromine A03AX02 NE  
Dilazep C01DX10 NE  
Diltiazem C08DB01 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Dimazole D01AE17 NE  
Dimecrotico acido It is not in 0 • No special advice 
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ATC list 
Dimefline R07AB08 NE  
Dimemorfan R05DA11 NE  
Dimetacrine N06AA18 NE  
Dimethoxanate R05DB28 NE  
Dimethyl sulfoxide M02AX03 NE  
DimethylaminopropionyIphenot
hiazine 
A03AC2 NE  
Dimethyltubocurarine M03AA04 III • Advise the patient not to drive or operate machinery until the effects of the 
anaesthetic, and the immediate effects of surgery have passed. 
• Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after 
anaesthesia 
Dimetindene D04AA13 0 • No special advice 
Dimetindene R06AB03 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
restlessness, sedation) 
• Advise the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Dimetofrine C01CA12 NE  
Dimetotiazine N02CX05 NE  
Diosmectite A07BC05 NE  
Diosmin C05CA03 0 • No special advice 
Diosmin, combinations C05CA53 0 • No special advice 
Diphemanil A03AB15 NE  
Diphemanil and psycholeptics A03CA08 NE  
Diphenadione B01AA10 NE  
Diphenhydramine  D04AA32 0 • No special advice 
Diphenhydramine R06AA02 III • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, blurred 
vision and reduced alertness) 
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• Advise the patient not to drive until the next visit after start of treatment and also to 
be careful in other situations (e.g. using machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Diphenhydramine 
methylbromide  
D04AA33 0 • No special advice 
 
Diphenhydramine, 
combinations 
R06AA52 III • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness and 
reduced alertness) 
• Advise the patient not to drive until the next visit after start of treatment and also to 
be careful in other situations (e.g. using machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Diphenoxylate A07DA01 NE  
Diphenylpyraline R06AA07 NE  
Diphenylpyraline, 
combinations 
R06AA57 NE  
Dipiperonylamino-ethanol, 
combinations 
N05CX06 NE  
Dipivefrine S01EA02 NE  
Diprophylline R03DA01 NE  
Diprophylline and adrenergics R03DB01 NE  
Diprophylline, combinations R03DA51 NE  
Dipyridamole B01AC07 0 • No special advice 
Dipyrocetil, combinations with 
psycholeptics 
N02BA79 NE  
Dipyrocetyl N02BA09 NE  
Dipyrocetyl and corticosteroids M01BA02 NE  
Dipyrocetyl, combinations excl. 
Psycholeptics 
N02BA59 NE  
Disopyramide C01BA03 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
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• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Distigmine N07AA03 NE  
Disulfiram N07BB01 II • Advise the patient (and explain to caregivers) not to drive during the first days of 
treatment and after changes in doses. 
• Advise the patient to strictly follow the prescribed doses and treatment procedures 
and to avoid any alcohol or other psychoactive substances during the treatment.  
• Alcohol cessation can also cause behavioural changes and requires follow-up and 
counselling. 
• Driving with this treatment should require an approval by driving licence 
administration. 
Ditazole B01AC01 NE  
Dithranol D05AC01 0 • No special advice 
Dithranol, combinations D05AC51 0 • No special advice 
Dixyrazine N05AB01 NE  
Dobutamine C01CA07 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Docosanol D06BB11 NE  
Docusate sodium A06AA02 0 • No special advice 
Docusate sodium, incl. 
combinations 
A06AG10 0 • No special advice 
Dodeclonium bromide, 
combinations 
D08AJ59 NE  
Dofetilide C01BD04 NE  
Dolasetron A04AA04 NE  
Domiodol R05CB08 NE  
Domiphen  A01AB06 NE  
Domperidone A03FA03 0 • No special advice 
Donepezil N06DA02 II • Inform your patient (and explain his/her caregiver) about the effects of the 
medication on reaction time as well as that the medication can cause side-effects 
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that impair driving abilities (e.g. dizziness, drowsiness, sleepiness, blurred vision, 
etc.). 
• Advise your patient (and explain his/her caregiver) not to drive for the first few weeks 
of treatment or until the next visit and to be careful in other situations, as well (e.g. 
operating machinery and working at heights). 
• Advise your patient (and explain his/her caregiver) not to drink alcohol nor use any 
other psychoactive substance when taking this medication. 
• In case of short-term use of the medication, advise your patient (and explain his/her 
caregiver) not to drive because his/her driving skills are still impaired for 
approximately 24 hours. 
• Driving with this treatment should require an approval by driving licence 
administration. 
Dopamine C01CA04 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Dopexamine C01CA14 NE  
Dornase alfa 
(desoxyribonuclease) 
R05CB13 0 • No special advice 
Dorzolamide S01EC03 I • Inform the patient that as with any ocular medication, if transient, blurred vision 
occurs at application.  
• Advice the patient that he/she should wait until his/her vision clears before driving or 
using machinery. 
Dosmalfato A02BX 0 • No special advice 
Dosulepin N06AA16 III • Inform your patient about the effects of the medication on reaction time as well as 
that the medication can cause side-effects that impair driving abilities (e.g. dizziness, 
drowsiness, sleepiness, blurred vision, etc.). 
• Advice your patient not to drive until the next visit and to be careful in other 
situations, as well (e.g. operating machinery and working at heights). 
• Advice your patient not to drink alcohol nor use any other psychoactive substance 
when taking this medication. 
• In case of short-term use of the medication, advice your patient not to drive because 
his/her driving skills are still impaired for approximately 24 hours. 
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Doxacurium chloride M03AC07 III • Advise the patient not to drive or operate machinery until the effects of the 
anaesthetic, and the immediate effects of surgery have passed. 
• Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after 
anaesthesia 
Doxapram R07AB01 I • Inform the patient about the effects that the medicine can have on reaction time and 
that the medication can cause side effects that impair driving (tremor, clonus, 
vertigo, dizziness, confusion, pupil dilatation) 
• Advise the patient not to drive when this side effects occur and also to be careful in 
other situations (e.g. using machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Doxazosin C02CA04 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Doxefazepam N05CD12 NE  
Doxepin N06AA12 III • Inform your patient about the effects of the medication on reaction time as well as 
that the medication can cause side-effects that impair driving abilities (e.g. dizziness, 
drowsiness, sleepiness, blurred vision, etc.). 
• Advice your patient not to drive until the next visit and to be careful in other 
situations, as well (e.g. operating machinery and working at heights). 
• Advice your patient not to drink alcohol nor use any other psychoactive substance 
when taking this medication. 
• In case of short-term use of the medication, advice your patient not to drive because 
his/her driving skills are still impaired for approximately 24 hours. 
Doxofylline R03DA11 NE  
Doxycycline A01AB22 0 • No special advice 
Doxylamine R06AA09 III • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness and 
reduced alertness) 
• Advise the patient not to drive until the next visit after start of treatment and also to 
be careful in other situations (e.g. using machinery and working at heights) 
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• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Dronabinol A04AD10 NE  
 Droperidol N01AX01 III • Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient (and explain to caregivers) not to drive until the next visit after start 
of treatment or after changes in dosage. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to strictly follow the prescribed doses and the intake scheme.  
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
• Opiate cessation can also cause behavioral changes and requires follow-up and 
counseling. 
Droperidol, injectable N05AD08 III • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advise the patient not to drive until the next visit after start of treatment and also to 
be careful in other situations (e.g. using machinery and working at heights) 
• Advise the patient not to drink alcohol when taking this medicine. 
• In short-term use (eg nausea and vomiting), inform your patient that his/her 
response is still reduced for approximately 24 hours. Advise the patient not to drive 
then. 
Dropropizine R05DB19 NE  
Drotaverine A03AD02 NE  
Drotrecogin alfa (activated) B01AD10 0 • No special advice 
Droxicam M01AC04 NE  
Droxypropine R05DB17 NE  
Duloxetine N06AX21 II  
• Inform your patient about the effects of the medication on reaction time as well as 
that the medication can cause side-effects that impair driving abilities (e.g. dizziness, 
drowsiness, sleepiness, blurred vision, etc.). 
• Advice your patient not to drive for the first few weeks of treatment or until the next 
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visit and to be careful in other situations, as well (e.g. operating machinery and 
working at heights). 
• Advice your patient not to drink alcohol nor use any other psychoactive substance 
when taking this medication. 
• In case of short-term use of the medication, advice your patient not to drive because 
his/her driving skills are still impaired for approximately 24 hours. 
 Dyclonine N01BX02 
R02AD04 
NE  
Dyhydroergotamine, 
combinations 
N02CA51 NE  
    
E ATC CODE CATEGORIZATION 
labelling 
INFORMATION FOR THE PATIENT 
Ebastine R06AX22 I • Inform the patient about the effects that the medicine can have on reaction time and 
that the medication can cause side effects that impair driving (drowsiness, 
somnolence) 
• Advise the patient not to drive when this side effects occur and also to be careful in 
other situations (e.g. using machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Econazole D01AC03 0 • No special advice 
Ecothiopate S01EB03 NE  
Edoxudine D06BB09 NE  
Eflornithine D11AX16 0 • No special advice 
Efloxate C01DX13 NE  
Electrolytes  B05BB01 0 • No special advice 
Electrolytes in combination 
with other drugs  
B05XA31 Depending on the 
medicine in 
combination 
• Depending on the medicine in combination 
Electrolytes with 
Carbohydrates 
B05BB02 0 • No special advice 
Eletriptan N02CC06 II • Advise the patient not to drive during the first times, the drug is administered, until 
he/she knows his/her reactions.   
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• Advise the patient not to drive within the first 4 hours after treatment. 
• Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to strictly follow the prescribed doses and intake scheme.  
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
Eltrombopag  B02BX05 0 • No special advice 
Emedastine S01GX06 I • Inform the patient that this ocular medication may cause side effects including local 
irritation, temporary blurred vision or other visual disturbances, transient stinging and 
burning after instillation. 
• Advise the patient that if he/she experiences these symptoms, he/she should wait 
until they have cleared before driving or using machinery. 
Emepronium and 
psycholeptics 
A03CA30 NE  
Emepronium, combinations N05CX05 NE  
Emodina A05AX 
Not yet 
determined 
NE  
Emylcamate N05BC03 NE  
Enalapril C09AA02 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Enalapril and diuretics C09BA02 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Enalapril and lercanidipine C09BB02 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
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etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Encainide C01BC08 NE  
Endralazine C02DB03 NE  
 Enflurane N01AB04 NE  
Enoxaparin  B01AB05 0 • No special advice 
Enoximone C01CE03 NE  
Enoxolone D03AX10 NE  
Enprostil  A02BB02 NE  
 Entacapone N04BX02 II • Advise the patient (and explain to caregivers) not to drive during the first days of 
treatment. 
• Inform patients that unwanted effects are seen rapidly during the dosage adjustment 
period. 
• Advise the patient (and explain to caregivers) not to drive at all if sufering from “sleep 
attacks”. 
• Advise the patient (and explain to caregivers) not to drive at all if suffering from 
severe fluctuations in mobility “(“on-off” phenomena). 
Eosin D08AX02 NE  
Epanolol C07AB10 NE  
Eperisone M03BX09 NE  
Ephedrine R01AB05 Depending on the 
medicine in 
combination 
• Depending on the medicine in combination 
Ephedrine R03CA02 I • Inform the patient about the effects that the medicine can have on reaction time and 
that the medication can cause side effects that impair driving (anxiety, restlessness, 
insomnia, tremor) 
• Advise the patient not to drive when this side effects occur and also to be careful in 
other situations (e.g. using machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Ephedrine S01FB02 NE  
Ephedrine, combinations A08AA56 NE  
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Epinastine R06AX24 I • Inform the patient about the effects that the medicine can have on reaction time and 
that the medication can cause side effects that impair driving (dizziness, drowsiness) 
• Advise the patient not to drive when this side effects occur and also to be careful in 
other situations (e.g. using machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Epinastine S01GX10 I • Inform the patient that this ocular medication may cause side effects including local 
irritation, temporary blurred vision or other visual disturbances, transient stinging and 
burning after instillation. 
• Advise the patient that if he/she experiences these symptoms, he/she should wait 
until they have cleared before driving or using machinery. 
Epinephrine A01AD01 
B02BC09 
0 • No special advice 
Epinephrine C01CA24 I Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) 
and not to drive as long as side-effects persist. 
 
Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Epinephrine R01AA14 
R03AA01 
S01EA01 
NE  
Epinephrine and other drugs 
for obstructive airway 
diseases  
R03AK01 NE  
Epinephrine, combinations S01EA51 NE  
Epitizide and potassium-
sparing agents 
(spironolactone) 
C03EA03 NE  
Eplerenone C03DA04 0 • No special advice 
Epomediol A05BA05 NE  
Epoprostenol B01AC09 0 • No special advice 
 
Eprazinone R05CB04 NE  
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Eprosartan C09CA02 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Eprosartan and diuretics C09DA02 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Eprozinol R03DX02 NE  
Eptacog alfa (activated)  B02BD08 0 • No special advice 
Eptifibatide  B01AC16 0 • No special advice 
Eptotermin alfa M05BC02 0 • No special advice 
Erdosteine R05CB15 0 • No special advice 
Ergocalciferol (in combinacion, 
Vitalipid) 
A11CC01 0 • No special advice 
Ergoloid mesylates C04AE01 NE  
Ergoloid mesylates, 
combinatiom 
C04AE51 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Ergotamine N02CA02 NE  
Ergotamine, combinations N02CA72 NE  
Ergotamine, combinations 
excl. psycholeptics 
N02CA52 I • Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
Eritrityl tetranitrate C01DA13 NE  
Eritrityl tetranitrate, C01DA63 NE  
 DRUID 6th Framework Programme         Deliverable D.4.4.1  
   Classification of medicinal drugs and driving: 
 Co-ordination and synthesis report.  
   Page 91 of 243 
 
  
 
   
 
 
combinations 
Erythrocytes B05AX01 NE  
Erythromycin D10AF02 0 • No special advice 
Erythromycin, combinations D10AF52 0 • No special advice 
Erythropoietin (epoetin alfa, 
beta, theta) 
B03XA01 0 • No special advice 
Erytromycin S01AA17 I • Inform the patient that as with any ocular medication, if transient, blurred vision 
occurs at application.  
• Advice the patient that he/she should wait until his/her vision clears before driving or 
using machinery. 
Escitalopram N06AB10 I • Inform your patient about the effects of the medication on reaction time as well as 
that the medication can cause side-effects that impair driving abilities (e.g. dizziness, 
drowsiness, sleepiness, blurred vision, etc.). 
• Advice your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities. 
• Advice your patient not to drive as long as side-effects persist. 
• Advice your patient not to drink alcohol nor use any other psychoactive substance 
when taking this medication. 
 Esketamine N01AX14 NE  
 Eslicarbazepine  N03AF04 II Advise the patient not to drive during the first days of treatment as well as after 
dose increases. 
 
General warnings: 
• Advise the patient to take the medicine as prescribed by the physician. 
• Advise the patient not to stop taking the medicine suddenly, and to inform the 
physician – doctor if he/she should do so. 
• Advise the patient not to drink alcohol while taking this medication. 
Esmolol C07AB09 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Esomeprazole A02BC05 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
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his/her driving abilities (e.g. dizziness) particularly during the first day of treatment, 
and not to drive as long as side-effects persist. 
Esomeprazole, amoxicillin and 
clarithromycin  
A02BD06 NE  
Estazolam N05CD04 NE  
Eszopiclone N05CF04 NE (SPC not yet 
published) 
 
Etacrynic acid C03CC01 NE  
Etafenone C01DX07 NE  
Etallobarbital N05CA20 NE  
Etamiphylline R03DA06 NE  
Etamiphylline and adrenergics R03DB06 NE  
Etamivan R07AB04 NE  
Etamsylate  B02BX01 0 • No special advice 
 Etanautine N04AB01 NE  
Ethacridine lactate B05CA08 
D08AA01 
NE  
Ethadione N03AC03 NE  
Ethanol D08AX08 0 • No special advice 
Ethchlorvynol N05CM08 NE  
Ethenzamide N02BA07 NE  
Ethenzamide, combinations 
excl. Psycholeptics 
N02BA57 NE  
Ethenzamide, combinations 
with psycholeptics 
N02BA77 NE  
 Ethosuximide combinations N03AD51 NE  
 Ethotoin N03AB01 NE  
 Ethoxusimide N03AD01 II Advise the patient not to drive during the first days of treatment as well as after 
dose increases. 
 
General warnings: 
• Advise the patient to take the medicine as prescribed by the physician. 
• Advise the patient not to stop taking the medicine suddenly, and to inform the 
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physician – doctor if he/she should do so. 
• Advise the patient not to drink alcohol while taking this medication. 
Ethulose A06AC02 NE  
Ethyl biscoumacetate B01AA08 NE  
 Ethyl chloride N01BX01 NE  
Ethyl hydroxybenzoate D01AE10 NE  
Ethyl loflazepate N05BA18 NE  
Ethylestrenol A14AB02 NE  
Ethylmorphine R05DA01 III • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness) 
• Advise the patient not to drive until the next visit after start of treatment and also to 
be careful in other situations (e.g. using machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Ethylmorphine S01XA06 NE  
 Etidocain combinations N01BB57 NE  
 Etidocaine N01BB07 NE  
Etidronic acid M05BA01 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. somnolence, dizziness   vertigo or ataxia), and not to 
drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication 
Etidronic acid and calcium, 
sequential 
M05BB01 NE  
Etifoxine N05BX03 NE  
Etilamfetamine A08AA06 NE  
Etilefrine C01CA01 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Etilefrine, combinations C01CA51 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
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etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
 Etilevodopa and  
decarboxylase inhibitor 
N04BA06 NE  
Etizolam N05BA19 NE  
Etodolac M01AB08 I • Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
Etofenamate M02AA06 0 • No special advice 
Etofibrate C10AB09 NE  
Etofylline nicotinate C04AD04 NE  
 Etomidate    
N01AX07 
III • Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient (and explain to caregivers) not to drive until the next visit after start 
of treatment or after changes in dosage. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to strictly follow the prescribed doses and the intake scheme.  
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
• Opiate cessation can also cause behavioral changes and requires follow-up and 
counseling. 
Etoperidone N06AB09 NE  
Etoricoxib M01AH05 I • Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
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Etozolin C03CX01 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Etretinate D05BB01 NE  
 Etybenzatropine N04AC30 NE  
Euflavine D08AA03 NE  
Exenatide A10BX04 I • Advise your patient to take precautions to avoid hypoglycaemia, this may constitute 
a risk in situations where these abilities are of special importance (e.g. driving a car 
or operating machinery), and not to drive as long as side-effects persist. 
• If your patient has frequent episodes or if he/she find it hard to recognise 
hypoglycaemia. The advisability of driving should be considered in these 
circumstances.  
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication 
Ezetimibe C10AX09 0 • No special advice 
    
F ATC CODE CATEGORIZATION 
labelling 
INFORMATION FOR THE PATIENT 
Factor VIII inhibitor bypassing 
activity 
B02BD03 0 • No special advice 
Famciclovir S01AD07 NE  
Famotidine A02BA03 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness) particularly during the first day of treatment, 
and not to drive as long as side-effects persist. 
Famotidine, combinations A02BA53 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness) particularly during the first day of treatment, 
and not to drive as long as side-effects persist. 
Fasudil C04AX32 NE  
Fat emulsions B05BA02 NE  
Fazadinium bromide  M03AC08 III • Advise the patient not to drive or operate machinery until the effects of the 
anaesthetic, and the immediate effects of surgery have passed. 
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• Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after 
anaesthesia 
Febarbamate M03BA05 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advice the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
• One time (occasional) use: inform your patient that his/her response is reduced. 
Advice your patient not to drive then. 
Febuxostat M04AA03 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. somnolence, dizziness   vertigo or ataxia), and not to 
drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
 
Fedrilate R05DB14 NE  
 Felbamate N03AX10 NE  
Felbinac M02AA08 0 • No special advice 
Felodipine C08CA02 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Femoxetine N06AB  
Not yet 
determined 
NE  
Fenazocine N02AD02 NE  
Fenbufen M01AE05 NE  
Fencamfamin N06BA06 NE  
Fendiline C08EA01 NE  
Fenetylline N06BA10 NE  
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Fenfluramine A08AA02 NE  
Fenofibrate C10AB05 0 • No special advice 
Fenoldopam C01CA19 NE  
Fenoprofen M01AE04 
N02BG 
NE  
Fenoterol R03AC04 0 • No special advice 
Fenoterol R03CC04 NE  
Fenoterol and other drugs for 
obstructive airway diseases  
R03AK03 NE  
Fenoverine A03AX05 NE  
Fenoxazoline R01AA12 NE  
Fenozolone N06BA08 NE  
Fenpiprane A03AX01 NE  
Fenpiverinium A03AB21 NE  
Fenproporex N06BA NE  
Fenquizone C03BA13 NE  
Fenspiride R03BX01 
R03DX03 
NE  
 Fentanyl 
 -  Oral administration 
- Parenteral administration 
- Transdermal administration   
N01AH01 
N02AB03 
 
 
 
 
 
 
 
 
 
III 
III 
III/II* 
*) prolonged release 
formulation; when a 
steady state of 
dosage has been 
reached 
• Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient (and explain to caregivers) not to drive until the next visit after start 
of treatment or after changes in dosage. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to strictly follow the prescribed doses and the intake scheme.  
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
• Opiate cessation can also cause behavioral changes and requires follow-up and 
counseling. 
Fentanyl combinations N01AH51 NE  
Fentiazac M01AB10 
M02AA14 
NE  
Fenticonazole D01AC12 0 • No special advice 
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Fentonium A03BB04 NE  
Fenyramidol M03BX30 NE  
Feprazone M01AX18 
M02AA16 
NE  
Feprazone, combinations M01AX68 NE  
Ferric acetyl transferrin B03AB08 NE  
Ferric citrate B03AB06 0 • No special advice 
Ferric hydroxide B03AB04 0 • No special advice 
Ferric oxide dextran complex B03AC06 0 • No special advice 
Ferric proteinsuccinylate B03AB09 0 • No special advice 
Ferric sodium citrate B03AB01 NE  
Ferric sodium gluconate 
complex 
B03AC07 NE  
Ferric sorbitol gluconic acid 
complex 
B03AC05 NE  
Ferrous amino acid complex B03AD01 0 • No special advice 
Ferrous ascorbate B03AA10 NE  
Ferrous aspartate B03AA09 NE  
Ferrous carbonate B03AA04 NE  
Ferrous chloride B03AA05 NE  
Ferrous fumarate B03AA02 
B03AD02 
0 • No special advice 
Ferrous gluconate B03AA03 0 • No special advice 
Ferrous glycine sulfate B03AA01 0 • No special advice 
Ferrous iodine B03AA11 NE  
Ferrous succinate B03AA06 NE  
Ferrous sulfate B03AA07 
B03AD03 
0 • No special advice 
Ferrous tartrate B03AA08 NE  
Fexofenadine R06AX26 I • Inform the patient about the effects that the medicine can have on reaction time and 
that the medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advise the patient not to drive when this side effects occur and also to be careful in 
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other situations (e.g. using machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Fibrinogen, human  B02BC10 0 • No special advice 
Fibrinolysin B01AD05 NE  
Fibrinolysin and 
desoxyribonuclease 
B06AA02 NE  
Finasteride  D11AX10 0  
Fipexide N06BX05 NE  
Flecainide C01BC04 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Floctafenine N02BG04 NE  
Flourometholone and 
antiinfectives 
- Drops 
- Oinment 
S01CA07  
0 
I 
• Inform the patient that as with any ocular medication, if transient, vision occurs at 
application.  
• Advice the patient that he/she should wait until his/her vision clears before driving or 
using machinery. 
Fluanisone N05AD09 NE  
Flubiprofen S01BC04 NE  
Fluclorolone D07AC02 0 • No special advice 
Fluconazole D01AC15 NE  
Flucytosine  D01AE21 NE  
Fludiazepam N05BA17 NE  
Fludrocortisone and 
antiinfectives 
- Drops 
- Oinment 
S01CA06  
0 
I 
• Inform the patient that as with any ocular medication, if transient, vision occurs at 
application.  
• Advice the patient that he/she should wait until his/her vision clears before driving or 
using machinery. 
Fludrocortisone and 
antiinfectives 
S02CA07 
S03CA05 
0 • No special advice 
 
Fludroxycortide D07AC07 NE  
Fludroxycortide and antibiotics D07CC03 NE  
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Flufenamic acid M01AG03 NE  
Flumetasone  D07AB03 
D07XB01 
0 • No special advice 
 
Flumetasone and antibiotics D07CB05 NE  
Flumetasone and antiinfectives S02CA02 NE  
Flumetasone and antiseptics D07BB01 0 • No special advice 
Flunarizine   N07CA03 II • Advise the patient (and explain to caregivers) not to drive during the first days of 
treatment.   
• The treatment has to be used according to the recommended dose.  
• Vertigo and hearing loss requiring this treatment can also impair ability to drive. 
Flunisolide R03BA03 NE  
Flunitrazepam N05CD03 III • Inform the patient about the effects of the medicine on reaction time, that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) and that reaction time can 
also be reduced without experiencing side effects. 
• Advice the patient not to drive until the next visit after start of treatment and also to 
be careful in other situations (e.g. using machinery and working at heights) 
• Advice the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
• One time (occasional) use: inform your patient that his/her response is still reduced 
for approximately 3 days to one week. Advice your patient not to drive then. 
Flunoxaprofen M01AE15 NE  
Fluocinolone acetonide C05AA10 
D07AC04 
0 • No special advice 
 
Fluocinolone acetonide S01BA15 
S02BA08 
NE  
Fluocinolone acetonide and 
antibiotics 
D07CC02 0 • No special advice 
Fluocinolone acetonide and 
antiinfectives 
S01CA10 NE  
Fluocinolone acetonide and 
antiinfectives 
S02CA05 0 • No special advice 
Fluocinolone acetonide and D07BC02 0 • No special advice 
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antiseptics 
Fluocinonide C05AA11 
D07AC08 
0 • No special advice 
Fluocinonide and antibiotics D07CC05 0 • No special advice 
Fluocortin D07AB04 0 • No special advice 
Fluocortolone C05AA08 NE  
Fluocortolone D07AC05 0 • No special advice 
Fluocortolone and antibiotics D07CC06 NE  
Fluocortolone and 
antiinfectives 
S01CA04 NE  
Fluocortolone and antiseptics D07BC03 0 • No special advice 
Fluorescein S01JA01 0 • No special advice 
Fluorescein, combinations S01JA51 Depending on the 
medicine in 
combination 
• Depending on the medicine in combination (Fluorescein + local anaesthetics cat I) 
Fluoride, combinations A12CD51 0 • No special advice 
Fluorocarbon blood substitutes B05AA03 NE  
Fluorometholone C05AA06 
D07XB04 
0 • No special advice 
Fluorometholone  
- Drops 
- Oinment 
S01BA07  
0 
I 
 
• Inform the patient that as with any ocular medication, if transient, blurred vision 
occurs at application.  
• Advice the patient that he/she should wait until his/her vision clears before driving or 
using machinery. 
Fluorometholone  D07AB06 
D10AA01 
NE  
Fluorometholone S01CB05 Depending on the 
mydriatic in 
combination 
• Depending on the mydriatic in combination 
Fluorometholone and 
antibiotics 
D07CB03 NE  
Fluorometholone and 
mydriatics 
S01BB03 Depending on the 
mydriatic in 
combination 
• Depending on the mydriatic in combination 
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Fluostigmine S01EB07 NE  
Fluoxetine N06AB03 I • Inform your patient about the effects of the medication on reaction time as well as 
that the medication can cause side-effects that impair driving abilities (e.g. dizziness, 
drowsiness, sleepiness, blurred vision, etc.). 
• Advice your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities. 
• Advice your patient not to drive as long as side-effects persist. 
• Advice your patient not to drink alcohol nor use any other psychoactive substance 
when taking this medication. 
Flupentixol 
- Oral administration 
 
 
 
 
 
 
 
- Parenteral administration: 
depot i.m. 
N05AF01  
II 
 
 
 
 
 
 
 
 
 
III 
Oral administration: 
• Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advice the patient not to drink alcohol when taking this medicine. 
• In short-term use, inform your patient that his/her response is still reduced for 
approximately 24 hours. Advice the patient not to drive then. 
 
Parenteral administration 
• Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive until the next visit after start of treatment and also to 
be careful in other situations (e.g. using machinery and working at heights) 
• Advice the patient not to drink alcohol when taking this medicine. 
• In short-term use, inform your patient that his/her response is still reduced for 
approximately 24 hours. Advice the patient not to drive then. 
Fluperolone D07AB05 NE  
Fluphenazine: injection depot 
i.m. 
N05AB02 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first few days of treatment or until the next visit 
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after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advice the patient not to drink alcohol when taking this medicine. 
Flupirtine N02BG07 NE  
Fluprednidene D07AB07 
D07XB03 
NE  
Fluprednidene and antibiotics D07CB02 NE  
Flurazepam N05CD01 III • Inform the patient about the effects of the medicine on reaction time, that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) and that reaction time can 
also be reduced without experiencing side effects. 
• Advice the patient not to drive until the next visit after start of treatment and also to 
be careful in other situations (e.g. using machinery and working at heights) 
• Advice the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
• One time(occasional) use: inform your patient that his/her response is still reduced 
for approximately 3 days to one week. Advice your patient not to drive then. 
Flurbiprofen M01AE09 I • Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
Flurbiprofen M02AA19 
R02AX01 
0 • No special advice 
Fluspirilene: injection i.m. N05AG01 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advice the patient not to drink alcohol when taking this medicine. 
Fluticasone  D07AC17 
R01AD08 
0 • No special advice 
• No special advice 
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R03BA05 • No special advice 
Fluticasone furoate R01AD12 0 • No special advice 
Flutrimazole D01AC16 0 • No special advice 
Fluvastatin C10AA04 0 • No special advice 
Fluvoxamine N06AB08 I • Inform your patient about the effects of the medication on reaction time as well as 
that the medication can cause side-effects that impair driving abilities (e.g. dizziness, 
drowsiness, sleepiness, blurred vision, etc.). 
• Advice your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities. 
• Advice your patient not to drive as long as side-effects persist. 
• Advice your patient not to drink alcohol nor use any other psychoactive substance 
when taking this medication. 
Folic acid B03BB01 0 • No special advice 
Folic acid, combinations B03BB51 0 • No special advice 
Fomivirsen S01AD08 NE  
Fondaparinux B01AX05 0 • No special advice 
Formocortal S01BA12 NE  
Formoterol R03AC13 0 • No special advice 
Formoterol and other drugs for 
obstructive airway diseases  
R03AK07 NE  
Fosaprepitant A04AD 0 • No special advice 
Fosinopril C09AA09 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Fosinopril and diuretics C09BA09 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
 Fosphenytoin N03AB05 NE  
Framycetin D09AA01 NE  
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R01AX08 
S01AA07 
Frovatriptan N02CC07 II • Advise the patient not to drive during the first times, the drug is administered, until 
he/she knows his/her reactions.   
• Advise the patient not to drive within the first 4 hours after treatment. 
• Inform the patient that the medication can cause side effects that impair driving 
and that reaction time can also be reduced without experiencing side effects. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to strictly follow the prescribed doses and intake scheme.  
• Advise the patient to avoid any alcohol or other psychoactive substances during 
the treatment. 
Fructose 1,6-diphosphate C01EB07 NE  
Fumaric acid D05AX01 NE  
Fumaric acid derivatives, 
combinations 
D05BX51 NE  
Funisolide R01AD04 0 • No special advice 
Furosemide C03CA01 0 • No special advice 
Furosemide and potassium C03CB01 0 • No special advice 
Furosemide and potassium-
sparing agents 
C03EB01 0 • No special advice 
Fusafungine R02AB03 NE  
Fusidic acid D06AX01 
D09AA02 
0 • No special advice 
Fusidic acid 
- Drops 
- Oinment 
S01AA13  
0 
I 
• Inform the patient that as with any ocular medication, if transient, blurred vision 
occurs at application.  
• Advice the patient that he/she should wait until his/her vision clears before driving or 
using machinery. 
    
 ATC CODE CATEGORIZATION 
labelling 
INFORMATION FOR THE PATIENT 
Gabapentin N03AX12  II 
 
Advise the patient not to drive during the first days of treatment as well as after dose 
increases. 
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General warnings: 
• Advise the patient to take the medicine as prescribed by the physician. 
• Advise the patient not to stop taking the medicine suddenly, and to inform the 
physician – doctor if he/she should do so. 
• Advise the patient not to drink alcohol while taking this medication. 
 
Neuropathic pain. 
• Advise the patient not to drive during the first days of treatment as well as after dose 
increases. 
Galantamine N06DA04 II • Inform your patient (and explain his/her caregiver) about the effects of the 
medication on reaction time as well as that the medication can cause side-effects 
that impair driving abilities (e.g. dizziness, drowsiness, sleepiness, blurred vision, 
etc.). 
• Advise your patient (and explain his/her caregiver) not to drive for the first few 
weeks of treatment or until the next visit and to be careful in other situations, as well 
(e.g. operating machinery and working at heights). 
• Advise your patient (and explain his/her caregiver) not to drink alcohol nor use any 
other psychoactive substance when taking this medication. 
• In case of short-term use of the medication, advise your patient (and explain his/her 
caregiver) not to drive because his/her driving skills are still impaired for 
approximately 24 hours. 
• Driving with this treatment should require an approval by driving licence 
administration. 
Gallamine  M03AC02 III • Advise the patient not to drive or operate machinery until the effects of the 
anaesthetic, and the immediate effects of surgery have passed. 
• Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after 
anaesthesia 
Gallopamil C08DA02 NE  
Galsulfase  A16AB08 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, somnolence, lethargy, lacrimation increased, 
tinnitus, vertigo, etc.) particularly during the first day of treatment, and not to drive 
as long as side-effects persist. 
Gamolenic acid, combinations D11AX52 NE  
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Ganciclovir S01AD09 0 • No special advice 
Gatifloxacin S01AX21 NE  
Gedocarnil N05BX02 NE  
Gefarnate A02BX07 NE  
Gefarnate, combinations with 
psycholeptics 
A02BX77 NE  
Gelatin agents B05AA06 0 • No special advice 
Gemfibrozil C10AB04 0 • No special advice 
Gentamicin  D06AX07 0 • No special advice 
Gentamicin 
- Drops 
- Oinment 
S01AA11  
0 
I 
• Inform the patient that as with any ocular medication, if transient, blurred vision 
occurs at application.  
• Advice the patient that he/she should wait until his/her vision clears before driving or 
using machinery. 
Gentamicin S02AA14 
S03AA06 
NE  
Gepefrine C01CA15 NE  
Gepirone N06AX19 NE  
Ginkgo Biloba N06DX02 0 • No special advice 
Gitoformate C01AA09 NE  
Glafenine N02BG03 NE  
Glibenclamide A10BB01 I • Advise your patient to take precautions to avoid hypoglycaemia, this may constitute 
a risk in situations where these abilities are of special importance (e.g. driving a car 
or operating machinery), and not to drive as long as side-effects persist. 
• If your patient has frequent episodes or if he/she find it hard to recognise 
hypoglycaemia. The advisability of driving should be considered in these 
circumstances. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication 
Glibornuride A10BB04 NE  
Gliclazide A10BB09 I • Advise your patient to take precautions to avoid hypoglycaemia, this may constitute 
a risk in situations where these abilities are of special importance (e.g. driving a car 
or operating machinery), and not to drive as long as side-effects persist. 
• If your patient has frequent episodes or if he/she find it hard to recognise 
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hypoglycaemia. The advisability of driving should be considered in these 
circumstances. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication 
Glimepiride A10BB12 I • Advise your patient to take precautions to avoid hypoglycaemia, this may constitute 
a risk in situations where these abilities are of special importance (e.g. driving a car 
or operating machinery), and not to drive as long as side-effects persist. 
• If your patient has frequent episodes or if he/she find it hard to recognise 
hypoglycaemia. The advisability of driving should be considered in these 
circumstances. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication 
Glimepiride and pioglitazone A10BD06 I • Advise your patient to take precautions to avoid hypoglycaemia, this may constitute 
a risk in situations where these abilities are of special importance (e.g. driving a car 
or operating machinery), and not to drive as long as side-effects persist. 
• If your patient has frequent episodes or if he/she find it hard to recognise 
hypoglycaemia. The advisability of driving should be considered in these 
circumstances. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication 
Glimepiride and rosiglitazone A10BD04 I • Advise your patient to take precautions to avoid hypoglycaemia, this may constitute 
a risk in situations where these abilities are of special importance (e.g. driving a car 
or operating machinery), and not to drive as long as side-effects persist. 
• If your patient has frequent episodes or if he/she find it hard to recognise 
hypoglycaemia. The advisability of driving should be considered in these 
circumstances. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication 
Glipizide A10BB07 I • Advise your patient to take precautions to avoid hypoglycaemia, this may constitute 
a risk in situations where these abilities are of special importance (e.g. driving a car 
or operating machinery), and not to drive as long as side-effects persist. 
• If your patient has frequent episodes or if he/she find it hard to recognise 
hypoglycaemia. The advisability of driving should be considered in these 
circumstances. 
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• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication 
Gliquidone A10BB08 I • Advise your patient to take precautions to avoid hypoglycaemia, this may constitute 
a risk in situations where these abilities are of special importance (e.g. driving a car 
or operating machinery), and not to drive as long as side-effects persist. 
• If your patient has frequent episodes or if he/she find it hard to recognise 
hypoglycaemia. The advisability of driving should be considered in these 
circumstances. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication 
Glisoxepide A10BB11 NE  
Glucosamine M01AX05 I • Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
Glucosaminoglykan polysulfate M01AX12 NE  
Glucose B05CX01 0 • No special advice 
Glucose, combinations C05BB56 0 • No special advice 
Glutamic acid hydrochloride A09AB01 NE  
Glutamine  A16AA03 0 • No special advice 
Glutethimide N05CE01 NE  
Glycerol A06AG04 
A06AX01 
0 • No special advice 
Glyceryl trinitrate C01DA02 
C05AE01 
I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Glyceryl trinitrate, 
combinations. 
C01DA52 NE  
Glycine B05CX03 0 • No special advice 
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Glycopyrronium A03AB02 0 • No special advice 
Glycopyrronium and 
psycholeptics 
A03CA05 NE  
Glycyrrhizic acid A05BA08 NE  
Glymidine A10BC01 NE  
Gramicidin R02AB30 NE  
Granisetron  A04AA02 0 • No special advice 
Griseofulvin D01AA08 NE  
Griseofulvin  D01BA01 0 • No special advice 
G-strophanthin C01AC01 NE  
Guacetisal N02BA14 NE  
Guaiacolsulfonate R05CA09 NE  
Guaiazulen S01XA01 NE  
Guaifenesin R05CA03 I • Inform the patient about the effects that the medicine can have on reaction time and 
that the medication can cause side effects that impair driving (dizziness, 
drowsiness) 
• Advise the patient not to drive when this side effects occur and also to be careful in 
other situations (e.g. using machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Guanazodine C02CC06 NE  
Guanethidine C02CC02 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Guanethidine S01EX01 NE  
Guanethidine and diuretics C02LF01 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist.  
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Guanfacine C02AC02 II • Inform your patient that the medication can cause side effects that impair driving 
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abilities (e.g. dizziness, drowsiness, hypotension, fatigue, etc.). 
• Advise your patient not to drive for the first few days of treatment and to be careful 
in other situations, as well (e.g. operating machinery and working at heights). 
• Advise the patient not to drink alcohol nor use any psychoactive substance when 
taking this medicine. 
Guanoclor C02CC05 NE  
Guanoxabenz C02CC07 NE  
Guanoxan C02CC03 NE  
Guar gum A10BX01 0 • No special advice 
    
H ATC CODE CATEGORIZATION 
labelling 
INFORMATION FOR THE PATIENT 
Hachimycin D01AA03 NE  
Halazepam N05BA13 NE  
Halcinonide D07AD02 NE  
Halometasone D07AC12 0 • No special advice 
Haloperidol 
- Oral administration 
 
 
 
 
 
 
 
 
 
 
- Parenteral 
administration:i.v./i.m. 
N05AD01  
II 
 
 
 
 
 
 
 
 
 
 
 
III 
Oral administration: 
• Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advice the patient not to drink alcohol when taking this medicine. 
• In short-term use (eg intractable hiccup, nausea and vomiting), inform your patient 
that his/her response is still reduced for approximately 24 hours. Advice the patient 
not to drive then. 
 
Parenteral administration: 
• Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive until the next visit after start of treatment and also to 
be careful in other situations (e.g. using machinery and working at heights) 
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• Advice the patient not to drink alcohol when taking this medicine. 
• In short-term use (eg intractable hiccup, nausea and vomiting), inform your patient 
that his/her response is still reduced for approximately 24 hours. Advice the patient 
not to drive then. 
Haloprogin D01AE11 NE  
 Halothane N01AB01 NE  
Hematin B06AB01 0 • No special advice 
Hemoglobin crosfumaril B05AA08 NE  
Hemoglobin glutamer (bovine) B05AA10 NE  
Hemoglobin raffimer B05AA09 NE  
Heparin B01AB01 
C05BA03 
0 • No special advice 
 
Heparin S01XA14 NE  
Heparin, combinations B01AB51 NE  
Heparin, combinations C05BA53 0 • No special advice 
Heparinoid, combinations C05BA51 0 • No special advice 
Heptabarbital N05CA11 NE  
Heptaminol C01DX08 NE  
Hexachlorophene D08AE01 NE  
Hexafluronium M03AC05 III • Advise the patient not to drive or operate machinery until the effects of the 
anaesthetic, and the immediate effects of surgery have passed. 
• Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after 
anaesthesia 
Hexamidine D08AC04 
R01AX07 
R02AA18 
S01AX08 
S03AA05 
NE  
Hexapropymate N05CM10 NE  
Hexetidine A01AB12 0 • No special advice 
 Hexobarbital N01AF02 
N05CA16 
NE  
Hexobendine C01DX06 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
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his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Hexocyclium A03AB10 NE  
Hexoprenaline R03AC06 
R03CC05 
NE  
Hexylresorcinol R02AA12 0 • No special advice 
Hidrosmin C05CA05 0 • No special advice 
Histapyrrodine R06AC02 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
restlessness, sedation) 
• Advise the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Histapyrrodine, combinations R06AC52 NE  
Homatropine S01FA05 III • Inform the patient that this ocular medication may cause transient blurring of vision 
or that he/she may suffer from photophobia and that this may impair their ability to 
drive under certain circumstances. Complete recovery from the effects of mydriatic 
anticholinergics may take up to 24 hours. 
• Advise the patients not to drive or operate hazardous machinery until 24 hours after 
receiving ocular medication (recovery occurs within 24 hours) or until vision is clear. 
Human fibrinogen B02BB01 0 • No special advice 
Human fibrinogen / Human 
thrombin (Evicel®) 
B02BC 0 • No special advice 
Hyaluronic acid R01AX09 
S01KA01 
D03AX05 
NE  
Hyaluronic acid M09AX01 0 • No special advice 
Hyaluronic acid, combinations S01KA51 NE  
Hyaluronidase B06AA03 0 • No special advice 
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Hydralazine C02DB02 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Hydralazine and diuretics C02LG02 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
 Hydrixybutiric acid N01AX11 NE  
Hydrochloric acid A09AB03 NE  
Hydrochloric acid B05XA13 0 • No special advice 
Hydrochlorothiazide C03AA03 0 • No special advice 
Hydrochlorothiazide and 
potassium 
C03AB03 0 • No special advice 
Hydrochlorothiazide and 
potassium-sparing agents 
(spironolactone) 
C03EA01 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Hydrochlorothiazide, 
combinations 
C03AX01 0 • No special advice 
Hydrocodone R05DA03 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, reduced alertness) 
• Advise the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Hydrocortisone A01AC03 
A07EA02 
C05AA01 
0 • No special advice 
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D07AA02 
D07XA01 
 
 
Hydrocortisone S01BA02 I  • Inform the patient that as with any ocular medication, if transient, blurred vision 
occurs at application.  
• Advice the patient that he/she should wait until his/her vision clears before driving or 
using machinery. 
Hydrocortisone (with 
mydriatics) 
S01CB03 Depending on the 
mydriatic in 
combination 
• Depending on the mydriatic in combination 
Hydrocortisone S02BA01 NE  
Hydrocortisone aceponate D07AC16 NE  
Hydrocortisone and antibiotics D07CA01 0 • No special advice 
Hydrocortisone and 
antiinfectives 
- Drops 
- Oinment 
S01CA03  
 
0 
I 
• Inform the patient that as with any ocular medication, if transient, vision occurs at 
application.  
• Advice the patient that he/she should wait until his/her vision clears before driving or 
using machinery. 
Hydrocortisone and 
antiinfectives 
S02CA03 0 • No special advice 
Hydrocortisone and 
antiinfectives 
S03CA04 0 
• No special advice 
Hydrocortisone and antiseptics D07BA04 0 • No special advice 
Hydrocortisone and mydriatics S01BB01 Depending on the 
mydriatic in 
combination 
• Depending on the mydriatic in combination 
Hydrocortisone buteprate D07AB11 NE  
Hydrocortisone butyrate D07AB02 0 • No special advice 
Hydrocortisone butyrate and 
antiseptics 
D07BB04 NE  
Hydrocortisone, combinations R01AD60 NE  
Hydroflumethiazide C03AA02 0 • No special advice 
Hydroflumethiazide and 
potassium 
C03AB02 0 • No special advice 
Hydroflumethiazide, C03AH02 NE  
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combinations 
Hydrogen peroxide A01AB02 
D08AX01 
0 • No special advice 
Hydrogen peroxide S02AA06 NE NE 
Hydromorphone  N02AA03 III/II* 
*) prolonged release 
formulation; when a 
steady state of 
dosage has been 
reached 
• Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient (and explain to caregivers) not to drive until the next visit after 
start of treatment or after changes in dosage. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to strictly follow the prescribed doses and intake scheme.  
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
• Opiate cessation can also cause behavioral changes and requires follow-up and 
counseling. 
Hydromorphone and 
antispasmodics 
N02AG04 NE  
Hydroquinidine C01BA NE  
Hydroquinine M09AA01 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. visual disturbances, vertigo), and not to drive as long as 
side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication 
Hydroquinone D11AX11 0 • No special advice 
Hydrotalcite A02AD04 0 • No special advice 
Hydroxocobalamin B03BA03 0 • No special advice 
Hydroxocobalamin, 
combinations 
B03BA53 0 • No special advice 
Hydroxybutyryc acid N07XX04 NE  
Hydroxyethylpromethazine R06AD05 NE  
Hydroxyethylpromethazine, 
combinations 
R06AD55 NE  
Hydroxyethylstarch B05AA07 0 • No special advice 
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Hydroxyzine N05BB01 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advice the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
• One time (occasional) use: inform your patient that his/her response is still reduced 
for a few days. Advice your patient not to drive then. 
Hydroxyzine, combinations N05BB51 NE  
Hymecromone A05AX02 NE  
Hyoscyamine A03BA03 NE  
Hyoscyamine and 
Psycholeptics 
A03CB31 NE  
Hypericine N06AX20 0 • No special advice 
Hypertonic solutions  B05DB 0 • No special advice 
Hypromellose S01KA02 0 • No special advice 
    
 ATC CODE CATEGORIZATION 
labelling 
INFORMATION FOR THE PATIENT 
Ibandronic acid  M05BA06 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. headache, dizziness, and not to drive as long as side-
effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication 
Ibopamine C01CA16 
S01FB03 
NE  
Ibudilast R03DC04 NE  
Ibuprofen C01EB16 NE  
Ibuprofen M02AA13 0 • No special advice 
Ibuprofen M01AE01 
N02BG 
I • Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
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• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
Ibuprofen, combinations M01AE51 I • Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
Ibuproxam M01AE13 NE  
Ibutilide C01BD05 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Icatibant C01EB19 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Ichtasol D10BX01 NE  
Idanpramine A03AX06 NE  
Idebenone N06BX13 NE  
Idoxuridine D06BB01 0 • No special advice 
Idoxuridine S01AD01 NE  
Idursulfase  A16AB09 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, somnolence, lethargy, lacrimation increased, 
tinnitus, vertigo, etc.) particularly during the first day of treatment, and not to drive as 
long as side-effects persist. 
Ifenprodil C04AX28 NE  
Iloprost (for inhalation use) B01AC11 II • Inform your patient that the medication can cause side effects that impair driving 
abilities (down blood pressure and may cause dizziness or light-headedness). Do 
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not drive or operate any tools or machines if you feel these effects of low blood 
pressure. 
• Advice the patient not to drive for the first few days of treatment until any effects on 
the individual have been determined and also to be careful in other situations (e.g. 
using machinery and working at heights) 
Imidapril C09AA16 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Imidazole salicylate N02BA16 NE  
Imiglucerase A16AB02 0 • No special advice 
Imipramine N06AA02 II • Inform your patient about the effects of the medication on reaction time as well as 
that the medication can cause side-effects that impair driving abilities (e.g. dizziness, 
drowsiness, sleepiness, blurred vision, etc.). 
• Advice your patient not to drive for the first few weeks of treatment or until the next 
visit and to be careful in other situations, as well (e.g. operating machinery and 
working at heights). 
• Advice your patient not to drink alcohol nor use any other psychoactive substance 
when taking this medication. 
• In case of short-term use of the medication, advice your patient not to drive because 
his/her driving skills are still impaired for approximately 24 hours. 
Imipramine oxide N06AA03 NE  
Imiquimod   D06BB10 0 • No special advice 
Imolamine C01DX09 NE  
Indacaterol R03AC18 0 • No special advice 
Indalpine N06AB 
Not yet 
determined 
NE  
Indapamide C03BA11 0 • No special advice 
Indobufen B01AC10 NE  
Indometacin C01EB03 
S01BC01 
NE  
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Indometacin M01AB01 I • Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
Indometacin M02AA23 0 • No special advice 
Indometacin, combinations M01AB51 I • Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
Indoprofen M01AE10 NE  
Indoramin C02CA02 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Inosine  D06BB05 0 • No special advice 
Inosine S01XA10 NE  
Inositol   A11HA07 0 • No special advice 
Inositol nicotinate C04AC03 0 • No special advice 
Insulins and analogues  
 
A10AB 
A10AC 
A10AD 
 
A10AE 
A10AF 
I • Advise your patient to take precautions to avoid hypoglycaemia, this may constitute 
a risk in situations where these abilities are of special importance (e.g. driving a car 
or operating machinery), and not to drive as long as side-effects persist. 
• If your patient have frequent episodes or if he/she find it hard to recognise 
hypoglycaemia. The advisability of driving should be considered in these 
circumstances.  
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication 
Interferon S01AD05 NE  
Invert sugar C05BB03 0 • No special advice 
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Iodine D08AG03 0 • No special advice 
Iodine/octylphenoxypolyglycole
ther  
D08AG01 NE  
Iodoform D09AA13 NE  
Iodoheparinate S01XA09 NE  
Ipecacuanha R05CA04 0 • No special advice 
Ipratropium bromide R01AX03 0 • No special advice 
Ipratropium bromide R03BB01 I • Inform the patient about the effects that the medicine can have on reaction time and 
that the medication can cause side effects that impair driving (dizziness, blurred 
vision) 
• Advise the patient not to drive when this side effects occur and also to be careful in 
other situations (e.g. using machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Iprazochrome N02CX03 NE  
Ipriflavone M05BX01 NE  
Iprindole N06AA13 NE  
Iproclozide N06AF06 NE  
Iproniazide N06AF05 NE  
Irbesartan C09CA04 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Irbesartan and diuretics C09DA04 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Iron and multivitamins B03AE03 0 • No special advice 
Iron, multivitamins and folic 
acid 
B03AE02 0 • No special advice 
Iron, multivitamins and B03AE04 0 • No special advice 
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minerals 
Iron, vitamin B12 and folic acid B03AE01 0 • No special advice 
Iron-sorbitol-citric acid complex B03AC03 NE  
Isoaminile R05DB04 NE  
Isobromindione M04AB04 NE  
Isocarboxazide N06AF01 NE  
Isoconazole D01AC05 NE  
Isoetarine R03AC07 
R03CC06 
NE  
 Isoflurane N01AB06 III • Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient (and explain to caregivers) not to drive until the next visit after start 
of treatment or after changes in dosage. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to strictly follow the prescribed doses and the intake scheme.  
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
• Opiate cessation can also cause behavioral changes and requires follow-up and 
counseling. 
Isometheptene  A03AX10 0 • No special advice 
Isoprenaline C01CA02 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Isoprenaline R03AB02 
R03CB01 
NE  
Isoprenaline and other drugs 
for obstructive airway 
diseases  
R03AK02 NE  
Isoprenaline, combinations R03CB51 NE  
Isopropamide A03AB09 NE  
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Isopropamide and 
psycholeptics 
A03CA01 NE  
Isopropanol D08AX05 NE  
Isosorbide dinitrate C01DA08 
C05AE02 
 
I 
• Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Isosorbide dinitrate, 
combinations 
C01DA58 NE  
Isosorbide mononitrate C01DA14 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Isothipendyl  D04AA22 NE  
Isothipendyl R06AD09 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advise the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Isotonic solutions B05DA 0 • No special advice 
Isotretinoin D10AD04 0 • No special advice 
Isotretinoin  
- Oral administration 
- Topical use 
D10BA01  
II 
0 
• Inform your patient that the medication can cause side effects that impair driving 
abilities (e.g., decreased night vision in some cases was sudden, visual and 
neurological disturbances etc.) 
• Advise your patient not to drive for the first few days of treatment and to be careful in 
other situations, as well (e.g. operating machinery and working at heights). 
• Advise the patient not to drink alcohol nor use any psychoactive substance when 
taking this medicine. 
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Isotretinoin, combinations (with 
erythromycin, topical use) 
D10AD54 0 • No special advice 
Isoxsuprine C04AA01 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Ispaghula (psylla seeds) A06AC01 0 • No special advice 
Ispaghula, combinations A06AC51 0 • No special advice 
Isradipine C08CA03 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Itramin tosilate C01DX01 NE  
Itramin tosilate, combinations C01DX51 NE  
Ivabradine C01EB17 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
    
K ATC CODE CATEGORIZATION 
labelling 
INFORMATION FOR THE PATIENT 
Kallidinogenase C04AF01 NE  
Kanamycin A07AA08 
S01AA24 
NE  
Kaolin A07BC02 NE  
Kebuzone M01AA06 NE  
 Ketamine N01AX03 III • Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient (and explain to caregivers) not to drive until the next visit after start 
of treatment or after changes in dosage. 
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• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to strictly follow the prescribed doses and the intake scheme.  
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
• Opiate cessation can also cause behavioral changes and requires follow-up and 
counseling. 
Ketanserin C02KD01 NE  
Ketazolam N05BA10 NE  
Ketobemidone N02AB01 NE  
Ketobemidone and 
antispasmodics 
N02AG02 NE  
Ketoconazole D01AC08 0 • No special advice 
Ketoprofen M02AA10 0 • No special advice 
Ketoprofen M01AE03 
N02BG 
I • Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
Ketoprofen, combinations M01AE53 I • Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
Ketorolac M01AB15 I • Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
Ketorolac S01BC05 0 • No special advice 
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Ketotifen R06AX17 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
insomnia) 
• Advise the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Ketotifen S01GX08 I • Inform the patient that this ocular medication may cause side effects including local 
irritation, temporary blurred vision or other visual disturbances, transient stinging and 
burning after instillation. 
• Advise the patient that if he/she experiences these symptoms, he/she should wait 
until they have cleared before driving or using machinery. 
    
L ATC CODE CATEGORIZATION 
labelling 
INFORMATION FOR THE PATIENT 
Labetalol C07AG01 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Labetalol and other diuretics C07CG01 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Labetalol and thiazides C07BG01 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Lacidipine C08CA09 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
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• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
 Lacosamide N03AX18 II Advise the patient not to drive during the first days of treatment as well as after 
dose increases. 
 
General warnings: 
• Advise the patient to take the medicine as prescribed by the physician. 
• Advise the patient not to stop taking the medicine suddenly, and to inform the 
physician – doctor if he/she should do so. 
• Advise the patient not to drink alcohol while taking this medication. 
Lactic acid producing 
organisms 
A07FA01 0 • No special advice 
 
Lactic acid producing 
organisms, combinations 
A07FA02 0 • No special advice 
Lactitol A06AD12 0 • No special advice 
Lactulose A06AD11 0 • No special advice 
Lactulose, combinations A06AD61 NE  
Lafutidine  A02BA08 NE  
 Lamotrigine N03AX09 II Advise the patient not to drive during the first days of treatment as well as after 
dose increases. 
 
Advise the patient that visual field testing should be done regularly. 
General warnings: 
• Advise the patient to take the medicine as prescribed by the physician. 
• Advise the patient not to stop taking the medicine suddenly, and to inform the 
physician – doctor if he/she should do so. 
• Advise the patient not to drink alcohol while taking this medication. 
Lanatoside C C01AA06 NE  
Lansoprazole A02BC03 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness) particularly during the first day of treatment, 
and not to drive as long as side-effects persist. 
Lansoprazole, amoxicillin and 
clarithromycin  
A02BD07 NE  
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Lansoprazole, amoxicillin and 
metronidazole  
A02BD03 NE  
Lansoprazole, tetracycline and 
metronidazole  
A02BD02 NE  
Laronidase  A16AB05 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, somnolence, lethargy, lacrimation increased, 
tinnitus, vertigo, etc.) particularly during the first day of treatment, and not to drive as 
long as side-effects persist. 
Latanoprost S01EE01 I • Inform the patient that as with any ocular medication, if transient, blurred vision 
occurs at application.  
• Advice the patient that he/she should wait until his/her vision clears before driving or 
using machinery. 
Laurilsulfate, incl. 
combinations 
A06AG11 0 • No special advice 
 
Lepirudin B01AE02 0 • No special advice 
Lercanidipine C08CA13 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Letosteine R05CB09 NE  
Levacetylmethadol N07BC03 NE  
 Levetiracetam N03AX14 II Advise the patient not to drive during the first days of treatment as well as after 
dose increases. 
 
General warnings: 
• Advise the patient to take the medicine as prescribed by the physician. 
• Advise the patient not to stop taking the medicine suddenly, and to inform the 
physician – doctor if he/she should do so. 
• Advise the patient not to drink alcohol while taking this medication. 
Levobunolol S01ED03 I • Inform the patient that as with any ocular medication, if transient, blurred vision 
occurs at application.  
• Advice the patient that he/she should wait until his/her vision clears before driving or 
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using machinery. 
 Levobupivacaine N01BB10  
 
 
0 
 
 
 
 
I 
 
 
 
 
 
II 
 
 
 
 
 
III 
Categorization, labelling and information to the patient  depending of the route of 
administration 
 
Topic administration (skin, mucous) 
 
Infiltration (dental anaesthesia) 
Intrarticular, intrabursal, tendon sheath administration, etc.. 
• Advise the patient not to drive or operate machinery until the effect of the 
anaesthesia and the immediate effects of surgery are passed. 
 
Ocular administration: 
• Advise at the patient that their sight may become blurred, and not to drive or operate 
machinery during the first 24 hours after using local anesthetics. 
 
Regional anaesthesia (nerve-block, intravenous regional anaesthesia). 
Spinal /Epidural 
• Advise the patient (and explain to caregivers), in the event an early discharge is 
envisaged following  regional / epidural / spinal anaesthesia, not to drive or operate 
machinery during the first 24 hours after anaesthesia.  
• Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after 
anaesthesia 
Levocabastine R01AC02 0 • No special advice 
Levocabastine S01GX02 I • Inform the patient that this ocular medication may cause side effects including local 
irritation, temporary blurred vision or other visual disturbances, transient stinging and 
burning after instillation. 
• Advise the patient that if he/she experiences these symptoms, he/she should wait 
until they have cleared before driving or using machinery. 
Levocarnitine A16AA01 0 • No special advice 
Levocetirizine R06AE09 I • Inform the patient about the effects that the medicine can have on reaction time and 
that the medication can cause side effects that impair driving (dizziness, drowsiness, 
fatigue, reduced alertness) 
• Advise the patient not to drive when this side effects occur and also to be careful in 
other situations (e.g. using machinery and working at heights) 
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• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
 Levodopa N04BA01  II • Advise the patient (and explain to caregivers) not to drive during the first days of 
treatment. 
• Inform patients that unwanted effects are seen rapidly during the dosage adjustment 
period. 
• Advise the patient (and explain to caregivers) not to drive at all if suffering from 
“sleep attacks”. 
• Advise the patient (and explain to caregivers) not to drive at all if suffering from 
severe fluctuations in mobility “(“on-off” phenomena). 
 Levodopa and    decarboxylase 
inhibitor 
Levodopa+carbidopa 
Levodopa+benserazide 
N04BA02 II • Advise the patient (and explain to caregivers) not to drive during the first days of 
treatment. 
• Inform patients that unwanted effects are seen rapidly during the dosage adjustment 
period. 
• Advise the patient (and explain to caregivers) not to drive at all if suffering from 
“sleep attacks”. 
• Advise the patient (and explain to caregivers) not to drive at all if suffering from 
severe fluctuations in mobility “(“on-off” phenomena). 
Levodopa, decarboxylase 
inhibitor and COMT inhibitor 
Levodopa+carbidopa+entocapo
ne 
N04BA03 II • Advise the patient (and explain to caregivers) not to drive during the first days of 
treatment. 
• Inform patients that unwanted effects are seen rapidly during the dosage adjustment 
period. 
• Advise the patient (and explain to caregivers) not to drive at all if suffering from 
“sleep attacks”. 
• Advise the patient (and explain to caregivers) not to drive at all if suffering from 
severe fluctuations in mobility “(“on-off” phenomena). 
Levodropropizine R05DB27 I • Inform the patient about the effects that the medicine can have on reaction time and 
that the medication can cause side effects that impair driving (fatigue, asthenia, 
numbness, drowsiness, dizziness) 
• Advise the patient not to drive when this side effects occur and also to be careful in 
other situations (e.g. using machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
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Levofloxacin S01AX19 NE  
Levomepromazine 
- Oral administration:  
- Parenteral administration 
N05AA02 III • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive until the next visit after start of treatment and also to 
be careful in other situations (e.g. using machinery and working at heights) 
• Advice the patient not to drink alcohol when taking this medicine. 
• In short-term use, inform your patient that his/her response is still reduced for 
approximately 24 hours. Advice the patient not to drive then. 
Levopenbutolol Not yet 
determined 
I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Levorphanol N02AF NE  
Levosimendan C01CX08 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Levosulpiride  N05AL07 
A04AD 
 
II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness). 
• Advise the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights). 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Levoverbenone R05CA11 NE  
Lidocaine S01HA07 
S02DA01 
NE  
Lidocaine (Anesthetics, local) N01BB02 
 
 
 
0 
Categorization, labelling and information to the patient  depending of the route 
of administration 
 
 DRUID 6th Framework Programme         Deliverable D.4.4.1  
   Classification of medicinal drugs and driving: 
 Co-ordination and synthesis report.  
   Page 132 of 243 
 
  
 
   
 
 
 
 
 
 
I 
 
 
 
 
II 
 
 
 
 
III 
Topic administration (skin, mucous) 
 
Infiltration (dental anaesthesia) 
Intrarticular, intrabursal, tendon sheath administration, etc.. 
• Advise the patient not to drive or operate machinery until the effect of the 
anaesthesia and the immediate effects of surgery are passed. 
 
Ocular administration: 
• Advise at the patient that their sight may become blurred, and not to drive or operate 
machinery during the first 24 hours after using local anesthetics. 
 
Regional anaesthesia (nerve-block, intravenous regional anaesthesia). 
Spinal /Epidural 
• Advise the patient (and explain to caregivers), in the event an early discharge is 
envisaged following  regional / epidural / spinal anaesthesia, not to drive or operate 
machinery during the first 24 hours after anaesthesia.  
• Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after 
anaesthesia 
lidocaine C05AD01 
D04AB01 
R02AD02 
0 • No special advice 
 
Lidocaine (Antiarrhytmics, 
parenteral use) 
C01BB01 I Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, etc.) 
and not to drive as long as side-effects persist. 
 
Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Lidocaine,  combinations 
(Anesthetics, local)  
N01BB52 
 
 
 
0 
 
 
 
 
Categorization, labelling and information to the patient  depending of the route 
of administration 
 
Topic administration (skin, mucous) 
 
Infiltration (dental anaesthesia) 
Intrarticular, intrabursal, tendon sheath administration, etc.. 
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I 
 
 
 
 
II 
 
 
 
 
III 
• Advise the patient not to drive or operate machinery until the effect of the 
anaesthesia and the immediate effects of surgery are passed. 
 
Ocular administration: 
• Advise at the patient that their sight may become blurred, and not to drive or operate 
machinery during the first 24 hours after using local anesthetics. 
 
Regional anaesthesia (nerve-block, intravenous regional anaesthesia). 
Spinal /Epidural 
• Advise the patient (and explain to caregivers), in the event an early discharge is 
envisaged following  regional / epidural / spinal anaesthesia, not to drive or operate 
machinery during the first 24 hours after anaesthesia.  
• Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after 
anaesthesia 
Lidoflazine C08EX01 NE  
Linopirdine N06BX09 NE  
Linseed A06AC05 0 • No special advice 
Linseed, combinations A06AC55 NE  
Linsidomine C01DX18 NE  
Liquid paraffin A06AA01 0 • No special advice 
Liquid paraffin, combinations A06AA51 0 • No special advice 
Liquid plaster D02AD 0 • No special advice 
Liraglutide A10BX07 I • Advise your patient to take precautions to avoid hypoglycaemia, this may constitute 
a risk in situations where these abilities are of special importance (e.g. driving a car 
or operating machinery), and not to drive as long as side-effects persist. 
• If your patient has frequent episodes or if he/she find it hard to recognise 
hypoglycaemia. The advisability of driving should be considered in these 
circumstances.  
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication 
Lisinopril C09AA03 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
 DRUID 6th Framework Programme         Deliverable D.4.4.1  
   Classification of medicinal drugs and driving: 
 Co-ordination and synthesis report.  
   Page 134 of 243 
 
  
 
   
 
 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Lisinopril and amlodipine C09BB03 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Lisinopril and diuretics C09BA03 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
 Lisuride N02CA07 
G02CB02 
NE  
Lithium N05AN01 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advice the patient not to drink alcohol when taking this medicine. 
Lithium succinate D11AX04 NE  
Lodoxamide S01GX05 I • Inform the patient that this ocular medication may cause side effects including local 
irritation, temporary blurred vision or other visual disturbances, transient stinging and 
burning after instillation. 
• Advise the patient that if he/she experiences these symptoms, he/she should wait 
until they have cleared before driving or using machinery. 
Lofepramine N06AA07 II • Inform your patient about the effects of the medication on reaction time as well as 
that the medication can cause side-effects that impair driving abilities (e.g. dizziness, 
drowsiness, sleepiness, blurred vision, etc.). 
• Advice your patient not to drive for the first few weeks of treatment or until the next 
visit and to be careful in other situations, as well (e.g. operating machinery and 
working at heights). 
• Advice your patient not to drink alcohol nor use any other psychoactive substance 
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when taking this medication. 
• In case of short-term use of the medication, advice your patient not to drive because 
his/her driving skills are still impaired for approximately 24 hours. 
Lofexidine N07BC04 NE  
Lomefloxacin 
- Drops 
- Oinment 
S01AX17  
0 
I 
• Inform the patient that as with any ocular medication, if transient, blurred vision 
occurs at application.  
• Advice the patient that he/she should wait until his/her vision clears before driving or 
using machinery. 
Lomoxicam M01AC05 NE  
Lonazolac M01AB09 NE  
Loperamide A07DA03 0 • No special advice 
Loperamide oxide A07DA05 NE  • No special advice 
Loperamide, combinations A07DA53 Depending on the 
medicine in 
combination 
• Depending on the medicine in combination 
Loprazolam N05CD11 III • Inform the patient about the effects of the medicine on reaction time, that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) and that reaction time can 
also be reduced without experiencing side effects. 
• Advice the patient not to drive until the next visit after start of treatment and also to 
be careful in other situations (e.g. using machinery and working at heights) 
• Advice the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
• One time (occasional) use: inform your patient that his/her response is still reduced 
for approximately 3 days. Advice your patient not to drive then. 
Lorajmine C01BA12 NE  
Loratadine R06AX13 I • Inform the patient about the effects that the medicine can have on reaction time and 
that the medication can cause side effects that impair driving (somnolence, 
insomnia, drowsiness) 
• Advise the patient not to drive when this side effects occur and also to be careful in 
other situations (e.g. using machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
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Lorazepam N05BA06 III • Inform the patient about the effects of the medicine on reaction time, that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) and that reaction time can 
also be reduced without experiencing side effects. 
• Advice the patient not to drive until the next visit after start of treatment and also to 
be careful in other situations (e.g. using machinery and working at heights) 
• Advice the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
• One time (occasional) use: inform your patient that his/her response is still reduced 
for approximately 3 days. Advice your patient not to drive then. 
Lorazepam, combinations N05BA56 NE  
Lorcainide C01BC07 NE  
Lormetazepam N05CD06 III • Inform the patient about the effects of the medicine on reaction time, that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) and that reaction time can 
also be reduced without experiencing side effects. 
• Advice the patient not to drive until the next visit after start of treatment and also to 
be careful in other situations (e.g. using machinery and working at heights) 
• Advice the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Losartan C09CA01 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Losartan and diuretics C09DA01 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Loteprednol S01BA14 NE  
Lovastatin C10AA02 0 • No special advice 
Lovastatin and nicotinic acid C10BA01 0 • No special advice 
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Loxapine N05AH01 NE  
Lubiprostone A06AX03 NE  
Lumiracoxib M01AH06 NE  
Lysine  B05XB03 NE  
Lysozyme  D06BB07 0 • No special advice 
    
M ATC CODE CATEGORIZATION 
labelling 
INFORMATION FOR THE PATIENT 
Macrogol A06AD15 0 • No special advice 
Macrogol, combinations A06AD65 0 • No special advice 
Mafenide D06BA03 NE  
Magaldrate A02AD02 0 • No special advice 
Magaldrate and antiflatulents A02AF01 0 • No special advice 
Magnesium (different salts in 
combination) 
A12CC30 0 • No special advice 
Magnesium aspartate A12CC05 NE  
Magnesium carbonate  A02AA01 0 • No special advice 
Magnesium carbonate  A06AD01 NE  
Magnesium chloride A12CC01 
B05XA11 
0 • No special advice 
 
Magnesium citrate A06AD19 
A12CC04 
B05CB03 
NE  
Magnesium gluconate A12CC03 NE  
Magnesium hydroxide A02AA04 0 • No special advice 
Magnesium lactate A12CC06 0 • No special advice 
Magnesium levulinate A12CC07 NE  
Magnesium orotate A12CC09 NE  
Magnesium oxide  A06AD02 NE  
Magnesium oxide A12CC10 0 • No special advice 
Magnesium peroxide  A02AA03 
A06AD03 
NE  
Magnesium phosphate B05XA10 0 • No special advice 
 DRUID 6th Framework Programme         Deliverable D.4.4.1  
   Classification of medicinal drugs and driving: 
 Co-ordination and synthesis report.  
   Page 138 of 243 
 
  
 
   
 
 
Magnesium pidolate A12CC08 0 • No special advice 
Magnesium pyridoxal 5-
phosphate glutamate 
C10AX07 NE  
Magnesium silicate  A02AA05 0 • No special advice 
Magnesium sulfate A06AD04 
B05XA05 
NE  
Magnesium sulfate A12CC02 
D11AX05 
NE  
Mandelic acid B05CA06 NE  
Manidipine C08CA11 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Mannitol A06AD16 NE  
Mannitol B05BC01 
B05CX04 
0 • No special advice 
• No special advice 
Maprotiline 
- Oral administration. 
 
 
 
 
 
 
 
  
- Parenteral administration 
N06AA21 II 
 
 
 
 
 
 
 
 
 
 
III 
Oral administration  
• Inform your patient about the effects of the medication on reaction time as well as 
that the medication can cause side-effects that impair driving abilities (e.g. dizziness, 
drowsiness, sleepiness, blurred vision, etc.). 
• Advice your patient not to drive for the first few weeks of treatment or until the next 
visit and to be careful in other situations, as well (e.g. operating machinery and 
working at heights). 
• Advice your patient not to drink alcohol nor use any other psychoactive substance 
when taking this medication. 
• In case of short-term use of the medication, advice your patient not to drive because 
his/her driving skills are still impaired for approximately 24 hours. 
 
Parenteral administration  
• Inform your patient about the effects of the medication on reaction time as well as 
that the medication can cause side-effects that impair driving abilities (e.g. dizziness, 
drowsiness, sleepiness, blurred vision, etc.). 
• Advice your patient not to drive until the next visit and to be careful in other 
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situations, as well (e.g. operating machinery and working at heights). 
• Advice your patient not to drink alcohol nor use any other psychoactive substance 
when taking this medication. 
• In case of short-term use of the medication, advice your patient not to drive because 
his/her driving skills are still impaired for approximately 24 hours. 
 Mazaticol N04AA10 NE  
Mazindol A08AA05 NE  
Mebeverine A03AA04 0 • No special advice 
Mebhydrolin R06AX15 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
insomnia) 
• Advise the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Mebutamate N05BC04 NE  
Mebutizide C03AA13 NE  
Mebutizide and potassium-
sparing agents 
(spironolactone) 
C03EA05 NE  
Meclocycline D10AF04 0 • No special advice 
Meclofenamic acid M01AG04 
M02AA18 
NE  
Meclofenoxate N06BX01 NE  
Meclozine R06AE05 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred vision and reduced alertness) 
• Advise the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Meclozine, combinations R06AE55 NE  
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Mecobalamin B03BA05 NE  
Medazepam N05BA03 NE  
Medicinal charcoal A07BA01 0 • No special advice 
 
Medicinal charcoal, 
combinations 
A07BA51 0 • No special advice 
Medifoxamine N06AX13 NE  
Medrysone S01BA08 NE  
Mefenamic Acid M01AG01 
N02BG 
I • Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
Mefenorex A08AA09 NE  
Mefruside C03BA05 NE  
Mefruside and potassium C03BB05 NE  
Meglutol C10AX05 NE  
Melagatran B01AE04 NE  
Melatonin N05CH01 I • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first 12 hours after taking the medicine and 
also to be careful in other situations (e.g. using machinery and working at heights) 
• Advice the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
 Melevodopa N04BA04 NE  
 Melevodopa and  
decarboxylase inhibitor 
N04BA05 NE  
 Melitracen N06AA14 NE  
Melitracen and psycholeptics N06AC02 NE  
Meloxicam M01AC06 I • Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
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• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
Melperone N05AD03 NE  
Memantine N06DX01 II • Inform your patient (and explain his/her caregiver) about the effects of the 
medication on reaction time as well as that the medication can cause side-effects 
that impair driving abilities (e.g. dizziness, drowsiness, sleepiness, blurred vision, 
etc.). 
• Advise your patient (and explain his/her caregiver) not to drive for the first few weeks 
of treatment or until the next visit and to be careful in other situations, as well (e.g. 
operating machinery and working at heights). 
• Advise your patient (and explain his/her caregiver) not to drink alcohol nor use any 
other psychoactive substance when taking this medication. 
• In case of short-term use of the medication, advise your patient (and explain his/her 
caregiver) not to drive because his/her driving skills are still impaired for 
approximately 24 hours. 
• Driving with this treatment should require an approval by driving licence 
administration. 
Menadione B02BA02 0 • No special advice 
Mepartricin A01AB16 
D01AA06 
NE  
Mepenzolate A03AB12 NE  
Mephenesin M03BX06 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advice the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
• One time (occasional) use: inform your patient that his/her response is reduced. 
Advice your patient not to drive then. 
Mephenoxalone N05BX01 NE  
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Mephentermine C01CA11 NE  
 Mephenytoin N03AB04 NE  
 Mephenytoin, combinations N03AB54 NE  
 Mepivacaine N01BB03  
 
0 
 
 
 
 
I 
 
 
 
 
II 
 
 
 
 
III 
Categorization, labelling and information to the patient  depending of the route of 
administration 
 
Topic administration (skin, mucous) 
 
Infiltration (dental anaesthesia) 
Intrarticular, intrabursal, tendon sheath administration, etc.. 
• Advise the patient not to drive or operate machinery until the effect of the 
anaesthesia and the immediate effects of surgery are passed. 
 
Ocular administration: 
• Advise at the patient that their sight may become blurred, and not to drive or operate 
machinery during the first 24 hours after using local anesthetics. 
 
Regional anaesthesia (nerve-block, intravenous regional anaesthesia). 
Spinal /Epidural 
• Advise the patient (and explain to caregivers), in the event an early discharge is 
envisaged following  regional / epidural / spinal anaesthesia, not to drive or operate 
machinery during the first 24 hours after anaesthesia.  
• Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after 
anaesthesia 
 Mepivacaine combinations N01BB53  
 
0 
 
 
 
 
I 
 
 
Categorization, labelling and information to the patient  depending of the route of 
administration 
 
Topic administration (skin, mucous) 
 
Infiltration (dental anaesthesia) 
Intrarticular, intrabursal, tendon sheath administration, etc.. 
• Advise the patient not to drive or operate machinery until the effect of the 
anaesthesia and the immediate effects of surgery are passed. 
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II 
 
 
 
 
III 
Ocular administration: 
• Advise at the patient that their sight may become blurred, and not to drive or operate 
machinery during the first 24 hours after using local anesthetics. 
 
Regional anaesthesia (nerve-block, intravenous regional anaesthesia). 
Spinal /Epidural 
• Advise the patient (and explain to caregivers), in the event an early discharge is 
envisaged following  regional / epidural / spinal anaesthesia, not to drive or operate 
machinery during the first 24 hours after anaesthesia.  
• Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after 
anaesthesia 
Mepixanox R07AB09 NE  
Meprobamate N05BC01 NE  
Meprobamate in association N05CX01 NE  
Meprobamate, combinations N05BC51 NE  
Meprotixol R05DB22 NE  
Meptazinol N02AX05 NE  
Mepyramine   D04AA02 0 • No special advice 
Mepyramine R06AC01 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
restlessness, sedation) 
• Advise the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Mequinol D11AX06 0 • No special advice 
Mequitazine R06AD07 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advise the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
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taking this medicine. 
Mercaptamine  A16AA04 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, somnolence, lethargy, lacrimation increased, 
tinnitus, vertigo, etc.) particularly during the first day of treatment, and not to drive as 
long as side-effects persist. 
Mercuric amidochloride D08AK01 NE  
Mercuric chloride D08AK03 NE  
Mercuric iodide D08AK30 NE  
Mercurochrome D08AK04 0 • No special advice 
Mercury compounds S01AX01 NE  
Mercury, metallic D08AK05 NE  
Mersalyl C03BC01 NE  
Mesalazine A07EC02 0 • No special advice 
Mesna R05CB05 NE  
Mesoridiazine N05AC03 NE  
Mesulfen D10AB05 NE  
 Mesuximide N03AD03 NE  
 Metabutethamine N01BA01 NE  
Metahexamide A10BB10 NE  
Metamfetamine N06BA03 NE  
Metamizole sodium 
(noramydopyrine) 
N02BB02 NE  
Metamizole sodium, 
combinations excl. 
Psycholeptics 
N02BB52 NE  
Metamizole sodium, 
combinations with. 
Psycholeptics 
N02BB72 NE  
Metandienone A14AA03 
D11AE01 
NE  
Metaraminol C01CA09 NE  
Metenolone A14AA04 0 • No special advice 
Metformin  A10BA02 0 • No special advice 
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Metformin and pioglitazone A10BD05 0 • No special advice 
Metformin and rosiglitazone A10BD03 0 • No special advice 
Metformin and sitagliptin  
 A10BD0
7 
I • Advise your patient to take precautions to avoid hypoglycaemia, this may constitute 
a risk in situations where these abilities are of special importance (e.g. driving a car 
or operating machinery), and not to drive as long as side-effects persist. 
• If your patient has frequent episodes or if he/she find it hard to recognise 
hypoglycaemia. The advisability of driving should be considered in these 
circumstances. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication 
Metformin and sulfonamides A10BD02 I • Advise your patient to take precautions to avoid hypoglycaemia, this may constitute 
a risk in situations where these abilities are of special importance (e.g. driving a car 
or operating machinery), and not to drive as long as side-effects persist. 
• If your patient has frequent episodes or if he/she find it hard to recognise 
hypoglycaemia. The advisability of driving should be considered in these 
circumstances. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication 
Metformin and vildagliptin A10BD08 I • Advise your patient to take precautions to avoid hypoglycaemia, this may constitute 
a risk in situations where these abilities are of special importance (e.g. driving a car 
or operating machinery), and not to drive as long as side-effects persist. 
• If your patient has frequent episodes or if he/she find it hard to recognise 
hypoglycaemia. The advisability of driving should be considered in these 
circumstances. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication 
 Methabarbital N03AA30 NE  
Methadone 
- Oral administration:  
- Parenteral administration 
N07BC02  
II 
 
III 
• Advise the patient (and explain to caregivers) not to drive during the first days of 
treatment and after changes in doses. 
• Advise the patient to strictly follow the prescribed doses, the treatment and delivery 
procedures and to avoid any alcohol or other psychoactive substances during the 
treatment. 
• Opiate cessation can also cause behavioural changes and requires follow-up and 
counselling. 
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• Driving with this treatment should require an approval by driving licence 
administration. 
Methadone. Comb. Excl. 
Psycholectics 
N02AC52 NE  
Methantheline A03AB07 NE  
Methapyrilene R06AC05 NE  
Methaqualone N05CM01 NE  
Methaqualone, combinations N05CX02 NE  
Methazolamide S01EC05 NE  
Methdilazine R06AD04 NE  
Methiosulfonium chloride  A02BX04 NE  
Methocarbamol M03BA03 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advice the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
• One time (occasional) use: inform your patient that his/her response is reduced. 
Advice your patient not to drive then. 
Methocarbamol, combinations 
excl. psycholeptics 
M03BA53 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advice the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
• One time (occasional) use: inform your patient that his/her response is reduced. 
Advice your patient not to drive then. 
Methocarbamol, combinations 
with psycholeptics 
M03BA73 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
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• Advice the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advice the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
• One time (occasional) use: inform your patient that his/her response is reduced. 
Advice your patient not to drive then. 
 Methohexital N01AF01 NE  
Methoserpidine C02AA06 NE  
Methoserpidine and diuretics C02LA04 NE  
Methoxamine C01CA10 NE  
Methoxsalen D05AD02 NE  
Methoxsalen  D05BA02 0 • No special advice 
Methoxy polyethylene glycol-
epoetin beta 
B03XA03 0 • No special advice 
 Methoxyflurane N01AB03 NE  
Methoxyphenamine R03CB02 NE  
Methyclothiazide C03AA08 NE  
Methyclothiazide and 
potassium. 
C03AB08 NE  
Methylatropine A03BB02 NE  
Methylcellulose A06AC06 0 • No special advice 
Methyldigoxin C01AA08 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Methyldopa (levorotatory) C02AB01 II • Inform your patient that the medication can cause side effects that impair driving 
abilities (e.g. dizziness, drowsiness, hypotension, fatigue, etc.). 
• Advise your patient not to drive for the first few days of treatment and to be careful in 
other situations, as well (e.g. operating machinery and working at heights). 
• Advise the patient not to drink alcohol nor use any psychoactive substance when 
taking this medicine. 
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Methyldopa (levorotatory) and 
diuretics 
C02LB01 II • Inform your patient that the medication can cause side effects that impair driving 
abilities (e.g. dizziness, drowsiness, hypotension, fatigue, etc.). 
• Advise your patient not to drive for the first few days of treatment and to be careful in 
other situations, as well (e.g. operating machinery and working at heights). 
• Advise the patient not to drink alcohol nor use any psychoactive substance when 
taking this medicine. 
Methyldopa (racemic) C02AB02 II • Inform your patient that the medication can cause side effects that impair driving 
abilities (e.g. dizziness, drowsiness, hypotension, fatigue, etc.). 
• Advise your patient not to drive for the first few days of treatment and to be careful in 
other situations, as well (e.g. operating machinery and working at heights). 
• Advise the patient not to drink alcohol nor use any psychoactive substance when 
taking this medicine. 
Methylhomatropine and 
psycholeptics 
A03CB04 NE  
Methylnaltrexone Bromide  A06AH01 0 • No special advice 
 
Methylpentynol N05CM15 NE  
Methylpentynol, combinations N05CX03 NE  
Methylphenidate N06BA04 II • Inform your patient about the effects of the medication on reaction time as well as 
that the medication can cause side-effects that impair driving abilities (e.g. dizziness, 
drowsiness, sleepiness, blurred vision, etc.). 
• Advise your patient not to drive for the first few weeks of treatment or until the next 
visit and to be careful in other situations, as well (e.g. operating machinery and 
working at heights). 
• Advise your patient not to drink alcohol nor use any other psychoactive substance 
when taking this medication. 
• In case of short-term use of the medication, advise your patient not to drive because 
his/her driving skills are still impaired for approximately 24 hours. 
 Methylphenobarbital N03AA01 NE  
Methylprednisolone  D07AA01 NE  
Methylprednisolone D10AA02 0  
Methylprednisolone aceponate D07AC14 0 • No special advice 
Methylprednisolone and D07CA02 NE  
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antibiotics 
Methylprednisolone and 
antiinfectives 
S01CA08 NE  
Methylpropylpropanediol 
dinitrate 
C01DA04 NE  
Methylpropylpropanediol 
dinitrate, combinations 
C01DA54 NE  
Methylprylon N05CE02 NE  
Methylrosaniline D01AE02 0 • No special advice 
Methylscopolamine A03BB03 
S01AF03 
NE  
Methylscopolamine and 
psycholeptics (with 
Chlordiazepoxide) 
A03CB01 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, visual accommodation disturbances, blurred/double vision and reduced 
alertness) 
• Advise the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights). 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Methysergide N02CA04 NE  
Meticrane C03BA09 NE  
Metipranolol S01ED04 NE  
Metipranolol and thiazides, 
combinations 
C07BA68 NE  
Metipranolol, combinations S01ED54 NE  
Metirosine C02KB01 NE  
 Metixene  N04AA03 NE  
Metizoline R01AA10 NE  
Metoclopramide  
- Oral administration 
 
 
 
A03FA01  
I 
 
 
 
Oral administration 
• Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. possible visual accommodation disturbances), and not 
to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
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- Parenteral administration  
 
 
 
 
II 
taking this medication. 
 
Parenteral administration 
• Inform the patient that this medication causes visual accommodation disturbances 
so you should not drive or operate machinery after parenteral administration until 
vision has normalised. 
• Advise the patient that he should wait until his sight returns to normal before driving 
or using any tools or machines. 
Metolazone C03BA08 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Metolazone and potassium-
sparing agents 
(spironolactone) 
C03EA12 NE  
Metopimazine A04AD05 NE  
Metoprolol C07AB02 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication.  
Metoprolol - chlortalidone C07BB02 NE  
Metoprolol - felodipin C07FB02 NE  
Metoprolol and other 
antihypertensives 
C07FB02 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Metoprolol and other diuretics C07CB02 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
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Metoprolol and thiazides C07BB02 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Metoprolol and thiazides, 
combinations 
C07BB52 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Metoprolol, combinations C07AB52 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Metronidazole  A01AB17 
D06BX01 
0 • No special advice 
 
Mexiletine C01BB02 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Mianserin N06AX03 III • Inform your patient about the effects of the medication on reaction time as well as 
that the medication can cause side-effects that impair driving abilities (e.g. dizziness, 
drowsiness, sleepiness, blurred vision, etc.). 
• Advice your patient not to drive until the next visit and to be careful in other 
situations, as well (e.g. operating machinery and working at heights). 
• Advice your patient not to drink alcohol nor use any other psychoactive substance 
when taking this medication. 
• In case of short-term use of the medication, advice your patient not to drive because 
his/her driving skills are still impaired for approximately 24 hours. 
Miconazole A01AB09 
A07AC01 
D01AC02 
0 • No special advice 
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Miconazole S02AA13 NE  
Miconazole, combinations D01AC52 0 • No special advice 
Micronomicin S01AA22 NE  
Midazolam N05CD08 III • Inform the patient about the effects of the medicine on reaction time, that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) and that reaction time can 
also be reduced without experiencing side effects. 
• Advice the patient not to drive until the next visit after start of treatment and also to 
be careful in other situations (e.g. using machinery and working at heights) 
• Advice the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
• One time (occasional) use: inform your patient that his/her response is still reduced 
for approximately 24 hours. Advice your patient not to drive then. 
Midodrine C01CA17 NE  
Miglitol A10BF02 0 • No special advice 
Miglustat  A16AX06 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness and fatigue) particularly during the first day of 
treatment, and not to drive as long as side-effects persist. 
Milnacipran N06AX17 NE  
Milrinone C01CE02 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Minaprine N06AX07 NE  
Mineral salts in combination A06AD10 NE  
Minocycline  A01AB23 0 • No special advice 
Minoxidil C02DC01 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Minoxidil D11AX01 0 • No special advice 
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Mirtazapine N06AX11 III • Inform your patient about the effects of the medication on reaction time as well as 
that the medication can cause side-effects that impair driving abilities (e.g. dizziness, 
drowsiness, sleepiness, blurred vision, etc.). 
• Advice your patient not to drive until the next visit and to be careful in other 
situations, as well (e.g. operating machinery and working at heights). 
• Advice your patient not to drink alcohol nor use any other psychoactive substance 
when taking this medication. 
• In case of short-term use of the medication, advice your patient not to drive because 
his/her driving skills are still impaired for approximately 24 hours. 
Misoprostol A02BB01 0 • No special advice 
Mitiglinide A10BX08 NE  
Mivacurium chloride M03AC10 III • Advise the patient not to drive or operate machinery until the effects of the 
anaesthetic, and the immediate effects of surgery have passed. 
• Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after 
anaesthesia 
Mizolastine R06AX25 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness) 
• Advise the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Moclobemide N06AG02 II • Inform your patient about the effects of the medication on reaction time as well as 
that the medication can cause side-effects that impair driving abilities (e.g. dizziness, 
drowsiness, sleepiness, blurred vision, etc.). 
• Advice your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities. 
• Advice your patient not to drive as long as side-effects persist. 
• Advice your patient not to drink alcohol nor use any other psychoactive substance 
when taking this medication. 
Modafinil NO6BA07 II • Inform your patient about the effects of the medication on reaction time as well as 
that the medication can cause side-effects that impair driving abilities (e.g. dizziness, 
drowsiness, sleepiness, blurred vision, etc.). 
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• Advise your patient not to drive for the first few weeks of treatment or until the next 
visit and to be careful in other situations, as well (e.g. operating machinery and 
working at heights). 
• Advise your patient not to drink alcohol nor use any other psychoactive substance 
when taking this medication. 
• In case of short-term use of the medication, advise your patient not to drive because 
his/her driving skills are still impaired for approximately 24 hours. 
Moexipril C09AA13 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Moexipril and diuretics C09BA13 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Mofebutazone M01AA02 
M02AA02 
NE  
Molindone N05AE02 NE  
Molsidomine C01DX12 NE  
Mometasone D07AC13 
D07XC03 
R01AD09 
R03BA07 
0 • No special advice 
• No special advice 
 
• No special advice 
 
Monobenzone D11AX13 NE  
Monoethanolamine oleate C05BB01 0 • No special advice 
Monoxerutin C05CA02 0 • No special advice 
Montelukast R03DC03 0 • No special advice 
Moperone N05AD04 NE  
Moracizine C01BG01 NE  
Morclofone R05DB25 NE  
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Morniflumate M01AX22 I • Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
Morphine 
- Oral administration  
- Parenteral administration 
N02AA01  
III/II* 
III 
*) prolonged release 
formulation; when a 
steady state of 
dosage has been 
reached 
• Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient (and explain to caregivers) not to drive until the next visit after 
start of treatment or after changes in dosage. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to strictly follow the prescribed doses and the intake scheme.  
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
• Opiate cessation can also cause behavioral changes and requires follow-up and 
counseling. 
Morphine and antispasmodics N02AG01 NE  
Morphine combinations N02AA51 NE  
Morphine, combinations. A07DA52 II • Inform the patient that the medication can cause side effects (dizziness, drowsiness 
and somnolence) Patients receiving it should not drive or operate machinery unless 
it has been shown that their physical and mental capacity remains unaffected. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
Morpholine salicylate N02BA08 NE  
Mosapramine N05AX10 NE  
Motretinide D10AD05 NE  
Moxaverine A03AD30 NE  
Moxifloxacin S01AX22 0 • No special advice 
Moxisylyte C04AX10 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
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etc.) and not to drive as long as side-effects persist.  
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Moxonidine C02AC05 II • Inform your patient that the medication can cause side effects that impair driving 
abilities (e.g. dizziness, drowsiness, hypotension, fatigue, etc.). 
• Advise your patient not to drive for the first few days of treatment and to be careful in 
other situations, as well (e.g. operating machinery and working at heights). 
• Advise the patient not to drink alcohol nor use any psychoactive substance when 
taking this medicine. 
Moxonidine and diuretics C02LC05 II • Inform your patient that the medication can cause side effects that impair driving 
abilities (e.g. dizziness, drowsiness, hypotension, fatigue, etc.). 
• Advise your patient not to drive for the first few days of treatment and to be careful in 
other situations, as well (e.g. operating machinery and working at heights). 
• Advise the patient not to drink alcohol nor use any psychoactive substance when 
taking this medicine. 
Multienzymes (lipase, protease 
etc.) 
A09AA02 0 • No special advice 
 
Multienzymes and acid 
preparations 
A09AC02 NE  
Multivitamins and calcium A11AA02 0 • No special advice 
Multivitamins and iron A11AA01 0 • No special advice 
Multivitamins and other 
minerals, incl. combinations 
A11AA03 0 • No special advice 
 
Multivitamins and trace 
elements 
A11AA04 0 • No special advice 
 
Mupirocin D06AX09 
R01AX06 
0 • No special advice 
• No special advice 
 
Muzolimine C03CD01 NE  
Myristyl-benzalkonium R02AA10 NE  
    
N ATC CODE CATEGORIZATION 
labelling 
INFORMATION FOR THE PATIENT 
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Nabilone  A04AD11 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (drowsiness, vertigo/dizziness, 
euphoria (high), ataxia, visual disturbance, concentration difficulties, sleep 
disturbance, dysphoria). 
• Advise the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment, because the effects of this medicine may persist for a 
variable and unpredictable period of time following its oral administration and also to 
be careful in other situations (e.g. using machinery and working at heights). 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Nabumetone M01AX01 I • Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
Nadolol C07AA12 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Nadolol and thiazides C07BA12 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Nadroparin B01AB06 0 • No special advice 
Naftidrofuryl C04AX21 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Naftifine  D01AE22 0 • No special advice 
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Nalbuphine N02AF02 NE  
Naltrexone N07BB04 II • Advise the patient (and explain to caregivers) not to drive during the first days of 
treatment and after changes in doses.  
• Advise the patient to strictly follow the prescribed doses and to avoid any alcohol or 
other psychoactive substances during the treatment. 
• Alcohol cessation can also cause behavioural changes and requires follow-up and 
counselling. 
• Driving with this treatment should require an approval by driving licence 
administration. 
Nandrolone A14AB01 0 • No special advice 
Nandrolone S01XA11 NE  
Naphazoline R01AA08 0 • No special advice 
Naphazoline R01AB02 NE  
Naphazoline S01GA01 I • Inform the patient that this ocular medication may cause side effects including local 
irritation, allergy, and an increase in IOP, as well as systemic effects: dilation of the 
pupils, dizziness, headaches, nausea, sweating, nervousness, weakness, increased 
redness, blurring, punctate keratitis, lacrimation with an increase in intraocular 
pressure and systemic effects due to absorption (hypertension, cardiac irregularities 
and hyperglycaemia). Some patients may experience drowsiness. 
• Advise the patient that if he/she experiences these symptoms, he/she should wait 
until they have cleared before driving or using machinery. 
Naphazoline, combinations S01GA51 Depending on the 
medicine in 
combination 
• Depending on the medicine in combination 
Naproxen M02AA12 NE  
Naproxen M01AE02 
N02BG 
I • Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
Naratriptan N02CC02 II • Advise the patient not to drive during the first times, the drug is administered, until 
he/she knows his/her reactions.   
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• Advise the patient not to drive within the first 4 hours after treatment. 
• Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to strictly follow the prescribed doses and intake scheme.  
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
 Narcobarbital N01AG01 NE  
Natamycin A01AB10 
A07AA03 
D01AA02 
S01AA10 
NE  
Nateglinide A10BX03 I • Advise your patient to take precautions to avoid hypoglycaemia, this may constitute 
a risk in situations where these abilities are of special importance (e.g. driving a car 
or operating machinery), and not to drive as long as side-effects persist. 
• If your patient has frequent episodes or if he/she find it hard to recognise 
hypoglycaemia. The advisability of driving should be considered in these 
circumstances.  
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication 
Natural phospholipids R07AA02 NE  
Nebivolol C07AB12 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Nedocromil R01AC07 
R03BC03 
0 • No special advice 
 
Nedocromil S01GX04 I • Inform the patient that this ocular medication may cause side effects including local 
irritation, temporary blurred vision or other visual disturbances, transient stinging and 
burning after instillation. 
• Advise the patient that if he/she experiences these symptoms, he/she should wait 
until they have cleared before driving or using machinery. 
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Nefazodone N06AX06 II • Inform your patient about the effects of the medication on reaction time as well as 
that the medication can cause side-effects that impair driving abilities (e.g. dizziness, 
drowsiness, sleepiness, blurred vision, etc.). 
• Advice your patient not to drive for the first few weeks of treatment or until the next 
visit and to be careful in other situations, as well (e.g. operating machinery and 
working at heights). 
• Advice your patient not to drink alcohol nor use any other psychoactive substance 
when taking this medication. 
• In case of short-term use of the medication, advice your patient not to drive because 
his/her driving skills are still impaired for approximately 24 hours. 
Nefopam N02BG06 II • Advise the patient (and explain to caregivers) not to drive during the first days of 
treatment. 
• Inform the patient that the medication can cause side effects that impair driving 
and that reaction time can also be reduced without experiencing side effects. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to strictly follow the prescribed doses and intake scheme..  
• Advise the patient to avoid any alcohol or other psychoactive substances during 
the treatment. 
Neltenexine R05CB14 NE  
Neomycin   A01AB08 
A07AA01 
D06AX04 
0 • No special advice 
 
Neomycin B05CA09 
R02AB01 
S02AA07 
S03AA01 
NE  
Neomycin 
- Drops 
- Oinment 
S01AA03  
0 
I 
• Inform the patient that as with any ocular medication, if transient, blurred vision 
occurs at application.  
• Advice the patient that he/she should wait until his/her vision clears before driving or 
using machinery. 
Neomycin, combinations A07AA51 0 • No special advice 
Neostigmine 
- Oral administration 
N07AA01  
II 
• Advise the patient (and explain to caregivers) not to drive during the first days of 
treatment.   
 DRUID 6th Framework Programme         Deliverable D.4.4.1  
   Classification of medicinal drugs and driving: 
 Co-ordination and synthesis report.  
   Page 161 of 243 
 
  
 
   
 
 
- Parenteral administration   III • The treatment can impair patient’s vision especially by night. 
Neostigmine S01EB06 NE  
Neostigmine, combinations N07AA51 NE  
Nepafenac S01BC10 NE  
Nepinalone R05DB26 NE  
Nesiritide C01DX19 NE  
Netilmicin S01AA23 NE  
Nialamide N06AF02 NE  
Niaprazine N05CM16 NE  
Nicardipine C08CA04 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Nicergoline C04AE02 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Niceritrol C10AD01 NE  
Nicofetamide A03AC04 NE  
Nicofuranose C10AD03 NE  
Nicomorphine N02AA04 NE  
Nicorandil C01DX16 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Nicotinamide  A11HA01 0 • No special advice 
Nicotine N07BA01 0 • The treatment has to be used according to the recommended dose to avoid side 
effect on driving.  
• Smoking cessation can also cause behavioural changes. 
Nicotinic acid C04AC01 0 • No special advice 
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C10AD02 
Nicotinic acid, combinations C10AD52 0 • No special advice 
Nicotinyl alcohol 
(pyridylcarbinol) 
C04AC02 
C10AD05 
NE  
Nicotinyl methylamide A05AB01 NE  
Nifedipine C08CA05 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Nifedipine, combinations C08CA55 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Nifenazone M02AA24 
N02BB05 
NE  
Nifenazone  NE  
Niflumic acid M01AX02 I • Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
Niflumic acid (topic use) M02AA17 0 • No special advice 
Nifuroxazide A07AX03 NE  
Nifurzide A07AX04 NE  
Nikethamide R07AB02 NE  
Nikethamide, combinations R07AB52 NE  
Nilvadipine C08CA10 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
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taking this medication. 
Nimesulide M01AX17 I • Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
Nimodipine C08CA06 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Niperotidine  A02BA05 NE  
Nisoldipine C08CA07 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Nitisinone  A16AX04 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g conjunctivitis, corneal opacity, keratitis, photophobia, eye 
pain, etc.) particularly during the first day of treatment, and not to drive as long as 
side-effects persist. 
Nitrazepam N05CD02 III • Inform the patient about the effects of the medicine on reaction time, that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) and that reaction time can 
also be reduced without experiencing side effects. 
• Advice the patient not to drive until the next visit after start of treatment and also to 
be careful in other situations (e.g. using machinery and working at heights) 
• Advice the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
• One time(occasional) use: inform your patient that his/her response is still reduced 
for approximately 3 days to one week. Advice your patient not to drive then. 
Nitrendipine C08CA08 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
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etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Nitric oxide R07AX01 0 • No special advice 
Nitrofural D08AF01 
D09AA03 
0 • No special advice 
Nitrofural B05CA03 
S01AX04 
S02AA02 
NE  
Nitroprusside C02DD01 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
 Nitrous acid combinations N01AX63 NE  
 Nitrous oxide N01AX13 III • Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient (and explain to caregivers) not to drive until the next visit after start 
of treatment or after changes in dosage. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to strictly follow the prescribed doses and the intake scheme.  
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
• Opiate cessation can also cause behavioral changes and requires follow-up and 
counseling. 
Nizatidine A02BA04 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness) particularly during the first day of treatment, 
and not to drive as long as side-effects persist. 
Nizofenone N06BX10 NE  
Nomifensine N06AX04 NE  
Nonacog alfa B02BD09 0 • No special advice 
Nordazepam N05BA16 NE  
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Norepinephrine C01CA03 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Norethandrolone A14AA09 NE  
Norfenefrine C01CA05 NE  
Norfloxacin S01AX12 0 • No special advice 
Normethadone R05DA06 NE  
Nortriptyline N06AA10 II • Inform your patient about the effects of the medication on reaction time as well as 
that the medication can cause side-effects that impair driving abilities (e.g. dizziness, 
drowsiness, sleepiness, blurred vision, etc.). 
• Advice your patient not to drive for the first few weeks of treatment or until the next 
visit and to be careful in other situations, as well (e.g. operating machinery and 
working at heights). 
• Advice your patient not to drink alcohol nor use any other psychoactive substance 
when taking this medication. 
• In case of short-term use of the medication, advice your patient not to drive because 
his/her driving skills are still impaired for approximately 24 hours. 
Noscapine R05DA07 0 • No special advice 
Noxytiolin B05CA07 NE  
Nystatin A07AA02 
D01AA01 
0 • No special advice 
• No special advice 
    
O ATC CODE CATEGORIZATION 
labelling 
INFORMATION FOR THE PATIENT 
Octinoxate D02BA02 0 • No special advice 
Octopamine C01CA18 NE  
Ofloxacin S01AX11 0 • No special advice 
Ofloxacin S02AA16 NE  
Oil A06AG06 0 • No special advice 
Olaflur A01AA03 NE  
Olanzapine N05AH03  Oral administration: 
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- Oral administration 
 
 
 
 
 
 
- Parenteral administration: 
i.m. 
II 
 
 
 
 
 
 
 
 
III 
• Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advice the patient not to drink alcohol when taking this medicine. 
 
Parenteral administration: 
• Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive until the next visit after start of treatment and also to 
be careful in other situations (e.g. using machinery and working at heights) 
• Advice the patient not to drink alcohol when taking this medicine. 
Olmesartan medoxomil C09CA08 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Olmesartan medoxomil and 
amlodipine 
C09DB02 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Olmesartan medoxomil and 
diuretics 
C09DA08 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Olopatadine S01GX09 I • Inform the patient that this ocular medication may cause side effects including local 
irritation, temporary blurred vision or other visual disturbances, transient stinging and 
burning after instillation. 
• Advise the patient that if he/she experiences these symptoms, he/she should wait 
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until they have cleared before driving or using machinery. 
Olopatadine R01AC08 NE  
Olsalazine  A07EC03 0 • No special advice 
Omalizumab R03DX05 0 • No special advice 
Omega-3-triglycerides C10AX06 NE  
Omeprazole A02BC01 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness) particularly during the first day of treatment, 
and not to drive as long as side-effects persist. 
Omeprazole, amoxicillin and 
clarithromycin  
A02BD05 NE  
Omeprazole, amoxicillin and 
metronidazole  
A02BD01 NE  
Omoconazole D01AC13 NE  
Ondansetron A04AA01 0 • No special advice 
Opipramol N06AA05 NE  
Opium  A07DA02 II • Inform the patient that the medication can cause side effects (dizziness, drowsiness 
and somnolence) Patients receiving it should not drive or operate machinery unless 
it has been shown that their physical and mental capacity remains unaffected. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
Opium N02AA02 NE  
Opium alkaloids with morphine R05DA05 NE  
Opium derivatives and 
expectorants 
R05FA02 II or higher 
depending on the 
medicine in 
combination 
• II or higher depending on the medicine in combination 
Opium derivatives and 
mucolytics 
R05FA01 NE  
Oral rehydration salt 
formulations 
A07CA 0 • No special advice 
Orciprenaline R03AB03 NE  
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Orciprenaline R03CB03 I • Inform the patient about the effects that the medicine can have on reaction time and 
that the medication can cause side effects that impair driving (anxiety, restlessness, 
insomnia, tremor) 
• Advise the patient not to drive when this side effects occur and also to be careful in 
other situations (e.g. using machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Orciprenaline, combinations R03CB53 NE  
Ordinary salt combinations A02AD01 0 • No special advice 
Ordinary salt combinations and 
antiflatulents 
A02AF02 0 • No special advice 
Organic nitrates in combination C01DA20 NE  
Organic nitrates in combination 
with psycholeptics 
C01DA70 NE  
Organo-heparinoid C05BA01 0 • No special advice 
Orgotein M01AX14 NE  
Orlistat  A08AB01 0 • No special advice 
Ornithine oxoglurate A05BA06 NE  
 Orphenadrine  N04AB02  II • Advise the patient (and explain to caregivers) not to drive during the first days of 
treatment. 
• Inform patients that unwanted effects are seen rapidly during the dosage adjustment 
period. 
• Advise the patient (and explain to caregivers) not to drive at all if suffering from “sleep 
attacks”. 
• Advise the patient (and explain to caregivers) not to drive at all if suffering from 
severe fluctuations in mobility “(“on-off” phenomena). 
Orphenadrine (citrate)  M03BC01 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advice the patient not to drink alcohol or use other psychoactive substances when 
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taking this medicine. 
• One time (occasional) use: inform your patient that his/her response is reduced. 
Advice your patient not to drive then. 
Orphenadrine, combinations M03BC51 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advice the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
• One time (occasional) use: inform your patient that his/her response is reduced. 
Advice your patient not to drive then. 
Other emollients and 
protectives 
D02AX 0 • No special advice 
Other plasma protein fractions B05AA02 NE  
Other preparations, 
combinations 
C05AX03 0 • No special advice 
Others (Medicated shampoos) D11AC30 NE  
Otilonium bromide A03AB06 0 • No special advice 
Otilonium bromide and 
psycholeptics 
A03CA04 NE  
Oxabolone cipionate A14AB03 NE  
Oxaceprol D11AX09 
M01AX24 
NE  
Oxaflozane N06AX10 NE  
Oxametacin M01AB13 NE  
Oxandrolone A14AA08 NE  
Oxaprotilin N06AA 
Not yet 
determined 
NE  
Oxaprozin M01AE12 NE  
Oxatomide R06AE06 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
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sleepiness, blurred vision and reduced alertness) 
• Advise the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Oxazepam N05BA04 III • Inform the patient about the effects of the medicine on reaction time, that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) and that reaction time can 
also be reduced without experiencing side effects. 
• Advice the patient not to drive until the next visit after start of treatment and also to 
be careful in other situations (e.g. using machinery and working at heights) 
• Advice the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
 Oxcarbazepine N03AF02 II Advise the patient not to drive during the first days of treatment as well as after 
dose increases. 
 
General warnings: 
• Advise the patient to take the medicine as prescribed by the physician. 
• Advise the patient not to stop taking the medicine suddenly, and to inform the 
physician – doctor if he/she should do so. 
• Advise the patient not to drink alcohol while taking this medication. 
Oxedrine C01CA08 
S01GA06 
NE  
Oxedrine, combinations S01GA56 NE  
Oxeladin R05DB09 NE  
Oxetacaine C05AD06 0 • No special advice 
Oxetorone N02CX06 NE  
Oxiconazole D01AC11 0 • No special advice 
Oxidized cellulose  B02BC02 NE  
Oxiracetam N06BX07 NE  
Oxitriptan N06AX01 NE  
Oxitropium bromide R03BB02 NE  
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Oxolamine R05DB07 NE  
Oxomemazine R06AD08 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advise the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Oxovinca (C04AX)  
Not yet 
determined 
NE  
Oxprenolol C07AA02 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Oxprenolol - chlortalidone (C07BA)  
Not yet 
determined 
NE  
Oxprenolol and other diuretics C07CA02 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Oxprenolol and thiazides C07BA02 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Oxybuprocaine D04AB03 NE  
Oxybuprocaine S01HA02 I • Inform the patient that his/her eyesight may become blurred.  
• Advise him/her not to drive or operate machinery during the first 24 hours following 
the useof a local anaesthetic. 
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Oxycinchophen M01CA03 NE  
Oxycodone  N02AA05 III/II* 
*) prolonged release 
formulation; when a 
steady state of 
dosage has been 
reached 
• Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient (and explain to caregivers) not to drive until the next visit after 
start of treatment or after changes in dosage. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to strictly follow the prescribed doses and the intake scheme.  
• Advise the patient  to avoid any alcohol or other psychoactive substances during the 
treatment. 
• Opiate cessation can also cause behavioral changes and requires follow-up and 
counseling. 
Oxyfedrine C01DX03 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Oxyfedrine, combinations C01DX53 NE  
Oxymetazoline R01AA05 0 • No special advice 
Oxymetazoline R01AB07 NE  
Oxymetazoline S01GA04 I • Inform the patient that this ocular medication may cause side effects including local 
irritation, allergy, and an increase in IOP, as well as systemic effects: dilation of the 
pupils, dizziness, headaches, nausea, sweating, nervousness, weakness, increased 
redness, blurring, punctate keratitis, lacrimation with an increase in intraocular 
pressure and systemic effects due to absorption (hypertension, cardiac irregularities 
and hyperglycaemia). Some patients may experience drowsiness. 
• Advise the patient that if he/she experiences these symptoms, he/she should wait 
until they have cleared before driving or using machinery. 
Oxymetholone A14AA05 NE  
Oxymorphone (N02AA)  
Not yet 
determined 
NE  
Oxypertine N05AE01 NE  
Oxyphenbutazone M01AA03 NE  
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M02AA04 
S01BC02 
Oxyphencyclimine A03AA01 NE  
Oxyphencyclimine and 
psycholeptics 
A03CA03 NE  
Oxyphenisatine A06AB01 NE  
Oxyphenonium A03AB03 NE  
Oxyquinoline  A01AB07 0 • No special advice 
Oxyquinoline D08AH03 NE  
Oxyquinoline R02AA14 NE  
Oxytetracycline D06AA03  • No special advice 
Oxytetracycline 
- Drops 
- Oinment 
S01AA04  
0 
I 
• Inform the patient that as with any ocular medication, if transient, blurred vision 
occurs at application.  
• Advice the patient that he/she should wait until his/her vision clears before driving or 
using machinery. 
    
P ATC CODE CATEGORIZATION 
labelling 
INFORMATION FOR THE PATIENT 
Paliperidone N05AX13 NE  
Palonosetron  A04AA05 0 • No special advice 
Pamidronic acid  M05BA03 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advice the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
• One time (occasional) use: inform your patient that his/her response is reduced. 
Advice your patient not to drive then. 
Pancuronium M03AC01 III • Advise the patient not to drive or operate machinery until the effects of the 
anaesthetic, and the immediate effects of surgery have passed. 
• Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after 
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anaesthesia 
Pantethine A11HA32 NE  
Pantoprazole A02BC02 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness) particularly during the first day of treatment, 
and not to drive as long as side-effects persist. 
Pantoprazole, amoxicillin and 
clarithromycin  
A02BD04 NE  
Papaveretum N02AA10 NE  
Papaverine A03AD01 NE  
Paracetamol N02BE01 0 • No special advice. 
Paracetamol, combinations 
excl psycholeptics 
N02BE51 NE  
Paracetamol, combinations 
with Psycholeptics 
N02BE71 NE  
Paraldehyde N05CC05 NE  
 Paramethadione N03AC01 NE  
Paraoxon S01EB10 NE  
Parecoxib M01AH04 
N02BG 
I • Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
Pargyline C02KC01 NE  
Pargyline and diuretics C02LL01 NE  
Parnaparin B01AB07 NE  
Paromomycin A07AA06 0 • No special advice 
Paroxetine N06AB05 I • Inform your patient about the effects of the medication on reaction time as well as 
that the medication can cause side-effects that impair driving abilities (e.g. dizziness, 
drowsiness, sleepiness, blurred vision, etc.). 
• Advice your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities. 
• Advice your patient not to drive as long as side-effects persist. 
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• Advice your patient not to drink alcohol nor use any other psychoactive substance 
when taking this medication. 
Passiflore aubepine C01EB  
Not yet 
determined 
NE  
Passiflore-extract N05CM20 NE  
Pecilocin D01AA04 NE  
Pectin  A07BC01 0 • No special advice 
Pegaptanib  S01LA03 III • Inform the patient that this ocular medication may cause transient visual 
disturbances such as abnormal vision, vision decrease, or visual field defects that 
may interfere with their ability to drive or use machines. Patients should not drive or 
use machines as long as these symptoms persist. 
• Advise the patients not to drive or operate hazardous machinery until your vision 
improves. 
Pegloticase M04AX02 NE  
Pemoline N06BA05 I • Inform your patient about the effects of the medication on reaction time as well as 
that the medication can cause side-effects that impair driving abilities (e.g. dizziness, 
drowsiness, sleepiness, blurred vision, etc.). 
• Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities. 
• Advise your patient not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any other psychoactive substance 
when taking this medication. 
Penbutolol C07AA23 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist.  
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Penbutolol and other diuretics C07CA23 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
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Penciclovir D06BB06 0 • No special advice 
Penfluridol N05AG03 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advice the patient not to drink alcohol when taking this medicine. 
Penicillamine M01CC01 0 • No special advice 
Pentaerithrityl A06AD14 NE  
Pentaerithrityl tetranitrate C01DA05 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Pentaerithrityl tetranitrate, 
combinations 
C01DA55 NE  
Pentazocine  N02AD01 NE  
Pentetrazol R07AB03 NE  
Pentetrazol, combinations R07AB53 NE  
Penthienate A03AB04 NE  
Pentifylline C04AD01 NE  
Pentobarbital N05CA01 NE  
Pentosan polysulfate sodium C05BA04 0 • No special advice 
Pentoxifylline C04AD03 0 • No special advice 
Pentoxyverine R05DB05 I • Inform the patient about the effects that the medicine can have on reaction time and 
that the medication can cause side effects that impair driving (drowsiness, 
sleepiness) 
• Advise the patient not to drive when this side effects occur and also to be careful in 
other situations (e.g. using machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Pepsin  A09AA03 0 • No special advice 
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Pepsin and acid preparations A09AC01 NE  
Perazine N05AB10 NE  
 Pergolide N04BC02 II • Advise the patient (and explain to caregivers) not to drive during the first days of 
treatment. 
• Inform patients that unwanted effects are seen rapidly during the dosage adjustment 
period. 
• Advise the patient (and explain to caregivers) not to drive at all if suffering from 
“sleep attacks” 
• Advise the patient (and explain to caregivers) not to drive at all if suffering from 
severe fluctuations in mobility “(“on-off” phenomena). 
Perhexiline C08EX02 NE  
Periciazine N05AC01 III • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive until the next visit after start of treatment and also to 
be careful in other situations (e.g. using machinery and working at heights) 
• Advice the patient not to drink alcohol when taking this medicine. 
Perindopril C09AA04 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Perindopril and amlodipine C09BB04 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Perindopril and diuretics C09BA04 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Perphenazine N05AB03 II • Inform the patient about the effects of the medicine on reaction time and that the 
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medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advice the patient not to drink alcohol when taking this medicine. 
Peruvoside C01AX02 NE  
Pethidine N02AB02 III • Advise the patient (and explain to caregivers) not to drive until the next visit after 
start of treatment or after changes in dosage. 
• Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
• Opiate cessation can also cause behavioral changes and requires follow-up and 
counseling. 
Pethidine and antispasmodics N02AG03 NE  
Pethidine, combinations excl. 
Psycholeptics 
N02AB52 NE  
Pethidine, combinations with. 
Psycholeptics 
N02AB72 NE  
Phedrine R01AA03 0 • No special advice 
 Phenacemide N03AX07 NE  
Phenacetin N02BE03 NE  
Phenacetin, combinations excl. 
Psycholeptics 
N02BE53 NE  
Phenacetin, combinations with 
Psycholeptics 
N02BE73 NE  
Phenazone N02BB01 
S02DA03 
NE  
Phenazone, combinations 
excl. Psycholeptics 
N02BB51 NE  
Phenazone, combinations N02BB71 NE  
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with. Psycholeptics 
Phenelzine N06AF03 II • Inform your patient about the effects of the medication on reaction time as well as 
that the medication can cause side-effects that impair driving abilities (e.g. dizziness, 
drowsiness, sleepiness, blurred vision, etc.). 
• Advice your patient not to drive for the first few weeks of treatment or until the next 
visit and to be careful in other situations, as well (e.g. operating machinery and 
working at heights). 
• Advice your patient not to drink alcohol nor use any other psychoactive substance 
when taking this medication. 
• In case of short-term use of the medication, advice your patient not to drive because 
his/her driving skills are still impaired for approximately 24 hours. 
 Pheneturide N03AX13 NE  
Phenformin A10BA01 NE  
Phenformin and sulfonamides A10BD01 NE  
 Phenglutarimide N04AA09 NE  
Phenindamine R06AX04 NE  
Phenindione B01AA02 NE  
Pheniramine R06AB05 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
restlessness, sedation) 
• Advise the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
 Phenobarbital N03AA02 III Advise the patient not to drive. 
 
General warnings: 
• Advise the patient to take the medicine as prescribed by the physician. 
• Advise the patient not to stop taking the medicine suddenly, and to inform the 
physician – doctor if he/she should do so. 
• Advise the patient not to drink alcohol while taking this medication. 
Phenobarbital - calcium 
gluconate and bromate 
C01EB 
Not yet 
NE  
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determined 
Phenol C05BB05 
D08AE03 
R02AA19 
0 • No special advice 
 
 
 Phenol (other local     
anesthetics) 
N01BX03  
 
 
0 
 
I 
 
 
 
 
 
 
 
II 
 
 
 
 
 
III 
 
Categorization, labelling and information to the patient  depending of the route of 
administration 
 
Topic administration (skin, mucous) 
 
Infiltration (dental anaesthesia) 
Intrarticular, intrabursal, tendon sheath administration, etc.. 
• Advise the patient not to drive or operate machinery until the effect of the 
anaesthesia and the immediate effects of surgery are passed. 
 
Ocular administration: 
• Advise at the patient that their sight may become blurred, and not to drive or operate 
machinery during the first 24 hours after using local anesthetics. 
 
Regional anaesthesia (nerve-block, intravenous regional anaesthesia). 
Spinal /Epidural 
• Advise the patient (and explain to caregivers), in the event an early discharge is 
envisaged following  regional / epidural / spinal anaesthesia, not to drive or operate 
machinery during the first 24 hours after anaesthesia.  
• Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after 
anaesthesia 
Phenolphthalein A06AB04 NE  
 Phenoperidine N01AH04 NE  
Phenoxybenzamine C04AX02 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist.  
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Phenprobamate M03BA01 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
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sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advice the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
• One time (occasional) use: inform your patient that his/her response is reduced. 
Advice your patient not to drive then. 
Phenprobamate, combinations 
excl. psycholeptics 
M03BA51 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advice the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
• One time (occasional) use: inform your patient that his/her response is reduced. 
Advice your patient not to drive then. 
Phenprobamate, combinations 
with psycholeptics 
M03BA71 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advice the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
• One time (occasional) use: inform your patient that his/her response is reduced. 
Advice your patient not to drive then. 
Phenprocoumon B01AA04 NE  
 Phensuximide N03AD02 NE  
Phentermine A08AA01 NE  
Phentolamine C04AB01 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
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• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Phenylbutazone M01AA01 
M02AA01 
NE  
Phenylbutazone and 
corticosteroids 
M01BA01 NE  
Phenylephrine R01AA04 0 • No special advice 
Phenylephrine R01BA03 0 • No special advice 
Phenylephrine C01CA06 NE  
Phenylephrine (<<< 10%, 
0.125%) 
S01GA05 I • Inform the patient that this ocular medication may cause side effects including local 
irritation, allergy, and an increase in IOP, as well as systemic effects: dilation of the 
pupils, dizziness, headaches, nausea, sweating, nervousness, weakness, increased 
redness, blurring, punctate keratitis, lacrimation with an increase in intraocular 
pressure and systemic effects due to absorption (hypertension, cardiac irregularities 
and hyperglycaemia). Some patients may experience drowsiness. 
• Advise the patient that if he/she experiences these symptoms, he/she should wait 
until they have cleared before driving or using machinery. 
Phenylephrine (≥ 10%) S01FB01 III • Inform the patient that this ocular medication may cause eye pain and stinging on 
instillation, transient blurring of vision or that he/she may suffer from photophobia, 
conjunctival sensitization and allergy as well as systemic effects: palpitations, 
tachycardia, extrasystoles, cardiac arrhythmias, hypertension and serious 
cardiovascular reactions including coronary artery spasm, ventricular arrhythmias 
and myocardial infarctions and that this may impair their ability to drive under certain 
circumstances. 
• Advise the patients not to drive or operate hazardous machinery until vision is clear 
or it has been shown that their physical and mental capacity remains unaffected. 
Phenylephrine, combinations R01BA53, 
S01GA55 
Depending on the 
medicine in 
combination 
• Depending on the medicine in combination 
Phenylephrine, 
sympathomimetics, 
combinations excl. 
corticosteroids  
R01AB01 Depending on the 
medicine in 
combination 
 
Phenylephrine+tetracaine S01FBP1 III • Inform the patient that this ocular medication may cause eye pain and stinging on 
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instillation, transient blurring of vision or that he/she may suffer from photophobia, 
conjunctival sensitization and allergy as well as systemic effects: palpitations, 
tachycardia, extrasystoles, cardiac arrhythmias, hypertension and serious 
cardiovascular reactions including coronary artery spasm, ventricular arrhythmias 
and myocardial infarctions and that this may impair their ability to drive under certain 
circumstances. 
• Advise the patients not to drive or operate hazardous machinery until vision is clear 
or it has been shown that their physical and mental capacity remains unaffected. 
Phenylmercuric borate D08AK02 NE  
Phenylmercuric nitrate D09AA04 NE  
Phenylpropanolamine R01BA01 0 • No special advice 
Phenylpropanolamine, 
Combinations 
R01BA51 NE  
 Phenytoin 
- Oral administration 
- Parenteral administration 
 
N03AB02  
 
III 
III 
Advise the patient not to drive. 
 
General warnings: 
• Advise the patient to take the medicine as prescribed by the physician. 
• Advise the patient not to stop taking the medicine suddenly, and to inform the 
physician – doctor if he/she should do so. 
• Advise the patient not to drink alcohol while taking this medication. 
 
Trigeminal neuralgia 
• Advise the patient not to drive. 
 Phenytoin, combinations N03AB052 III Advise the patient not to drive. 
 
General warnings: 
• Advise the patient to take the medicine as prescribed by the physician. 
• Advise the patient not to stop taking the medicine suddenly, and to inform the 
physician – doctor if he/she should do so. 
• Advise the patient not to drink alcohol while taking this medication 
Phloroglucinol A03AX12 NE  
Pholcodine R05DA08 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
excitation, confusion) 
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• Advise the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Phthalylsulfathiazole A07AB02 NE  
Physostigmine S01EB05 NE  
Phytomenadione B02BA01 0 • No special advice 
Picloxydine S01AX16 NE  
Picodralazine and diuretics C02LG03 NE  
Picodralazine and diuretics, 
combinations with 
psycholeptics. 
C02LG73 NE  
Picotamide B01AC03 NE  
Pilocarpine 
  
N07AX01 
 
 
II 
 
• Advise the patient (and explain to caregivers) not to drive during the first days of 
treatment.   
• The treatment can impair patient’s vision especially by night and may require an 
ophthalmological advice. 
Pilocarpine 
 
S01EB01 II 
 
• Inform the patient that this ocular medication causes miosis which usually results in 
difficulties for his/her sight to adapt to the dark.  
• Advise the patients to exercise caution in night driving and other hazardous 
occupations in conditions of poor illumination. 
Pilocarpine, combinations S01EB51 NE  
Pimecrolimus (topical use) D11AH02 0 • No special advice 
Pimethixene R06AX23 II • Inform the patient about the effects that the medicine can have on reaction time and 
that the medication can cause side effects that impair driving (drowsiness, 
somnolence) 
• Advise the patient not to drive when this side effects occur and also to be careful in 
other situations (e.g. using machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Pimozide N05AG02 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
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sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advice the patient not to drink alcohol when taking this medicine. 
Pinacidil C02DG01 NE  
Pinacidil and diuretics C02LX01 NE  
Pinaverium A03AX04 0 • No special advice 
Pinazepam N05BA14 NE  
Pindolol C07AA03 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Pindolol and other diuretics C07CA03 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Pioglitazone A10BG03 0 • No special advice 
Pioglitazone and alogliptin A10BD09 NE  
Pipamperone N05AD05 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advice the patient not to drink alcohol when taking this medicine. 
Pipazetate R05DB11 NE  
Pipecuronium bromide M03AC06 III • Advise the patient not to drive or operate machinery until the effects of the 
anaesthetic, and the immediate effects of surgery have passed. 
• Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after 
anaesthesia 
 DRUID 6th Framework Programme         Deliverable D.4.4.1  
   Classification of medicinal drugs and driving: 
 Co-ordination and synthesis report.  
   Page 186 of 243 
 
  
 
   
 
 
Pipenzolate A03AB14 NE  
Piperidione R05DB23 NE  
Piperidolate A03AA30 NE  
Pipotiazine palmitate: injection 
depot i.m. 
N05AC04 III • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive until the next visit after start of treatment and also to 
be careful in other situations (e.g. using machinery and working at heights) 
• Advice the patient not to drink alcohol when taking this medicine. 
Pipradrol N06BX15 NE  
Piprozolin A05AX01 NE  
Piracetam N06BX03 II • Inform your patient about the effects of the medication on reaction time as well as 
that the medication can cause side-effects that impair driving abilities (e.g. dizziness, 
drowsiness, sleepiness, blurred vision, etc.). 
• Advise your patient not to drive for the first few weeks of treatment or until the next 
visit and to be careful in other situations, as well (e.g. operating machinery and 
working at heights). 
• Advise your patient not to drink alcohol nor use any other psychoactive substance 
when taking this medication. 
• In case of short-term use of the medication, advise your patient not to drive because 
his/her driving skills are still impaired for approximately 24 hours. 
Pirbuterol R03AC08 
R03CC07 
NE  
Pirenzepine  A02BX03 NE  
Piretanide C03CA03 0 • No special advice 
Piribedil N04AX13 
C04AX13 
II • Inform your patient that the medication can cause side effects that impair driving 
abilities (e.g. dizziness, drowsiness, hypotension, fatigue, etc.). 
• Advise your patient not to drive for the first few days of treatment and to be careful in 
other situations, as well (e.g. operating machinery and working at heights). 
• Advise the patient not to drink alcohol nor use any psychoactive substance when 
taking this medicine. 
 Piribedil N04BC08 NE  
Pirisunadol N06BX08 NE  
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Piritramide N02AC03 NE  
Pirlindole N06AF 
Not yet 
detemined 
NE  
Piroxicam M01AC01 I • Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
Piroxicam S01BC06 NE  
Piroxicam (topical use) M02AA07 0  
Pirprofen M01AE08 NE  
Pitavastatin C10AA08 NE  
Pitofenone and analgesics A03DA02 NE  
Pivagabine N06AX15 NE  
Pizotifen N02CX01 II • Advise the patient not to drive during the first times, the drug is administered, until 
he/she knows his/her reactions.   
• Advise the patient not to drive within the first 4 hours after treatment. 
• Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to strictly follow the prescribed doses and intake scheme.  
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
Podophyllotoxin D06BB04 0 • No special advice 
Poldine A03AB11 NE  
Policosanol C10AX08 NE  
Policresulen D08AE02 NE  
Polidocanol C05BB02 0 • No special advice 
Polihexanide D08AC05 NE  
Polycarbophil calcium A06AC08 NE  
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Polymyxin  S02AA11 NE  
Polymyxin B A07AA05 
S01AA18 
S03AA03 
NE  
Polynoxylin  A01AB05 
D01AE05 
NE  
Polythiazide C03AA05 NE  
Polythiazide and potassium C03AB05 NE  
Potassium acetate B05XA17 0 • No special advice 
Potassium canrenoate C03DA02 0 • No special advice 
Potassium chloride A12BA01 
B05XA01 
0 • No special advice 
 
Potassium chloride, 
Combinations  
A12BA51 Depending on the 
medicine in 
combination 
• Depending on the medicine in combination 
Potassium citrate A12BA02 0 • No special advice 
Potassium clorazepate 
- Oral administration 
 
 
 
 
 
 
 
 
- Parenteral administration 
N05BA05 II 
 
 
 
 
 
 
 
 
 
 
 
III 
Oral administration 
• Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advice the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
• One time (occasional) use: inform your patient that his/her response is still reduced 
for approximately 3 days to one week. Advice your patient not to drive then. 
•  
Parenteral administration 
• Inform the patient about the effects of the medicine on reaction time, that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) and that reaction time can 
also be reduced without experiencing side effects. 
• Advice the patient not to drive until the next visit after start of treatment and also to 
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be careful in other situations (e.g. using machinery and working at heights) 
• Advice the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
• One time (occasional) use: inform your patient that his/her response is still reduced 
for approximately 3 days to one week. Advice your patient not to drive then. 
Potassium gluconate A12BA05 0 • No special advice 
Potassium hydrogencarbonate A12BA04 0 • No special advice 
Potassium hydrogentartrate A12BA03 0 • No special advice 
Potassium iodide R05CA02 
S01XA04 
NE  
Potassium lactate B05XA15 0 • No special advice 
Potassium permanganate D08AX06 NE  
Potassium phosphate, incl. 
comb. with other potassium 
salts 
B05XA06 0 • No special advice 
 
Potassium salicylate N02BA12 NE  
Povidone-iodine D08AG02 
D09AA09 
D11AC06 
R02AA15 
0 • No special advice 
 
 
 
Povidone-iodine S01AX18 NE  
Practolol C07AB01 NE  
Prajmaline C01BA08 NE  
 Pramipexole N04BC05 II • Advise the patient (and explain to caregivers) not to drive during the first days of 
treatment. 
• Inform patients that unwanted effects are seen rapidly during the dosage adjustment 
period. 
• Advise the patient (and explain to caregivers) not to drive at all if suffering from 
“sleep attacks” 
• Advise the patient (and explain to caregivers) not to drive at all if suffering from 
severe fluctuations in mobility “(“on-off” phenomena). 
Pramlintide A10BX05 NE  
Pramocaine C05AD07 0 • No special advice 
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D04AB07 
Pranlukast R03DC02 NE  
Pranoprofen S01BC09 0 • No special advice 
Prasterone A14AA07 NE  
Prasugrel B01AC22 0 • No special advice 
Pravastatin C10AA03 0 • No special advice 
Pravastatin and acetylsalicylic 
acid 
C10BX02 NE  
Pravastatin and fenofibrate C10BA03 0 • No special advice 
Prazepam N05BA11 III • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advice the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
• One time (occasional) use: inform your patient that his/her response is still reduced 
for approximately 3 days to one week. Advice your patient not to drive then. 
Prazosin C02CA01 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Prazosin and diuretics C02LE01 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist.  
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Prednicarbate D07AC18 0 • No special advice 
Prednisolone A07EA01 
C05AA04 
D07AA03 
0 • No special advice 
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D07XA02 
S01BA04 
 
 
Prednisolone R01AD02 
S02BA03 
S03BA02 
NE  
Prednisolone 
(Corticosteroids/antiinfectives/
mydriatics in combination) 
S01CB02 Depending on the 
mydriatic in 
combination 
• Depending on the mydriatic in combination 
Prednisolone and antibiotics D07CA03 NE  
Prednisolone and 
antiinfectives 
- Drops 
- Oinment 
S01CA02  
 
0 
I 
• Inform the patient that as with any ocular medication, if transient, vision occurs at 
application.  
• Advice the patient that he/she should wait until his/her vision clears before driving or 
using machinery. 
Prednisolone and 
antiinfectives 
S02CA01 NE  
Prednisolone and 
antiinfectives 
S03CA02 0 • No special advice 
Prednisolone and antiseptics D07BA01 NE  
Prednisolone and mydriatics S01BB02 Depending on the 
mydriatic in 
combination 
• Depending on the mydriatic in combination 
Prednisolone, Combinations A01AC54 0 • No special advice 
Prednisolone, combinations R01AD52 NE  
Prednisone A07EA03 0 • No special advice 
 Pregabalin N03AX16 II Advise the patient not to drive during the first days of treatment as well as after 
dose increases. 
 
General warnings: 
• Advise the patient to take the medicine as prescribed by the physician. 
• Advise the patient not to stop taking the medicine suddenly, and to inform the 
physician – doctor if he/she should do so. 
• Advise the patient not to drink alcohol while taking this medication. 
 
Neuropathic pain; Generalised Anxiety Disorder 
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• Advise the patient not to drive during the first days of treatment as well as after dose 
increases. 
Prenalterol C01CA13 NE  
Prenoxdiazine R05DB18 NE  
Prenylamine C01DX02 NE  
Prenylamine, combinations C01DX52 NE  
Prethcamide R07AB06 NE  
Pridinol M03BX03 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advice the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
• One time (occasional) use: inform your patient that his/her response is reduced. 
Advice your patient not to drive then. 
Prifinium bromide A03AB18 NE  
 Prilocaine N01BB04  
 
 
0 
 
 
 
I 
 
 
 
II 
 
 
 
III 
Categorization, labelling and information to the patient  depending of the route of 
administration 
 
Topic administration (skin, mucous) 
 
Infiltration (dental anaesthesia) 
Intrarticular, intrabursal, tendon sheath administration, etc.. 
• Advise the patient not to drive or operate machinery until the effect of the 
anaesthesia and the immediate effects of surgery are passed. 
 
Ocular administration: 
• Advise at the patient that their sight may become blurred, and not to drive or operate 
machinery during the first 24 hours after using local anesthetics. 
 
Regional anaesthesia (nerve-block, intravenous regional anaesthesia). 
Spinal /Epidural 
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• Advise the patient (and explain to caregivers), in the event an early discharge is 
envisaged following  regional / epidural / spinal anaesthesia, not to drive or operate 
machinery during the first 24 hours after anaesthesia.  
• Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after 
anaesthesia 
 Prilocaine combinations N01BB54  
 
 
0 
 
 
 
I 
 
 
 
II 
 
 
 
III 
Categorization, labelling and information to the patient  depending of the route of 
administration 
 
Topic administration (skin, mucous) 
 
Infiltration (dental anaesthesia) 
Intrarticular, intrabursal, tendon sheath administration, etc.. 
• Advise the patient not to drive or operate machinery until the effect of the 
anaesthesia and the immediate effects of surgery are passed. 
 
Ocular administration: 
• Advise at the patient that their sight may become blurred, and not to drive or operate 
machinery during the first 24 hours after using local anesthetics. 
 
Regional anaesthesia (nerve-block, intravenous regional anaesthesia). 
Spinal /Epidural 
• Advise the patient (and explain to caregivers), in the event an early discharge is 
envisaged following  regional / epidural / spinal anaesthesia, not to drive or operate 
machinery during the first 24 hours after anaesthesia.  
• Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after 
anaesthesia 
 Primidone N03AA03 III Advise the patient not to drive. 
 
General warnings: 
• Advise the patient to take the medicine as prescribed by the physician. 
• Advise the patient not to stop taking the medicine suddenly, and to inform the 
physician – doctor if he/she should do so. 
• Advise the patient not to drink alcohol while taking this medication. 
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Essential tremor 
• Advise the patient not to drive  
Probenecid M04AB01 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. somnolence, dizziness   vertigo or ataxia), and not to 
drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Probucol C10AX02 NE  
Procainamide C01BA02 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Procaine C05AD05 0 • No special advice 
Procaine S01HA05 NE  
Procaine (Anesthetic, local)(En 
la otra table no aparece: 
“Anesthetic, local” 
N01BA02 
 
 
 
 
0 
 
 
 
I 
 
 
 
II 
 
 
 
III 
Categorization, labelling and information to the patient  depending of the route 
of administration 
 
Topic administration (skin, mucous) 
 
Infiltration (dental anaesthesia) 
Intrarticular, intrabursal, tendon sheath administration, etc.. 
• Advise the patient not to drive or operate machinery until the effect of the 
anaesthesia and the immediate effects of surgery are passed. 
 
Ocular administration: 
• Advise at the patient that their sight may become blurred, and not to drive or operate 
machinery during the first 24 hours after using local anesthetics. 
 
Regional anaesthesia (nerve-block, intravenous regional anaesthesia). 
Spinal /Epidural 
• Advise the patient (and explain to caregivers), in the event an early discharge is 
envisaged following  regional / epidural / spinal anaesthesia, not to drive or operate 
machinery during the first 24 hours after anaesthesia.  
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• Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after 
anaesthesia 
Procaine combinations N01BA52  
 
 
0 
 
 
 
I 
 
 
 
II 
 
 
 
III 
Categorization, labelling and information to the patient  depending of the route 
of administration 
 
Topic administration (skin, mucous) 
 
Infiltration (dental anaesthesia) 
Intrarticular, intrabursal, tendon sheath administration, etc.. 
• Advise the patient not to drive or operate machinery until the effect of the 
anaesthesia and the immediate effects of surgery are passed. 
 
Ocular administration: 
• Advise at the patient that their sight may become blurred, and not to drive or operate 
machinery during the first 24 hours after using local anesthetics. 
 
Regional anaesthesia (nerve-block, intravenous regional anaesthesia). 
Spinal /Epidural 
• Advise the patient (and explain to caregivers), in the event an early discharge is 
envisaged following  regional / epidural / spinal anaesthesia, not to drive or operate 
machinery during the first 24 hours after anaesthesia.  
• Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after 
anaesthesia 
Procaterol R03AC16 
R03CC08 
NE  
Prochlorperazine N05BA04 NE  
 Procyclidine N04AA04 II • Advise the patient (and explain to caregivers) not to drive during the first days of 
treatment. 
• Inform patients that unwanted effects are seen rapidly during the dosage adjustment 
period. 
• Advise the patient (and explain to caregivers) not to drive at all if suffering from 
“sleep attacks”. 
• Advise the patient (and explain to caregivers) not to drive at all if suffering from 
severe fluctuations in mobility “(“on-off” phenomena). 
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 Profenamine N04AA05 NE  
 Progabide N03AG05 NE  
Proglumetacin M01AB14 NE  
Proglumide A02BX06 NE  
Prolintane N06BX14 NE  
Promazine N05AA03 III • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive until the next visit after start of treatment and also to 
be careful in other situations (e.g. using machinery and working at heights) 
• Advice the patient not to drink alcohol when taking this medicine. 
• In short-term use, inform your patient that his/her response is still reduced for 
approximately 24 hours. Advice the patient not to drive then. 
Promethazine D04AA10 0 • No special advice 
Promethazine R06AD02 III • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred vision, tremor and reduced alertness) 
• Advise the patient not to drive until the next visit after start of treatment and also to 
be careful in other situations (e.g. using machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Promethazine, combinations R06AD52 III • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advise the patient not to drive until the next visit after start of treatment and also to 
be careful in other situations (e.g. using machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Propacetamol N02BE05 NE  
Propafenone C01BC03 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
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taking this medication. 
Propamidine D08AC03 NE  
Propanamidine S01AX15 NE  
 Propanidid N01AX04 NE  
Propanol D08AX03 NE  
Propanol, combinations D08AX53 NE  
Propantheline A03AB05 0 • No special advice 
Propantheline and 
psycholeptics 
A03CA34 NE  
Propatylnitrate C01DA07 NE  
Propatylnitrate, combinations C01DA57 NE  
Propiomazine N05CM06 NE  
Propiphenazone, combinations 
with. Psycholeptics 
N02BB74 NE  
Propofol N01AX10 III • Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient (and explain to caregivers) not to drive until the next visit after start 
of treatment or after changes in dosage. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to strictly follow the prescribed doses and the intake scheme.  
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
• Opiate cessation can also cause behavioral changes and requires follow-up and 
counseling. 
Propranolol C07AA05 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Propranolol and other 
antihypertensives 
C07FA05 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
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• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Propranolol and thiazides C07BA05 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Propyphenazone N02BB04 NE  
Propyphenazone, 
combinations excl. 
Psycholeptics 
N02BB54 NE  
Proquazone  M01AX13 NE  
Proscillaridin C01AB01 NE  
Proscillaridin, combinations C01AB51 NE  
Protein C B01AD12 0 • No special advice 
Protein hydrolysates B05BA04 0 • No special advice 
Prothipendyl N05AX07 NE  
Protriptyline N06AA11 NE  
Proxazole A03AX07 NE  
Proxibarbital N05CA22 NE  
Proxymetacaine S01HA04 NE  
Proxyphylline  R03DA03 NE  
Proxyphylline and adrenergics R03DB03 NE  
Prucalopride  A03AE04 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness and fatigue) particularly during the first day of 
treatment, and not to drive as long as side-effects persist. 
Pseudoephedrine R01BA02 I • Inform the patient about the effects that the medicine can have on reaction time and 
that the medication can cause side effects that impair driving (anxiety, restlessness, 
termor, insomnia) 
• Advise the patient not to drive when this side effects occur and also to be careful in 
other situations (e.g. using machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
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Pseudoephedrine, 
combinations 
+ loratadine 
 
 
 
 
 
 
 
+ triprolidine 
R01BA52 I 
 
 
 
 
 
 
 
 
III 
+ loratadine 
• Inform the patient about the effects that the medicine can have on reaction time and 
that the medication can cause side effects that impair driving (anxiety, restlessness, 
tremor, insomnia, dizziness, fatigue) 
• Advise the patient not to drive when this side effects occur and also to be careful in 
other situations (e.g. using machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
 
+ triprolidine 
• Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (anxiety, restlessness, tremor, 
insomnia, drowsiness) 
• Advise the patient not to drive until the next visit after start of treatment and also to 
be careful in other situations (e.g. using machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Pyridostigmine N07AA02 II • Advise the patient (and explain to caregivers) not to drive during the first days of 
treatment.   
• The treatment can impair patient’s vision especially by night. 
Pyridoxal phosphate A11HA06 0 • No special advice 
Pyridoxine (vit B6)  A11HA02 0 • No special advice 
Pyrithione zinc D11AX12 0  
Pyrithyldione N05CE03 NE  
Pyritinol N06BX02 NE  
Pyrrobutamine R06AX08 NE  
Pyrrobutamine, combinations R06AX58 NE  
Pyrrolnitrin D01AA07 NE  
    
Q ATC CODE CATEGORIZATION 
labelling 
INFORMATION FOR THE PATIENT 
Quazepam N05CD10 NE  
Quetiapine N05AH04 II Start of treatment: 
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• Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive until the next visit after start of treatment and also to 
be careful in other situations (e.g. using machinery and working at heights) 
• Advice the patient not to drink alcohol when taking this medicine. 
 
Continuation treatment: 
• Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advice the patient not to drink alcohol when taking this medicine. 
Quinapril C09AA06 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Quinapril  and diuretics C09BA06 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Quinbolone A14AA06 NE  
Quinethazone C03BA02 NE  
Quinethazone and potassium C03BB02 NE  
Quinidine C01BA01 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Quinidine, combinations excl. C01BA51 NE  
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psycholeptics 
Quinidine, combinations with 
psycholeptics 
C01BA71 NE  
Quinine, combinations with 
psycholeptics 
M09AA72 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. visual disturbances, vertigo), and not to drive as long as 
side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication 
Quinisocaine D04AB05 NE  
    
R ATC CODE CATEGORIZATION 
labelling 
INFORMATION FOR THE PATIENT 
Rabeprazole A02BC04 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness) particularly during the first day of treatment, 
and not to drive as long as side-effects persist. 
Racecadotril A07XA04 0 • No special advice 
Ramelteon N05CH02 NE  
Ramipril C09AA05 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Ramipril and diuretics C09BA05 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Ramipril and felodipine C09BB05 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Ranibizumab S01LA04 III • Inform the patient that this ocular medication may cause transient visual 
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disturbances such as abnormal vision, vision decrease, or visual field defects that 
may interfere with their ability to drive or use machines. Patients should not drive or 
use machines as long as these symptoms persist. 
• Advise the patients not to drive or operate hazardous machinery until your vision 
improves. 
Ranitidine A02BA02 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness) particularly during the first day of treatment, 
and not to drive as long as side-effects persist. 
Ranitidine bismuth citrate A02BA07 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness) particularly during the first day of treatment, 
and not to drive as long as side-effects persist. 
Ranolazine C01EB18 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
 Rasagiline N04BD02 I Monotherapy:  
 
• Advise the patient (and explain to caregivers) not to drive during the first days of 
treatment. 
 
In adjunct therapy with levodopa: 
 
• Advise the patient (and explain to caregivers) not to drive during the first days of 
treatment. 
• Inform patients that unwanted effects are seen rapidly during the dosage adjustment 
period. 
• Advise the patient (and explain to caregivers) not to drive at all if suffering from “sleep 
attacks”. 
• Advise the patient (and explain to caregivers) not to drive at all if suffering from 
severe fluctuations in mobility “(“on-off” phenomena). 
Rauwolfia alkaloids, whole root C02AA04 NE  
Rauwolfia alkaloids, whole root 
and diuretics 
C02LA08 NE  
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Reboxetine N06AX18 I • Inform your patient about the effects of the medication on reaction time as well as 
that the medication can cause side-effects that impair driving abilities (e.g. dizziness, 
drowsiness, sleepiness, blurred vision, etc.). 
• Advice your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities. 
• Advice your patient not to drive as long as side-effects persist. 
• Advice your patient not to drink alcohol nor use any other psychoactive substance 
when taking this medication. 
Regadenoson C01EB21 NE  
 Remifentanil N01AH06 III • Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient (and explain to caregivers) not to drive until the next visit after start 
of treatment or after changes in dosage. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to strictly follow the prescribed doses and the intake scheme.  
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
• Opiate cessation can also cause behavioral changes and requires follow-up and 
counseling. 
Remikiren C09XA01 NE  
Remoxipride N05AL04 NE  
Repaglinide A10BX02 I • Advise your patient to take precautions to avoid hypoglycaemia, this may constitute 
a risk in situations where these abilities are of special importance (e.g. driving a car 
or operating machinery), and not to drive as long as side-effects persist. 
• If your patient has frequent episodes or if he/she find it hard to recognise 
hypoglycaemia. The advisability of driving should be considered in these 
circumstances.  
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication 
Reposal N05CA12 NE  
Reproterol R03AC15 
R03CC14 
NE  
Reproterol and other drugs for R03AK05 NE  
 DRUID 6th Framework Programme         Deliverable D.4.4.1  
   Classification of medicinal drugs and driving: 
 Co-ordination and synthesis report.  
   Page 204 of 243 
 
  
 
   
 
 
obstructive airway diseases  
Rescinnamine C02AA01 NE  
Rescinnamine and diuretics C02LA02 NE  
Rescinnamine and diuretics, 
combinations with other drugs 
C02LA52 NE  
Reserpine C02AA02 NE  
Reserpine and diuretics C02LA01 NE  
Reserpine and diuretics, 
combinations with other drugs 
C02LA51 NE  
Reserpine and diuretics, 
combinations with 
psycholeptics 
C02LA71 NE  
Reserpine, combinations C02AA52 NE  
Resorcinol D10AX02 
S01AX06 
NE  
Retapamulin D06AX13 0 • No special advice 
Reteplase B01AD07 0 • No special advice 
Retinol D10AD02 
R01AX02 
S01XA02 
NE  
Retinol (vit A) A11CA01 0 • No special advice 
Reviparin B01AB08 NE  
Riboflavin (vit B2) A11HA04 0 • No special advice 
Rifamycin S01AA16 0 • Inform the patient that as with any ocular medication, if transient, blurred vision 
occurs at application.  
• Advice the patient that he/she should wait until his/her vision clears before driving or 
using machinery. 
Rifamycin S02AA12 NE  
Rifaximin A07AA11 0 • No special advice 
Rifaximin  D06AX11 NE  
Rilanomer D03AX09 NE  
Rilmenidine C02AC06 II • Inform your patient that the medication can cause side effects that impair driving 
abilities (e.g. dizziness, drowsiness, hypotension, fatigue, etc.). 
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• Advise your patient not to drive for the first few days of treatment and to be careful in 
other situations, as well (e.g. operating machinery and working at heights). 
• Advise the patient not to drink alcohol nor use any psychoactive substance when 
taking this medicine. 
Riluzole N07XX02 I • The treatment has to be used according to the recommended dose to avoid side 
effect on driving. 
• Driving ability might be evaluated depending of the severity of the disease. 
Rimazolium N02BG02 NE  
Rimexolone 
- Drops 
- Oinment 
S01BA13  
0 
 
I 
 
• Inform the patient that as with any ocular medication, if transient, blurred vision 
occurs at application.  
• Advice the patient that he/she should wait until his/her vision clears before driving or 
using machinery. 
Rimiterol R03AC05 NE  
Rimonabant  A08AX01 NE  
Risedronic acid M05BA07 0 • No special advice 
Risedronic acid and calcium, 
sequential 
M05BB02 NE  
Risedronic acid, calcium and 
colecalciferol, sequential  
M05BB04 NE  
Risperidone 
- Oral administration 
 
 
 
 
 
 
- Parenteral administration: 
depot i.m. 
N05AX08 II 
 
 
 
 
 
 
 
 
III 
Oral administration: 
• Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advice the patient not to drink alcohol when taking this medicine. 
 
Parenteral administration 
• Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive until the next visit after start of treatment and also to 
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be careful in other situations (e.g. using machinery and working at heights) 
• Advice the patient not to drink alcohol when taking this medicine. 
Ritanserin N06AX 
Not yet 
determined 
NE  
Ritiometan R01AX05 NE  
Rivaroxaban  B01AX06 0 • No special advice 
Rivastigmine N06DA03 II • Inform your patient (and explain his/her caregiver) about the effects of the 
medication on reaction time as well as that the medication can cause side-effects 
that impair driving abilities (e.g. dizziness, drowsiness, sleepiness, blurred vision, 
etc.). 
• Advise your patient (and explain his/her caregiver) not to drive for the first few weeks 
of treatment or until the next visit and to be careful in other situations, as well (e.g. 
operating machinery and working at heights). 
• Advise your patient (and explain his/her caregiver) not to drink alcohol nor use any 
other psychoactive substance when taking this medication. 
• In case of short-term use of the medication, advise your patient (and explain his/her 
caregiver) not to drive because his/her driving skills are still impaired for 
approximately 24 hours. 
• Driving with this treatment should require an approval by driving licence 
administration. 
Rizatriptan N02CC04 II • Advise the patient not to drive during the first times, the drug is administered, until 
he/she knows his/her reactions.   
• Advise the patient not to drive within the first 4 hours after treatment. 
• Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to strictly follow the prescribed doses and intake scheme.  
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
Rociverine  A03AA06 NE  
Rocuronium bromide M03AC09 III • Advise the patient not to drive or operate machinery until the effects of the 
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anaesthetic, and the immediate effects of surgery have passed 
• Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after 
anaesthesia 
Rofecoxib M01AH02 NE  
Roflumilast R03DX07 0 • No special advice 
Romiplostim (subcutaneous 
via) 
B02BX04 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, paraesthesia, etc.) and not to drive as long as 
side-effects persist. 
Ronifibrate C10AB07 NE  
 Ropinirole N04BC04 II • Advise the patient (and explain to caregivers) not to drive during the first days of 
treatment. 
• Inform patients that unwanted effects are seen rapidly during the dosage adjustment 
period. 
• Advise the patient (and explain to caregivers) not to drive at all if suffering from 
“sleep attacks” 
• Advise the patient (and explain to caregivers) not to drive at all if suffering from 
severe fluctuations in mobility “(“on-off” phenomena). 
 Ropivacaine N01BB09  
 
 
0 
 
 
 
I 
 
 
 
II 
 
 
 
III 
Categorization, labelling and information to the patient  depending of the route of 
administration 
 
Topic administration (skin, mucous) 
 
Infiltration (dental anaesthesia) 
Intrarticular, intrabursal, tendon sheath administration, etc.. 
• Advise the patient not to drive or operate machinery until the effect of the 
anaesthesia and the immediate effects of surgery are passed. 
 
Ocular administration: 
• Advise at the patient that their sight may become blurred, and not to drive or operate 
machinery during the first 24 hours after using local anesthetics. 
 
Regional anaesthesia (nerve-block, intravenous regional anaesthesia). 
Spinal /Epidural 
• Advise the patient (and explain to caregivers), in the event an early discharge is 
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envisaged following  regional / epidural / spinal anaesthesia, not to drive or operate 
machinery during the first 24 hours after anaesthesia.  
• Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after 
anaesthesia 
Rosa bengal sodium S01JA02 NE  
Rosiglitazone A10BG02 0 • No special advice 
Rosuvastatin C10AA07 0 • No special advice 
 Rotigotin N04BC09 II • Advise the patient (and explain to caregivers) not to drive during the first days of 
treatment. 
• Inform patients that unwanted effects are seen rapidly during the dosage adjustment 
period. 
• Advise the patient (and explain to caregivers) not to drive at all if suffering from 
“sleep attacks”. 
• Advise the patient (and explain to caregivers) not to drive at all if suffering from 
severe fluctuations in mobility “(“on-off” phenomena). 
Roxatidine A02BA06 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness) particularly during the first day of treatment, 
and not to drive as long as side-effects persist. 
 Rufinamide N03AF03 II Advise the patient not to drive during the first days of treatment as well as after 
dose increases. 
General warnings: 
• Advise the patient to take the medicine as prescribed by the physician. 
• Advise the patient not to stop taking the medicine suddenly, and to inform the 
physician – doctor if he/she should do so. 
• Advise the patient not to drink alcohol while taking this medication. 
 
Rupatadine R06AX28 I • Inform the patient about the effects that the medicine can have on reaction time and 
that the medication can cause side effects that impair driving (dizziness, drowsiness, 
somnolence) 
• Advise the patient not to drive when this side effects occur and also to be careful in 
other situations (e.g. using machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
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Rutoside C05CA01 0 • No special advice 
Rutoside, combinations C05CA51 0 • No special advice 
    
S ATC CODE CATEGORIZATION 
labelling 
INFORMATION FOR THE PATIENT 
Saccharated iron oxide B03AC02 0 • No special advice 
Saccharomyces boulardii A07FA02 0 • No special advice 
Sacrosidase A16AB06 NE  
Salbutamol R03AC02 
R03CC02 
0 
0 
• No special advice 
• No special advice 
Salbutamol and other drugs for 
obstructive airway diseases  
R03AK04 NE  
Salicylamide N02BA05 NE  
Salicylamide , combinations 
with psycholeptics 
N02BA75 NE  
Salicylamide, combinations 
excl. Psycholeptics 
N02BA55 NE  
Salicylic acid  D01AE12 0 • No special advice 
Salicylic acid S01BC08 NE  
Salicylic acid preparations D02AF 0  
Salmeterol R03AC12 0 • No special advice 
Salmeterol and other drugs for 
obstructive airway diseases  
R03AK06 NE  
Salsalate N02BA06 NE  
Sapropterin A16AX07 0 • No special advice 
Saruplase B01AD08 NE  
S-atenol C07AB11 NE  
Saxagliptin A10BH03 I • Advise your patient to take precautions to avoid hypoglycaemia, this may constitute 
a risk in situations where these abilities are of special importance (e.g. driving a car 
or operating machinery), and not to drive as long as side-effects persist. 
• If your patient has frequent episodes or if he/she find it hard to recognise 
hypoglycaemia. The advisability of driving should be considered in these 
circumstances.  
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• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication 
Scopolamine  
- Oral and rectal 
administration 
 
 
 
 
- Parenteral administration 
A04AD01  
I 
 
 
 
 
 
II 
Oral and rectal administration 
• Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. possible visual accommodation disturbances), and not 
to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
 
Parenteral administration 
• Inform the patient that this medication causes visual accommodation disturbances 
so you should not drive or operate machinery after parenteral administration until 
vision has normalised. 
• Advise the patient that should wait until until your sight returns to normal before 
driving or using any tools or machines. 
Scopolamine N05CM05 
S01FA02 
NE  
Scopolamine, combinations A04AD51 NE  
 Selegiline N04BD01 I Monotherapy:  
• Advise the patient (and explain to caregivers) not to drive during the first days of 
treatment. 
 
In adjunct therapy with levodopa: 
• Advise the patient (and explain to caregivers) not to drive during the first days of 
treatment. 
• Inform patients that unwanted effects are seen rapidly during the dosage adjustment 
period. 
• Advise the patient (and explain to caregivers) not to drive at all if suffering from “sleep 
attacks”. 
• Advise the patient (and explain to caregivers) not to drive at all if suffering from 
severe fluctuations in mobility “(“on-off” phenomena). 
Selenium compounds D11AC03 0 • No special advice 
Selenium sulfide  D01AE13 NE  
Senega R05CA06 0 • No special advice 
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Senna glycosides A06AB06 0 • No special advice 
Senna glycosides, 
combinations 
A06AB56 0 • No special advice 
Seratrodast R03DX06 NE  
Serobarbital N05CA06 NE  
Sertaconazole D01AC14 0 • No special advice 
Sertindole N05AE03 NE  
Sertraline N06AB06 I • Inform your patient about the effects of the medication on reaction time as well as 
that the medication can cause side-effects that impair driving abilities (e.g. dizziness, 
drowsiness, sleepiness, blurred vision, etc.). 
• Advice your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities. 
• Advice your patient not to drive as long as side-effects persist. 
• Advice your patient not to drink alcohol nor use any other psychoactive substance 
when taking this medication. 
 Sevoflurane N01AB08 III • Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient (and explain to caregivers) not to drive until the next visit after start 
of treatment or after changes in dosage. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to strictly follow the prescribed doses and the intake scheme.  
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
• Opiate cessation can also cause behavioral changes and requires follow-up and 
counseling. 
Sibutramine  A08AA10 NE  
Silicone products D02AA 0 • No special advice 
Silicones A03AX13 0 • No special advice 
Silver D08AL30 NE  
Silver compounds S01AX02 NE  
Silver nitrate D08AL01 0  
Silver sulfadiazine D06BA01 0 • No special advice 
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Silver sulfadiazine, 
combinations 
D06BA51 0 • No special advice 
 
Silymarin A05BA03 0 • No special advice 
Simfibrate C10AB06 NE  
Simvastatin C10AA01 0 • No special advice 
Simvastatin and acetylsalicylic 
acid 
C10BX01 NE  
Simvastatin and ezetimibe C10BA02 0 • No special advice 
Sitagliptin A10BH01 I • Advise your patient to take precautions to avoid hypoglycaemia, this may constitute 
a risk in situations where these abilities are of special importance (e.g. driving a car 
or operating machinery), and not to drive as long as side-effects persist. 
• If your patient has frequent episodes or if he/she find it hard to recognise 
hypoglycaemia. The advisability of driving should be considered in these 
circumstances.  
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication 
Sitaxentan C02KX03 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Sobrerol R05CB07 NE  
Sodium acetate B05XA08 0 • No special advice 
Sodium apolate C05BA02 0 • No special advice 
Sodium aurothiomalate M01CB01 0  
Sodium aurothiosulfate M01CB02 NE  
Sodium bicarbonate B05CB04 
B05XA02 
0 • No special advice 
• No special advice 
Sodium borate S01AX07 NE  
Sodium chloride A12CA01 
B05CB01 
B05XA03 
0 • No special advice 
• No special advice 
• No special advice 
Sodium chloride, hypertonic S01XA03 0 • No special advice 
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Sodium citrate B05CB02 0 • No special advice 
Sodium edetate S01XA05 0 • No special advice 
Sodium feredetate B03AB03 0 • No special advice 
Sodium fluoride A01AA01 
A12CD01 
0 • No special advice 
• No special advice 
Sodium fluoride, combinations A01AA51 NE NE 
Sodium glycerophosphate B05XA14 0 • No special advice 
Sodium hypochlorite D08AX07 NE  
sodium Monofluorophosphate A01AA02 NE  
Sodium monofluorophosphate A12CD02 0 • No special advice 
Sodium perborate A01AB19 0 • No special advice 
Sodium phenylbutyrate  A16AX03 I • No special advice 
Sodium phosphate A06AG01 
B05XA09 
0 • No special advice 
 
Sodium phosphate A06AD17 NE  
Sodium picosulfate A06AB08 0 • No special advice 
Sodium picosulfate, 
combinations 
A06AB58 0 • No special advice 
Sodium propionate S01AX10 NE  
Sodium salicilate N02BA04 NE  
Sodium selenate A12CE01 0 • No special advice 
Sodium selenite A12CE02 0 • No special advice 
Sodium sulfate A12CA02 
A06AD13 
0 • No special advice 
Sodium tartrate A06AD21 NE  
Sodium tetradecyl sulfate C05BB04 0 • No special advice 
Soft paraffin and fat products D02AC 0 • No special advice 
Sorbitol B05CX02 0 • No special advice 
Sorbitol A06AD18 
A06AG07 
NE  
Sotalol C07AA07 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
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• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication.  
Sotalol and thiazides C07BA07 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Sotalol, combination C07AA57 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Spaglumic acid S01GX03 I • Inform the patient that this ocular medication may cause side effects including local 
irritation, temporary blurred vision or other visual disturbances, transient stinging and 
burning after instillation. 
• Advise the patient that if he/she experiences these symptoms, he/she should wait 
until they have cleared before driving or using machinery. 
Spaglumic acid R01AC05 NE  
Sparteine C01BA04 NE  
Spirapril C09AA11 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Spironolactone C03DA01 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Stannous fluoride A01AA04 NE  
Stanozolol  A14AA02 0 • No special advice 
Stem cells from umbilical cord 
blood 
B05AX04 NE  
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Stepronin R05CB11 NE  
Sterculia A06AC03 0 • No special advice 
Sterculia, combinations A06AC53 NE  
 Stiripentol N03AX17 NE  
Stramoni preparations R03BB03 NE  
Streptokinase B01AD01 0 • No special advice 
Streptokinase, combinations B06AA55 NE  
Streptomycin A07AA04 0 • No special advice 
Streptomycin, combinations A07AA54 NE  
Strontium ranelate M05BX03 0 • No special advice 
Styramate M03BA04 NE  
Succinylsulfathiazole A07AB04 NE  
Sucralfate A02BX02 0 • No special advice 
 Sufentanil N01AH03 NE  
Sulbentine D01AE09 NE  
Sulbutiamine A11DA02 0 • No special advice 
Sulconazole D01AC09 NE  
Sulfacetamide S01AB04 NE  
Sulfadicramide S01AB03 NE  
Sulfafena S01AB05 NE  
Sulfafurazole S01AB02 NE  
Sulfaguanidine A07AB03 NE  
Sulfamerazine D06BA06 NE  
Sulfamethizole B05CA04 
D06BA04 
S01AB01 
NE  
Sulfanilamide D06BA05 0 • No special advice 
Sulfasalazine A07EC01 0 • No special advice 
Sulfathiazole  D06BA02 0 • No special advice 
Sulfinpyrazone M04AB02 NE  
Sulfur D10AB02 0 • No special advice 
Sulfur compounds D11AC08 0 • No special advice 
Sulglicotide A02BX08 NE  
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Sulindac M01AB02 I • Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
Suloctidil C04AX19 NE  
Sulodexide B01AB11 0 • No special advice 
Sulpiride N05AL01 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advice the patient not to drink alcohol when taking this medicine. 
 Sultiame N03AX03 NE  
Sultopride N05AL02 NE  
Sumatriptan N02CC01 II • Advise the patient not to drive during the first times, the drug is administered, until 
he/she knows his/her reactions.   
• Advise the patient not to drive within the first 4 hours after treatment. 
• Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to strictly follow the prescribed doses and intake scheme.  
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
Suprofen M01AE07 NE  
Suxamethonium M03AB01 III • Advise the patient not to drive or operate machinery until the effects of the 
anaesthetic, and the immediate effects of surgery have passed. 
• Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after 
anaesthesia 
Suxibuzone M01AA90 NE  
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M02AA22 
Syrosingopine and diuretics C02LA09 NE  
    
T ATC CODE CATEGORIZATION 
labelling 
INFORMATION FOR THE PATIENT 
Tacalcitol D05AX04 
 
0 • No special advice 
Tacrine N06DA01 NE  
Tacrine N06DA01 NE  
Tacrolimus 
- Intravenous administration 
- Oral administration 
- Topical use 
L04AD02 
 
 
D11AH01 
 
III 
II 
0 
• Inform the patient about the effects of the medicine and that the medication can 
cause side effects that impair driving (visual and neurological disturbances). 
• Advice the patient not to drive until the next visit after start of treatment and also to 
be careful in other situations (e.g. using machinery and working at heights). 
• Advice the patient not to drink alcohol when taking this medicine. This adverses 
effect may be enhanced if is administered in association with alcohol. 
Tafluprost S01EE05 I • Inform the patient that as with any ocular medication, if transient, blurred vision 
occurs at application.  
• Advice the patient that he/she should wait until his/her vision clears before driving or 
using machinery. 
Talastine R06AB07 NE  
Talbutal N05CA07 NE  
Talinolol C07AB13 NE  
Tasosartan C09CA05 NE  
Taurolidine B05CA05 NE  
Tazarotene D05AX05 0 • No special advice 
Tedisamil C01BD06 NE  
Tegaserod A03AE02 NE  
Telmisartan C09CA07 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Telmisartan and amlodipine C09DB04 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
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his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Telmisartan and diuretics C09DA07 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Temazepam N05CD07 III • Inform the patient about the effects of the medicine on reaction time, that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) and that reaction time can 
also be reduced without experiencing side effects. 
• Advice the patient not to drive until the next visit after start of treatment and also to 
be careful in other situations (e.g. using machinery and working at heights) 
• Advice the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Temocapril C09AA14 NE  
Tenecteplase B01AD11 0 • No special advice 
Tenidap M01AX23 NE  
Tenitramine C01DA38 NE  
Tenoxicam M01AC02 I • Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
Terbinafine D01AE15 0 • No special advice 
Terbinafine  D01BA02 0 • No special advice 
Terbutaline R03AC03 
R03CC03 
0 
0 
• No special advice 
• No special advice 
Terbutaline, combinations R03CC53 NE  
Terfenadine R06AX12 I • Inform the patient about the effects that the medicine can have on reaction time and 
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that the medication can cause side effects that impair driving (somnolence, 
insomnia, drowsiness) 
• Advise the patient not to drive when this side effects occur and also to be careful in 
other situations (e.g. using machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Tertatolol C07AA16 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Tetrabenazine N07XX06 NE  
Tetracaine C05AD02 
D04AB06 
0 • No special advice 
 
Tetracaine S01HA03 NE  
Tetracaine (anesthetic, local) N01BA03  
 
 
0 
 
 
 
I 
 
 
 
II 
 
 
 
III 
Categorization, labelling and information to the patient  depending of the route 
of administration 
 
Topic administration (skin, mucous) 
 
Infiltration (dental anaesthesia) 
Intrarticular, intrabursal, tendon sheath administration, etc.. 
- Advise the patient not to drive or operate machinery until the effect of the 
anaesthesia and the immediate effects of surgery are passed. 
 
Ocular administration: 
- Advise at the patient that their sight may become blurred, and not to drive or operate 
machinery during the first 24 hours after using local anesthetics. 
 
Regional anaesthesia (nerve-block, intravenous regional anaesthesia). 
Spinal /Epidural 
- Advise the patient (and explain to caregivers), in the event an early discharge is 
envisaged following  regional / epidural / spinal anaesthesia, not to drive or operate 
machinery during the first 24 hours after anaesthesia.  
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- Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after 
anaesthesia 
Tetracycline A01AB13 
D06AA04 
0 • No special advice 
 
Tetracycline S01AA09 
S02AA08 
S03AA02 
NE  
Tetragalacturonic acid 
hydroxymethylester  
B02BC03 NE  
Tetrazepam M03BX07 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advice the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
• One time (occasional) use: inform your patient that his/her response is reduced. 
Advice your patient not to drive then. 
Tetryzoline S01GA02 I • Inform the patient that this ocular medication may cause side effects including local 
irritation, allergy, and an increase in IOP, as well as systemic effects: dilation of the 
pupils, dizziness, headaches, nausea, sweating, nervousness, weakness, increased 
redness, blurring, punctate keratitis, lacrimation with an increase in intraocular 
pressure and systemic effects due to absorption (hypertension, cardiac irregularities 
and hyperglycaemia). Some patients may experience drowsiness. 
• Advise the patient that if he/she experiences these symptoms, he/she should wait 
until they have cleared before driving or using machinery. 
Tetryzoline  R01AA06 
R01AB03 
NE  
Tetryzoline, combinations S01GA52 NE  
Thebacone R05DA10 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (drowsiness, confusion, 
vertigo, blurred vision) 
• Advise the patient not to drive for the first few days of treatment or until the next visit 
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after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Thenalidine D04AA03 
R06AX03 
NE  
Thenalidine, combinations R06AX53 NE  
Theobromine C03BD01 
R03DA07 
NE  
Theobromine, combinations R03DA57 NE  
Theodrenaline C01CA23 NE  
Theophylline 
- Oral administration 
- Parenteral administration 
R03DA04 0 
 
I 
Oral: 
• No special advice  
Parenteral: 
• Inform the patient about the effects that the medicine can have on reaction time and 
that the medication can cause side effects that impair driving (insomnia, confusion, 
anxiety, vertigo, dizziness, tremor, visual disturbances) 
• Advise the patient not to drive when this side effects occur and also to be careful in 
other situations (e.g. using machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Theophylline and adrenergics R03DB04 Depending on 
medicine in 
combination 
• Depending on medicine in combination 
Theophylline, combinations 
excl. psycholeptics 
R03DA54 NE  
Theophylline, combinations 
with   psycholeptics 
R03DA74 NE  
Thiamine (vit B1) A11DA01 0 • No special advice 
 
Thiazinam  R06AD06 NE  
Thiethylperazine R06AD03 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
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• Advise the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Thiocolchicoside M03BX05 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advice the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
• One time (occasional) use: inform your patient that his/her response is reduced. 
Advice your patient not to drive then. 
Thiomersal D08AK06 0 • No special advice 
 Thiopental N01AF03 
 
 
III • Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient (and explain to caregivers) not to drive until the next visit after start 
of treatment or after changes in dosage. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to strictly follow the prescribed doses and the intake scheme.  
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
• Opiate cessation can also cause behavioral changes and requires follow-up and 
counseling. 
Thiopental N05CA19 
 
III • Inform the patient about the effects of the medicine on reaction time, that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) and that reaction time can 
also be reduced without experiencing side effects. 
• Advise the patient not to drive until the next visit after start of treatment and also to 
be careful in other situations (e.g. using machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
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taking this medicine. 
• One time (occasional) use: inform your patient that his/her response is still reduced 
for a few days. Advise your patient not to drive then. 
Thiopropazate N05BA05 NE  
Thioproperazine N05AB08 NE  
Thioridazine N05AC02 NE  
Thonzylamine D04AA01 
R01AC06 
R06AC06 
NE  
Thrombin  B02BD30 0 • No special advice 
Thrombin (with human 
fibrinogen)  
B02BC06 0 • No special advice 
Thrombocytes B05AX02 NE  
Tiabendazole D01AC06 NE  
Tiadenol C10AX03 0 • No special advice 
 Tiagabine N04AG06 II Advise the patient not to drive during the first days of treatment as well as after 
dose increases. 
 
Advise the patient that visual field testing should be done regularly. 
 
General warnings: 
• Advise the patient to take the medicine as prescribed by the physician. 
• Advise the patient not to stop taking the medicine suddenly, and to inform the 
physician – doctor if he/she should do so. 
• Advise the patient not to drink alcohol while taking this medication. 
Tianeptine N06AX14 NE  
Tiapride N05AL03 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advice the patient not to drink alcohol when taking this medicine. 
• In short-term use, inform your patient that his/her response is still reduced for 
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approximately 24 hours. Advice the patient not to drive then. 
Tiaprofenic acid M01AE11 I • Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
Tibezonium iodide A01AB15 NE  
Ticlatone D01AE08 NE  
Ticlopidine B01AC05 0 • No special advice 
Tidiacic arginine A05BA07 NE  
Tiemonium iodide A03AB17 NE  
Tiemonium iodide and 
analgesics 
A03DA07 NE  
Tienilic acid C03CC02 NE  
Tilactase A09AA04 NE  
Tilidine N02AX01 NE  
Tiludronic acid  M05BA05 0 • No special advice 
Timepidium bromide A03AB19 NE  
Timolol C07AA06 
 
 
 
 
 
I 
• Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Timolol S01ED01 I • Inform the patient that as with any ocular medication, if transient, blurred vision 
occurs at application.  
• Advice the patient that he/she should wait until his/her vision clears before driving or 
using machinery. 
Timolol - amiloride - 
hydrochlorothiazide 
C07DA06 NE  
Timolol and thiazides C07BA06 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
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etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Timolol, combinations 
Timolol+brinzolamide (Azarga) 
S01ED51 I • Inform the patient that as with any ocular medication, if transient, blurred vision 
occurs at application.  
• Advice the patient that he/she should wait until his/her vision clears before driving or 
using machinery. 
Timolol, thiazide and other 
diuretics 
C07DA06 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Tinzaparin B01AB10 0 • No special advice 
Tioclomarol B01AA11 NE  
Tioconazole D01AC07 0 • No special advice 
Tioctic acid A16AX01 NE  
Tiopronin R05CB12 NE  
Tiotixene N05AF04 NE  
Tiotropium bromide R03BB04 I • Inform the patient about the effects that the medicine can have on reaction time and 
that the medication can cause side effects that impair driving (dizziness, blurred 
vision) 
• Advise the patient not to drive when this side effects occur and also to be careful in 
other situations (e.g. using machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Tioxolone D10AB03 NE  
Tipepidine R05DB24 NE  
Tiracizine C01EB11 NE  
Tiratricol D11AX08 NE  
Tirilazad N07XX01 NE  
Tirofiban  B01AC17 0 • No special advice 
Tiropramide A03AC05 NE  
Tisopurine M04AA02 NE  
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Titoqualine R06AX21 NE  
Tixocortol A07EA05 
R01AD07 
NE  
Tixocortol, combinations R01AD57 NE  
Tizanidine M03BX02 II • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advice the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
• One time (occasional) use: inform your patient that his/her response is reduced. 
Advice your patient not to drive then. 
Tobramycin 
- Drops 
- Oinment 
S01AA12  
0 
I 
• Inform the patient that as with any ocular medication, if transient, blurred vision 
occurs at application.  
• Advice the patient that he/she should wait until his/her vision clears before driving or 
using machinery. 
Tocainide C01BB03 NE  
Tocofersolan (paediatric 
patients) 
A11HA08 0 • No special advice 
Tocopherol (vit E) A11HA03 0 • No special advice 
Tofisopam N05BA23 NE  
Tolazamide A10BB05 NE  
Tolazoline C04AB02 
M02AX02 
NE  
Tolbutamide A10BB03 I • Advise your patient to take precautions to avoid hypoglycaemia, this may constitute 
a risk in situations where these abilities are of special importance (e.g. driving a car 
or operating machinery), and not to drive as long as side-effects persist. 
• If your patient has frequent episodes or if he/she find it hard to recognise 
hypoglycaemia. The advisability of driving should be considered in these 
circumstances. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication 
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Tolcapone N04BX01 II • Advise the patient (and explain to caregivers) not to drive during the first days of 
treatment. 
• Inform patients that unwanted effects are seen rapidly during the dosage adjustment 
period. 
• Advise the patient (and explain to caregivers) not to drive at all if sufering from “sleep 
attacks”. 
• Advise the patient (and explain to caregivers) not to drive at all if suffering from 
severe fluctuations in mobility “(“on-off” phenomena). 
Tolciclate  D01AE19 NE  
Tolfenamic acid M01AG02 I • Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
Tolmetin M01AB03 
M02AA21 
NE  
Tolnaftate  D01AE18 0 • No special advice 
Toloxatone N06AG03 NE  
Tolperisone M03BX04 NE  
Tolpropamine D04AA12 NE  
Tolrestat A10XA01 NE  
Tolvaptan C03XA01 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Tonics A13A 0 • No special advice 
 Topiramate N03AX11 II Advise the patient not to drive during the first days of treatment as well as after 
dose increases. 
 
General warnings: 
• Advise the patient to take the medicine as prescribed by the physician. 
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• Advise the patient not to stop taking the medicine suddenly, and to inform the 
physician – doctor if he/she should do so. 
• Advise the patient not to drink alcohol while taking this medication. 
 
Prophylaxis of migraine headache 
• Advise the patient not to drive during the first days of treatment as well as after dose 
increases. 
Torasemide C03CA04 0 • No special advice 
Tosylchloramide sodium D08AX04 NE  
Tramadol N02AX02 III • Advise the patient (and explain to caregivers) not to drive until the next visit after 
start of treatment or after changes in dosage. 
• Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
• Opiate cessation can also cause behavioral changes and requires follow-up and 
counseling. 
Tramadol, combinations N02AX52 NE  
Tramazoline R01AA09 0 • No special advice 
Trandolapril C09AA10 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Trandolapril and verapamil C09BB10 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Tranexamic acid B02AA02 0 • No special advice 
Tranylcypromine N06AF04 II • Inform your patient about the effects of the medication on reaction time as well as 
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that the medication can cause side-effects that impair driving abilities (e.g. dizziness, 
drowsiness, sleepiness, blurred vision, etc.). 
• Advice your patient not to drive for the first few weeks of treatment or until the next 
visit and to be careful in other situations, as well (e.g. operating machinery and 
working at heights). 
• Advice your patient not to drink alcohol nor use any other psychoactive substance 
when taking this medication. 
• In case of short-term use of the medication, advice your patient not to drive because 
his/her driving skills are still impaired for approximately 24 hours. 
 Trapatepine N04AA12 NE  
Trapidil C01DX11 NE  
Travoprost S01EE04 I • Inform the patient that as with any ocular medication, if transient, blurred vision 
occurs at application.  
• Advice the patient that he/she should wait until his/her vision clears before driving or 
using machinery. 
Trazodone N06AX05 III 
 
• Inform your patient about the effects of the medication on reaction time as well as 
that the medication can cause side-effects that impair driving abilities (e.g. dizziness, 
drowsiness, sleepiness, blurred vision, etc.). 
• Advice your patient not to drive until the next visit and to be careful in other 
situations, as well (e.g. operating machinery and working at heights). 
• Advice your patient not to drink alcohol nor use any other psychoactive substance 
when taking this medication. 
• In case of short-term use of the medication, advice your patient not to drive because 
his/her driving skills are still impaired for approximately 24 hours. 
Trepibutone A03AX09 NE  
Treprostinil B01AC21 NE  
Tretinoin D10AD01 0 • No special advice 
Tretinoin, combinations 
(with erythromycin, topical use) 
D10AD51 0 • No special advice 
Tretoquinol R03AC09 
R03CC09 
NE  
Triamcinolone A01AC01 
A07EA 
D07AB09 
0 • No special advice 
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D07XB02 
R01AD11 
Triamcinolone R03BA06 
S01BA05 
C05AA12 
NE  
Triamcinolone and antibiotics D07CB01 0 • No special advice 
Triamcinolone and 
antiinfectives 
S02CA04 0 • No special advice 
Triamcinolone and antiseptics D07BB03 NE  
Triamterene C03DB02 0 • No special advice 
Triazolam N05CD05 III • Inform the patient about the effects of the medicine on reaction time, that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) and that reaction time can 
also be reduced without experiencing side effects. 
• Advice the patient not to drive until the next visit after start of treatment and also to 
be careful in other situations (e.g. using machinery and working at heights) 
• Advice the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
• One time (occasional) use: inform your patient that his/her response is still reduced 
for approximately 24 hours. Advice your patient not to drive then. 
Tribenoside C05AX05 NE  
Tribenoside C05CX01 0 • No special advice 
Tribromometacresol D01AE03 NE  
Trichlormethiazide C03AA06 NE  
Trichlormethiazide and 
potassium 
C03AB06 NE  
Trichlormethiazide and 
potassium-sparing agents 
(spironolactone) 
C03EA02 NE  
Trichloroethylene N01AB05 NE  
Triclofos N05CM07 NE  
Triclosan D08AE04 
D09AA06 
0 • No special advice 
Tridihexethyl A03AB08 NE  
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Trifluoperazine N05AA05 NE  
Trifluoperazine N05AB06 III • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive until the next visit after start of treatment and also to 
be careful in other situations (e.g. using machinery and working at heights) 
• Advice the patient not to drink alcohol when taking this medicine. 
• In short-term use, inform your patient that his/her response is still reduced for 
approximately 24 hours. Advice the patient not to drive then. 
Trifluperidol N05AD02 NE  
Trifluridine S01AD02 NE  
Triflusal B01AC18 0 • No special advice 
 Trihexyphenidyl N04AA01 II • Advise the patient (and explain to caregivers) not to drive during the first days of 
treatment. 
• Inform patients that unwanted effects are seen rapidly during the dosage adjustment 
period. 
• Advise the patient (and explain to caregivers) not to drive at all if suffering from 
“sleep attacks”. 
• Advise the patient (and explain to caregivers) not to drive at all if suffering from 
severe fluctuations in mobility “(“on-off” phenomena). 
Trimazosin C02CA03 NE  
Trimebutine A03AA05 0 • No special advice 
Trimetazidine C01EB15 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
 Trimethadione N03AC02 NE  
Trimethyldiphenylpropylamine A03AX30 NE  
Trimipramine N06AA06 II • Inform your patient about the effects of the medication on reaction time as well as 
that the medication can cause side-effects that impair driving abilities (e.g. dizziness, 
drowsiness, sleepiness, blurred vision, etc.). 
• Advice your patient not to drive for the first few weeks of treatment or until the next 
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visit and to be careful in other situations, as well (e.g. operating machinery and 
working at heights). 
• Advice your patient not to drink alcohol nor use any other psychoactive substance 
when taking this medication. 
• In case of short-term use of the medication, advice your patient not to drive because 
his/her driving skills are still impaired for approximately 24 hours. 
Trioxysalen D05AD01 
D05BA01 
NE  
Tripelennamine D04AA04 0 • No special advice 
Tripelennamine R06AC04 NE  
Triprolidine  R06AX07 III • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (drowsiness, sleep 
disturbance) 
• Advise the patient not to drive until the next visit after start of treatment and also to 
be careful in other situations (e.g. using machinery and working at heights) 
• Advise the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Triticum (wheat fibre) A06AC07 NE  
Troglitazone A10BG01 NE  
Trolnitrate C01DA09 NE  
Trolnitrate, combinations C01DA59 NE  
Tromantadine D06BB02 0 • No special advice 
Trometamol B05BB03 0 • No special advice 
Trometamol (only in 
combination) 
B05XX02 NE  
Tropenzilone and analgesics A03DA01 NE  
Tropicamide S01FA06 III • Inform the patient that this ocular medication may cause transient blurring of vision 
or that he/she may suffer from photophobia and that this may impair their ability to 
drive under certain circumstances. Complete recovery from the effects of mydriatic 
anticholinergics may take up to 24 hours. 
• Advise the patients not to drive or operate hazardous machinery until 24 hours after 
receiving ocular medication (recovery occurs within 24 hours) or until vision is clear. 
Tropicamide, combinations S01FA56 III • Inform the patient that this ocular medication may cause transient blurring of vision 
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or that he/she may suffer from photophobia and that this may impair their ability to 
drive under certain circumstances. Complete recovery from the effects of mydriatic 
anticholinergics may take up to 24 hours. 
• Advise the patients not to drive or operate hazardous machinery until 24 hours after 
receiving ocular medication (recovery occurs within 24 hours) or until vision is clear. 
Tropisetron  A04AA03 0 • No special advice 
Trospium and analgesics A03DA06 NE  
Troxerutin C05CA04 0 • No special advice 
Troxerutin, combinations C05CA54 0 • No special advice 
Troxipide A02BX11 NE  
Trypsin D03BA01 0 • No special advice 
Trypsin B06AA07 NE  
Trypsin, combinations M09AB52 NE  
Tryptophan N06AX02 NE  
Tuaminoheptane R01AA11 
R01AB08 
NE  
Tubocurarine  M03AA02 III • Advise the patient not to drive or operate machinery until the effects of the 
anaesthetic, and the immediate effects of surgery have passed 
• Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after 
anaesthesia 
Tulobuterol R03AC11 NE  
Tulobuterol R03CC11 NE  
Tyloxapol  R05CA01 NE  
Tymazoline R01AA13 NE  
Tyrothricin D06AX08 
R02AB02 
0 • No special advice 
 
Tyrothricin S01AA05 NE  
    
U ATC CODE CATEGORIZATION 
labelling 
INFORMATION FOR THE PATIENT 
Ubidecarenone C01EB09 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
 DRUID 6th Framework Programme         Deliverable D.4.4.1  
   Classification of medicinal drugs and driving: 
 Co-ordination and synthesis report.  
   Page 234 of 243 
 
  
 
   
 
 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Ulobetasol D07AC21 NE  
Undecylenic acid D01AE04 NE  
Undecylenic acid, 
combinations 
D01AE54 NE  
Unoprostone S01EE02 NE  
Urapidil C02CA06 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Urate oxidase  M04AX01 NE  
Urokinase B01AD04 0 • No special advice 
Ursodeoxycholic acid A05AA02 0 • No special advice 
    
V ATC CODE CATEGORIZATION 
labelling 
INFORMATION FOR THE PATIENT 
Valerian N05CM09 I • Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first 8 hours after taking the medicine and also 
to be careful in other situations (e.g. using machinery and working at heights) 
• Advice the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Valnoctamide N05CM13 NE  
 Valproic acid 
-  Oral administration 
-  Parenteral administration 
N03AG01  
II 
III 
Advise the patient not to drive during the first days of treatment as well as after 
dose increases. 
 
General warnings: 
• Advise the patient to take the medicine as prescribed by the physician. 
• Advise the patient not to stop taking the medicine suddenly, and to inform the 
physician – doctor if he/she should do so. 
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• Advise the patient not to drink alcohol while taking this medication. 
 Valpromide N03AG02 NE  
Valsartan C09CA03 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Valsartan and aliskiren C09DX02 NE  
Valsartan and amlodipine C09DB01 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Valsartan and diuretics C09DA03 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Valsartan, amlodipine and 
hydrochlorothiazide 
C09DX01 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Vancomycin A07AA09 NE  
Varenicline N07BA03 I • Advise the patient (and explain to caregivers) not to drive during the first days of 
treatment and after changes in doses. 
• The treatment has to be used according to the recommended dose. 
• Advise the patient about possibles effects on behavior.  
• Smoking cessation can also cause behavioural changes. 
Various (Antiinfectives and 
antiseptics for local oral 
treatment) 
A01AB11 0 • No special advice 
Various (Antiseptics) R02AA20 NE  
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Various (Other agents for local 
oral treatment) 
A01AD11 NE  
Various (Other nasal 
preparations) 
R01AX10 NE  
Various (Other topical products 
for joint and muscular pain) 
M02AX10 NE  
Various combinations (Iron in 
other combinations) 
B03AE10 0 • No special advice 
Various combinations (Other 
anti-acne preparations for 
topical use) 
D10AX30 NE  
Vecuronium M03AC03 III • Advise the patient not to drive or operate machinery until the effects of the 
anaesthetic, and the immediate effects of surgery have passed. 
• Advise the patient (and explain to caregivers) not to drink any alcohol 24 hours after 
anaesthesia 
Velaglucerase alfa A16AB10 NE  
Venlafaxine N06AX16 II • Inform your patient about the effects of the medication on reaction time as well as 
that the medication can cause side-effects that impair driving abilities (e.g. dizziness, 
drowsiness, sleepiness, blurred vision, etc.). 
• Advice your patient not to drive until the next visit and to be careful in other 
situations, as well (e.g. operating machinery and working at heights). 
• Advice your patient not to drink alcohol nor use any other psychoactive substance 
when taking this medication. 
• In case of short-term use of the medication, advice your patient not to drive because 
his/her driving skills are still impaired for approximately 24 hours. 
Veralipride N05AL06 NE  
Verapamil C08DA01 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Verapamil, combinations  C0
8DA51 
I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
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• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Veratrum C02KA01 NE  
Veratrum and diuretics C02LK01 NE  
Verteporfin  S01LA01 III • Inform the patient that this ocular medication may cause transient visual 
disturbances such as abnormal vision, vision decrease, or visual field defects that 
may interfere with their ability to drive or use machines. Patients should not drive or 
use machines as long as these symptoms persist. 
• Advise the patients not to drive or operate hazardous machinery until your vision 
improves. 
Vidarabine S01AD06 NE  
 Vigabatrin N03AG04 II Advise the patient not to drive during the first days of treatment as well as after dose 
increases. 
 
Advise the patient that visual field testing should be done regularly. 
 
General warnings: 
• Advise the patient to take the medicine as prescribed by the physician. 
• Advise the patient not to stop taking the medicine suddenly, and to inform the 
physician – doctor if he/she should do so. 
• Advise the patient not to drink alcohol while taking this medication. 
Vildagliptin A10BH02 I • Advise your patient to take precautions to avoid hypoglycaemia, this may constitute 
a risk in situations where these abilities are of special importance (e.g. driving a car 
or operating machinery), and not to drive as long as side-effects persist. 
• If your patient has frequent episodes or if he/she find it hard to recognise 
hypoglycaemia. The advisability of driving should be considered in these 
circumstances.  
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication 
Viloxazine N06AX09 NE  
Viminol N02BG05 NE  
Vinbarbital N05CA09 NE  
Vinburnine C04AX17 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
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etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Vincamine C04AX07 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist.  
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Vinpocetine N06BX18 NE  
 Vinyl ether N01AA02 NE  
Vinylbarbital N05CA08 NE  
Virginiamycin D06AX10 NE  
Visnadine C04AX24 NE  
Vitamins B05XC 0 • No special advice 
Vitamin B-complex, plain A11EA 0 • No special advice 
Vitamin B-complex with 
vitamin C 
A11EB 0 • No special advice 
Vitamin B-complex with 
minerals 
A11EC 0 • No special advice 
Vitamin B-complex with 
anabolic steroids 
A11ED 0 • No special advice 
Vitamin B-complex, other 
combinations 
A11EX 0 • No special advice 
Voglibose A10BF03 NE  
Von Willebrand factor and 
coagulation factor VIII in 
combination  
B02BD06 0 • No special advice 
    
W ATC CODE CATEGORIZATION 
labelling 
INFORMATION FOR THE PATIENT 
Warfarin B01AA03 0 • No special advice 
    
X ATC CODE CATEGORIZATION INFORMATION FOR THE PATIENT 
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labelling 
Xamoterol C01CX07 NE  
Xantinol nicotinate C04AD02 NE  
 Xenon N01AX15 NE  
Xenysalate D11AC09 NE  
Ximelagatran B01AE05 NE  
Xipamide C03BA10 0 • No special advice 
Xylometazoline  
 R01AA0
7 
0 • No special advice 
Xylometazoline  R01AB06 
S01GA03 
NE  
Xylometazoline, combinations S01GA53 NE  
    
Z ATC CODE CATEGORIZATION 
labelling 
INFORMATION FOR THE PATIENT 
Zafirlukast R03DC01 0 • No special advice 
Zaleplon 
- after 12h 
N05CF03 III 
I 
• Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first 12 hours after taking the medicine and 
also to be careful in other situations (e.g. using machinery and working at heights) 
• Advice the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Ziconotide N02BG08 III • Advise the patient (and explain to caregivers) not to drive until the next visit after 
start of treatment or after changes in dosage. 
• Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights).  
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
Zimeldine N06AB02 NE  
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Zinc acetate A16AX05 0 • No special advice 
Zinc bandage with 
supplements 
D09AB02 0 • No special advice 
Zinc bandage without 
supplements 
D09AB01 0 • No special advice 
Zinc chloride B05XA12 0 • No special advice 
Zinc compounds S01AX03 NE  
Zinc gluconate A12CB02 NE  
Zinc preparations C05AX04 0 • No special advice 
Zinc products D02AB 0 • No special advice 
Zinc protein complex A12CB03 NE  
Zinc sulphate  A12CB01 0 • No special advice 
Zipeprol R05DB15 NE  
Ziprasidone 
- Oral administration 
 
 
 
 
 
 
- Parenteral administration: 
i.m. 
N05AE04  
II 
 
 
 
 
 
 
 
III 
Oral administration: 
• Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advice the patient not to drink alcohol when taking this medicine. 
 
Parenteral administration 
• Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive until the next visit after start of treatment and also to 
be careful in other situations (e.g. using machinery and working at heights) 
• Advice the patient not to drink alcohol when taking this medicine. 
Zofenopril C09AA15 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
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taking this medication. 
Zofenopril and diuretics C09BA15 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, fatigue, hypotension, decreased attention, 
etc.) and not to drive as long as side-effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication. 
Zoledronic acid M05BA08 I • Advise your patient not to drive if he/she experiences side-effects that can impair 
his/her driving abilities (e.g. headache, dizziness, and not to drive as long as side-
effects persist. 
• Advise your patient not to drink alcohol nor use any psychoactive substances when 
taking this medication 
Zolimidine A02BX10 NE  
Zolmitriptan  N02CC03 II • Advise the patient not to drive during the first times, the drug is administered, until 
he/she knows his/her reactions.   
• Advise the patient not to drive within the first 4 hours after treatment. 
• Inform the patient that the medication can cause side effects that impair driving and 
that reaction time can also be reduced without experiencing side effects. 
• Advise the patient also to be careful in other situations than driving (e.g. using 
machinery and working at heights) 
• Advise the patient to strictly follow the prescribed doses and intake scheme.  
• Advise the patient to avoid any alcohol or other psychoactive substances during the 
treatment. 
Zolpidem 
- after 8h 
N05CF02 III 
II 
• Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first 8 hours  after taking the medicine and also 
to be careful in other situations (e.g. using machinery and working at heights) 
• Advice the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
Zomepirac M01AB04 NE  
 Zonisamide N03AX15 II Advise the patient not to drive during the first days of treatment as well as after 
dose increases. 
 
General warnings: 
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• Advise the patient to take the medicine as prescribed by the physician. 
• Advise the patient not to stop taking the medicine suddenly, and to inform the 
physician – doctor if he/she should do so. 
• Advise the patient not to drink alcohol while taking this medication. 
Zopiclone N05CF01 III • Inform the patient about the effects of the medicine on reaction time, that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) and that reaction time can 
also be reduced without experiencing side effects. 
• Advice the patient not to drive until the next visit after start of treatment and also to 
be careful in other situations (e.g. using machinery and working at heights) 
• Advice the patient not to drink alcohol or use other psychoactive substances when 
taking this medicine. 
• One time use: inform your patient that his/her response is still reduced for 
approximately 24 hours. Advice your patient not to drive then. 
Zotepine N05AX11 NE  
Zucapsaicin M02AB02 NE  
Zuclopenthixol 
- Oral administration 
 
 
 
 
 
- Parenteral administration: 
depot i.m. 
N05AF05 II 
 
 
 
 
 
 
 
 
III 
Oral administration: 
• Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive for the first few days of treatment or until the next visit 
after the start of treatment and also to be careful in other situations (e.g. using 
machinery and working at heights) 
• Advice the patient not to drink alcohol when taking this medicine. 
 
Parenteral administration 
• Inform the patient about the effects of the medicine on reaction time and that the 
medication can cause side effects that impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and reduced alertness) 
• Advice the patient not to drive until the next visit after start of treatment and also to 
be careful in other situations (e.g. using machinery and working at heights) 
• Advice the patient not to drink alcohol when taking this medicine. 
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*NE: Not evaluated. No proposed categorization and labelling because this medicine is not available in most of the DRUID WP4 countries as well as in the UK 
and Ireland. 
*ATC: Anatomical Therapeutic Chemical (ATC) classification system. 
*SmPC: Summary of Product Characteristics 
 
 
 
 
 
